Biosynthesis and recovery of glycosidic products

JP2023550496A5Pending Publication Date: 2024-11-29MANUS BIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530874
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-24
Filing Date
2021-11-24
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

There is a need for economical methods to produce high-value glycosides, such as rebaudioside M and mogrosides, which are minor products in natural plant extracts, and existing extraction and purification processes face challenges with low yield and purity, leading to undesirable aftertastes and commercial limitations.

Method used

The use of bacterial cells expressing UDP-dependent glycosyltransferase (UGT) enzymes for glycosylation through whole-cell bioconversion processes, combined with genetic modifications to enhance UDP-sugar availability and sucrose synthase expression, followed by optimized recovery methods to achieve high yield and purity of glycoside products.

Benefits of technology

This approach enables the production of high-purity glycosides like rebaudioside M and mogrosides with improved solubility and recovery rates, overcoming the limitations of traditional methods by enhancing glycosylation efficiency and simplifying downstream purification.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000086_0000
    Figure 00000086_0000
  • Figure 00000086_0001
    Figure 00000086_0001
  • Figure 00000086_0002
    Figure 00000086_0002
Patent Text Reader

Abstract

In various aspects and embodiments, the present disclosure provides methods for producing glycosylated products, as well as bacterial cells and uridine diphosphate (UDP)-dependent glycosyltransferase (UGT) enzymes useful therefor. In other aspects and embodiments, the present disclosure provides methods for the high-yield and / or high-purity recovery of such glycoside products from microbial cultures or cell-free reactions. In various aspects and embodiments, the present disclosure provides whole-cell bioconversion processes that involve glycosylation of a desired substrate and / or recovery of the glycosylated product in high yield and / or purity.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] Small molecule glycosyltransferases are encoded by a large multigene family in the plant kingdom. These enzymes transfer sugars from nucleotide sugars to a wide range of secondary metabolites, thereby changing the physical and chemical properties of the acceptor molecules. For example, steviol glycosides are a class of compounds found in the leaves of Stevia rebaudiana Bertoni, a perennial shrub of the Asteraceae (Compositae) family native to certain regions of South America. These are structurally characterized by the core terpenoid steviol and differ in that carbohydrate residues are present at the C13 and C19 positions. They accumulate in the leaves of stevia and account for about 10% - 20% of the total dry weight. On a dry weight basis, the four major glycosides found in stevia leaves usually include stevioside, rebaudioside A, rebaudioside C, and dulcoside A. Other steviol glycosides, including rebaudioside B, D, E, F, G, H, I, J, K, L, M, and O, dulcoside B, steviolbioside, and rubusoside, are present in small or trace amounts.

[0002] Rebaudioside M (RebM), a minor glycosylated product, is estimated to be about 200 - 350 times more potent than sucrose and is described as having a clean sweet taste with a slightly bitter or licorice aftertaste. Prakash I.et al., Development of Next Generation Stevia Sweetener: Rebaudioside M, Foods 3(1), 162 - 175(2014). RebM has attracted great interest in the global food industry, but due to its low prevalence in stevia extracts, an innovative process for synthesis is needed.

[0003] As another example, mogrosides are specialized secondary metabolites derived from triterpenes found in the fruit of the cucurbit plant Siraitia grosvenorii (also known as monk fruit or luo han guo). Their biosynthesis in the fruit involves numerous sequential glycosylations of aglycone mogrol. In the food industry, the use of mogroside fruit extracts as a natural, non-sugar food sweetener is increasing. For example, mogroside V (mog.V) has a sweetness capacity approximately 250 times that of sucrose (Kasai et al., Agric Biol Chem (1989)). Furthermore, additional health benefits of mogrosides have been identified (Li et al., Chin J Nat Med (2014)).

[0004] Purified Mog.V is approved in Japan as a high-intensity sweetener, and its extract has obtained GRAS status in the United States as a non-nutrition sweetener and flavor enhancer. Extracting mogrosides from fruit can yield products of varying purities, often resulting in an undesirable aftertaste. Furthermore, due to low plant yields and specific cultivation requirements, the yield of mogrosides from cultivated fruit is poor. Mogrosides are present in fresh fruit at approximately 1% and dried fruit at approximately 4%. Mog.V is the main component, present in dried fruit at 0.5% to 1.4%. Additionally, the difficulty of purification limits the purity of Mog.V, and commercially available products from plant extracts are standardized to approximately 50% Mog.V. Pure Mog.V products are less likely to produce off-odors, are easier to incorporate into products, and have good solubility, making them more likely to achieve commercial success than mixtures. Therefore, producing sweet mogroside compounds through biotechnology processes is advantageous.

[0005] There remains a need for economical methods for producing high-value glycosides, including those that are small-volume products of natural plant extracts. [Overview of the project]

[0006] In various embodiments, the Disclosure provides methods for producing glycosylated products, as well as useful bacterial cells and uridine diphosphate (UDP)-dependent glycosyltransferase (UGT) enzymes. In other embodiments, the Disclosure provides methods for high-yield and / or high-purity recovery of glycoside products by microbial culture or cell-free reactions. In various embodiments, the Disclosure provides a whole-cell biotransformation process comprising glycosylation of a desired substrate and subsequent high-yield and / or high-purity recovery of the glycosylated product.

[0007] In one embodiment, the present invention provides bacterial cells and methods for producing glycosylation products. In particular, the present disclosure provides bacterial cells expressing one or more UGT enzymes for glycosylation of a desired substrate according to a whole-cell bioconversion process. In some embodiments, the bacterial cells express one or more recombinant sucrose synthase enzymes. Expression of sucrose synthase can dramatically enhance whole-cell glycosylation of the supplied substrate. Alternatively or additionally, the bacterial cells include one or more genetic modifications that increase the availability of UDP-sugars. The bacterial cells are cultured in the presence of a substrate for glycosylation, and optionally, the glycosylation product is recovered using the recovery process described herein.

[0008] Since cells regenerate UDP-glucose cofactor, whole-cell bioconversion systems have advantages over cell-free systems. In embodiments of the present invention, the catalytic reaction (glycosylation) is carried out using living bacterial cells, and the recycling of UDP-glucose cofactor is performed using cellular metabolism without requiring the supply of enzymes or expensive substrates for UDP-glucose regeneration. Various bacterial species, including E. coli, can be used in accordance with this disclosure.

[0009] In some embodiments, bacterial cells express recombinant sucrose synthase enzymes, and the bacterial cells can be cultured in the presence of sucrose. In some embodiments, the sucrose synthase enzyme comprises an amino acid sequence having at least about 70% sequence identity with an amino acid sequence selected from SEQ ID NOs: 1-12.

[0010] In some embodiments, microbial cells have one or more genetic modifications that increase UDP-glucose availability, such as deletion, inactivation, or reduction of activity or expression of a gene encoding an enzyme that consumes UDP-glucose. Other UDP-glucose sinks that can be reduced or removed include removal or reduction of activity or expression of genes responsible for lipid glycosylation and LPS biosynthesis, as well as genes involved in the glycosylation of undecaprenyl diphosphate (UPP). In these or other embodiments, bacterial cells have deletion, inactivation, or reduction of activity or expression of a gene encoding an enzyme that consumes a precursor of UDP-glucose. In these or other embodiments, cells have overexpression or increased activity of one or more genes encoding an enzyme involved in converting glucose-6-phosphate to UDP-glucose. Alternatively or additionally, bacterial cells have one or more genetic modifications that increase glucose transport. Alternatively or additionally, microbial cells have one or more genetic modifications that increase UTP production and recycling. Alternatively or additionally, microbial cells have one or more genetic modifications that increase UDP production. Alternatively or additionally, microbial cells may have one or more genetic modifications that eliminate or reduce the regulation of glucose uptake. Alternatively or additionally, microbial cells may have one or more genetic modifications that reduce the dephosphorylation of glucose-1-phosphate. Alternatively or additionally, bacterial cells may have one or more genetic modifications that reduce the conversion of glucose-1-phosphate to TDP-glucose. Alternatively or additionally, bacterial cells may have one or more genetic modifications that reduce the conversion of glucose-1-phosphate to ADP-glucose.

[0011] In various embodiments, the substrate for glycosylation is provided as a plant extract or fraction thereof, or is produced synthetically or by a biosynthetic process. Exemplary substrates include a variety of secondary metabolites selected from terpenoids or terpenoid glycosides, flavonoids or flavonoid glycosides, cannabinoids or cannabinoid glycosides, polyketides or polyketide glycosides, stilbenoids or stilbenoid glycosides, and polyphenols or polyphenol glycosides. The plant extract can be fractionated or otherwise concentrated to obtain the desired substrate. In some embodiments, the substrate includes terpenoid glycosides such as steviol or steviol glycoside, or mogol or mogol glycoside. The UGT enzyme and associated substrates (including fractions concentrated with the desired substrate) can be selected to produce the desired glycosylation product. In some embodiments, the glycosylation product includes, among other things, one or more steviol glycosides such as RebM, RebE, RebD, RebB, and / or RebI, or mogol glycosides such as mog.IV, mog.IVA, mog.V, mog.VI, isomog.V, and / or siamenoside.

[0012] In other embodiments and configurations, the present invention provides a modified UDP-dependent glycosyltransferase (UGT) enzyme having high productivity for glycosylation of substrates, including those comprising terpenoid glycoside substrates and relating to bacterial cells and methods described herein. In some embodiments, the modified UGT enzyme comprises an amino acid sequence having at least about 70% sequence identity with SEQ ID NO: 13 and having one or more amino acid modifications that improve glycosylation activity to terpenoid glycoside substrates (e.g., steviol glycoside substrates). In yet another embodiment, the UGT enzyme comprises an amino acid sequence having at least about 70% sequence identity with SEQ ID NO: 14 and having one or more amino acid modifications that improve glycosylation activity to terpenoid glycoside substrates (e.g., steviol glycoside substrates). In yet another embodiment, the UGT enzyme comprises an amino acid sequence having at least about 70% sequence identity with SEQ ID NO: 15 and having one or more amino acid substitutions that improve glycosylation activity to terpenoid glycoside substrates (e.g., steviol glycoside substrates).

[0013] In other embodiments and settings, the present invention provides a UGT enzyme (including microbial cells expressing it) for glycosylation of mogrol or mogrol glycoside substrates. In these embodiments and settings, the method comprises contacting the substrate with the UGT enzyme in the presence of a UDP-sugar. The UGT enzyme may include an amino acid sequence having at least about 80% sequence identity with an amino acid sequence selected from SEQ ID NOs: 84, 80, 46, 83, 82, 73, 72, 78, 54, 74, 75, 76, 13, 14, 15, 16, 29, and 79. In these embodiments, mogrol or mogrol glycoside substrates may be provided as a plant extract or fraction thereof, such as monk fruit extract or fraction thereof. For example, the substrate may include (or be concentrated with) one or more substrates selected from mogol, mog.IA, mog.IE, mog.II-A, mog.II-E, mog III, mog IVA, mog.IV, and siamenoside. In some embodiments, the glycosylation product may include one or more of mog.IV, mog.IVA, mog.V, mog VI, isomog.V, and siamenoside. In various embodiments, the UGT enzyme may be capable of primary glycosylation of the C3 and C24 hydroxyls of the mogol core, as well as 1-2 and 1-6 branched glycosylation of the primary glycosyl groups of C3 and / or C24.

[0014] In some embodiments relating to the production of mogol glycosides, the substrate is cultured with microbial cells expressing the UGT enzyme. Exemplary microbial cells include bacterial cells modified for the whole-cell biotransformation process described herein. In yet another embodiment, the microbial cell is a yeast cell. However, in yet another embodiment, the substrate is incubated with a cell lysate containing the UGT enzyme or with purified recombinant UGT enzyme according to known methods.

[0015] In some embodiments, the present invention provides a method for producing and recovering glycoside products. In such embodiments, the method comprises converting a substrate for glycosylation to a target glycoside product by enzymatic transfer of one or more sugar moieties in a cell-free reaction or in a microbial culture, which may optionally be done using methods such as UGT enzymes and / or microbial strains described herein. The method further comprises recovering the glycoside product from the reaction product or culture (recovery comprising adjusting the pH of the reaction product or culture to less than about pH 5 or greater than about pH 10, raising the temperature to at least about 50°C, and adding one or more glycoside solubilizers, followed by removal of enzymes or biomass).

[0016] Conventionally, biomass removal is the first step in recovery, removing large cell debris and avoiding cell destruction that would complicate downstream purification. However, according to embodiments of the present invention, culture materials can be highly viscous and difficult to process. By processing the culture materials described herein before biomass or enzyme removal, it is possible to produce products with desirable qualities, including high purity glycoside products, attractive color, easy solubilization, odorlessness, and / or high recovery rates. For example, adjusting the initial pH and temperature of the culture can alter the fluid properties of the broth, potentially improving the efficiency of the disc stack separator for biomass removal. Furthermore, adjusting the pH and / or temperature, and / or adding glycoside solubilizers, can substantially increase the solubility of the glycoside product and the resulting yield.

[0017] Other aspects and embodiments of this disclosure will become apparent from the following detailed disclosure and examples. [Brief explanation of the drawing]

[0018] [Figure 1]This study demonstrates the improved steviol glycoside bioconversion in modified E. coli cells expressing the UGT enzyme, achieved through two chromosomal modifications: (1) ΔotsA-otsB; (2) ΔotsA-otsB, with insertion of ugpA. The improvement factor refers to the total steviol glycoside conversion. [Figure 2] This study demonstrates improved bioconversion of steviol glycosides from overexpressed genes in modified E. coli cells expressing UGT enzymes. The genes were complemented on plasmids. The improvement multipliers relate to total steviol glycoside conversion. The complemented genes, from left to right, are: (1) control (empty plasmid), (2) pgm (sequence number 92) and galU (sequence number 93), (3) pgm (sequence number 92), (4) galU (sequence number 93), (5) ugpA (sequence number 95), (6) ycjU (sequence number 94), (7) adk (sequence number 96), (8) ndk (sequence number 97), (9) pyrH, and (10) cmk (sequence number 98). [Figure 3] This study demonstrates enhanced steviol glycoside bioconversion by modified E. coli cells expressing the UGT enzyme and possessing overexpressed sucrose synthase. The gene was complemented on a plasmid. The enhancement factor relates to total steviol glycoside conversion. The complemented genes, from left to right, are: (1) control (empty plasmid), (2) StSus1 (sequence number 1), (3) StSus2 (sequence number 2), (4) StSus2_S11E (sequence number 3), (5) AcSuSy (sequence number 4), (6) AcSuSy_L637M-T640V (sequence number 5), (7) AtSus1 (sequence number 6), (8) AtSus3 (sequence number 7), (9) VrSS1 (sequence number 8), (10) VrSS1_S11E (sequence number 9), (11) GmSS (sequence number 10), (12) GmSS_S11E (sequence number 11), and (13) AtSusA (sequence number 12). [Figure 4]This shows improved steviol glycoside bioconversion by modified E. coli cells expressing UGT enzymes and containing various gene knockouts. The improvement factor is related to total steviol glycoside conversion. The deletions are (from left to right): (1) ΔotsA, (2) Δugd, (3) ΔrfaQPSBIJ, (4) ΔyfdGHI, (5) ΔwcaJ, and (6) ΔglgC. [Figure 5] This shows improved steviol glycoside bioconversion by modified E. coli cells expressing the UGT enzyme (MbUGT1,2.3) defined in Sequence ID No. 14. The improvement factor is related to the steviol glycoside conversion rate (%) of the parent UGT enzyme (Sequence ID No. 13). [Figure 6] This shows improved steviol glycoside bioconversion by modified E. coli cells expressing the UGT enzyme (MbUGT1,2.4) defined in Sequence ID No. 15. The improvement factor is related to the steviol glycoside conversion rate (%) of the parent UGT enzyme (Sequence ID No. 14). [Figure 7] This shows improved steviol glycoside bioconversion by modified E. coli cells expressing the UGT enzyme (MbUGT1,2.5) defined in Sequence ID No. 16. The improvement factor is related to the steviol glycoside conversion rate (%) of the parent UGT enzyme (Sequence ID No. 15). [Figure 8] This demonstrates the biotransformation of stevia leaf extract into a mixture of rebaudioside E and rebaudioside D by expressing the UGT enzyme (MbUGT1,2.4) of SEQ ID NO: 15, and into rebaudioside I by expressing the UGT enzyme (MbUGT1-3.3) of SEQ ID NO: 25, using a modified E. coli biotransformation strain. [Figure 9] This demonstrates the biotransformation of stevia leaf extract into a mixture of rebaudioside B and steviolbioside by a modified E. coli-converted strain, induced by the expression of the UGT enzymes of Sequence ID No. 31 and Sequence ID No. 99. [Figure 10]This flowchart shows a conventional process for recovering steviol glycosides. Typically, biomass removal is performed first to remove large cell debris, enzymes, and whole intact cells in order to facilitate the purification of the desired product. [Figure 11] This flowchart shows an exemplary process for recovering glycoside products according to embodiments of the present invention. Before biomass removal, pH and / or temperature adjustment and / or solubilizer addition are used to improve the physical properties of the culture material for processing, thereby facilitating biomass removal while increasing the production of glycoside products. [Figure 12] This study demonstrates the effectiveness of various treatments for separating biomass from aqueous broth after centrifugation. The density of the pellets and the clarity of the supernatant serve as indicators of the ease of biomass removal. The tubes, from left to right, represent: (1) 22°C (room temperature), pH 6.64; (2) 22°C (room temperature), ethanol; (3) 22°C (room temperature), pH 3.78, +ethanol; (4) 22°C (room temperature), pH 3.78; (5) 70°C, pH 6.64; (6) 70°C, ethanol; (7) 70°C, pH 3.78, +ethanol; and (8) 70°C, pH 3.78. [Figure 13] This demonstrates that filtration of the solution before recrystallization affects its purity, and the choice of filter material significantly impacts the quality of the final product. Figure 13 compares the use of polypropylene (PP) (left) and polyethersulfone (PES) (right) materials for filtering the solution before recrystallization. The final product of high-purity RebM (>98%) is dissolved in propylene glycol to a concentration of 10% by weight. Using a PP filter yields a very turbid solution, while using a PES filter yields a clear solution. [Figure 14] The solubility curve (lower curve) and metastable limit curve (upper curve) that define the width of the metastable region determined for RebM in water, enabling control of crystal growth, are shown. [Figure 15]A and B show the solubility (lower curve) and metastable limit curve (upper curve) that define the metastable region width, determined for RebM in 67% water / 33% ethanol at pH 7, enabling control of crystal growth in this solvent system. A is 0% glycerol, while B contains 0.5% glycerol. [Figure 16] A and B show the solubility (lower curve) and metastable limit curve (upper curve) that define the metastable region width, determined for RebM in 67% water / 33% ethanol at pH 11, enabling control of crystal growth in this solvent system. A is 0% glycerol, while B contains 0.5% glycerol. [Figure 17A] Bioconversion of mogrol to mogroside compounds (mogIIE, mog-IE, and mog-IA) using a modified E. coli strain expressing either enzyme 1 (SEQ ID NO: 71) or enzyme 2 (SEQ ID NO: 33) is shown. [Figure 17B] Bioconversion of mogrol to mogroside-IA using a modified E. coli strain expressing enzyme 1 (SEQ ID NO: 71), enzyme 3 (SEQ ID NO: 81), enzyme 4 (SEQ ID NO: 82), and enzyme 5 (SEQ ID NO: 83) is shown. [Figure 18] A and B show the bioconversion of mog-IA (Figure 18A) or mog-IE (Figure 18B) to mog-IIE using a modified E. coli strain expressing either enzyme 1 (SEQ ID NO: 84), enzyme 2 (SEQ ID NO: 71), or enzyme 3 (SEQ ID NO: 33). [Figure 19] Production of Mog-III or cyanomogroside from MogII-E by a modified E. coli strain expressing enzyme 1 (SEQ ID NO: 72), enzyme 2 (SEQ ID NO: 54), or enzyme 3 (SEQ ID NO: 13) is shown. [Figure 20] In vitro production of MogII-A2 by E. coli cells expressing enzyme 1 (SEQ ID NO: 73) is shown. [Figure 21] Glycosylated products generated by the action of UGT enzymes on steviol and steviol glycoside intermediates are shown. [Figure 22]This diagram illustrates the glycosylation pathway to Mog.V. The bubble structures represent various mogrosides. The white tetracyclic core represents mogrol. The numbers below each structure indicate specific glycosylated mogrosides. Black circles represent C3 or C24 glucosylation. Dark gray vertical circles represent 1,6-glucosylation. Light gray horizontal circles represent 1,2-glucosylation. Abbreviations: Mog, mogrol; shea, siamenoside. [Modes for carrying out the invention]

[0019] In various embodiments, the Disclosure provides methods for producing glycosylated products, as well as useful bacterial cells and uridine diphosphate (UDP)-dependent glycosyltransferase (UGT) enzymes. In other embodiments, the Disclosure provides methods for high-yield and / or high-purity recovery of glycoside products by microbial culture or cell-free reactions. In various embodiments, the Disclosure provides a whole-cell biotransformation process comprising glycosylation of a desired substrate and subsequent high-yield and / or high-purity recovery of the glycosylated product.

[0020] In one embodiment, the present invention provides bacterial cells and a method for producing glycosylation products. The bacterial cells express one or more UGT enzymes to glycosylate a desired substrate. In some embodiments, the bacterial cells further express one or more recombinant sucrose synthase enzymes. Expression of sucrose synthase can dramatically enhance whole-cell glycosylation of the supplied substrate (see Figure 3). Alternatively or additionally, the bacterial cells include one or more genetic modifications that increase the availability of UDP-sugars. The bacterial cells are cultured in the presence of a substrate for glycosylation, and optionally, the glycosylation products are recovered using the recovery process described herein.

[0021] Since cells regenerate UDP-glucose cofactor, whole-cell bioconversion systems have advantages over cell-free systems for glycosylation reactions. This is in contrast to processes that use enzymes or extracellular secretions from cell lysis, which require an exogenous supply of UDP-glucose or UDP-glucose precursors or UDP-glucose regeneration mechanisms or UDP-glucose regeneration enzyme systems. In embodiments of the present invention, the catalytic reaction (glycosylation) is carried out using living bacterial cells, and the recycling of UDP-glucose cofactor is performed using cellular metabolism without requiring the supply of enzymes or expensive substrates for UDP-glucose regeneration. Various bacterial species may be used according to this disclosure, including species of Escherichia, Bacillus, Rhodobacter, Zymomonas, or Pseudomonas. In some embodiments, the bacterial cell is Escherichia coli, Bacillus subtilis, Rhodobacter capsulatus, Rhodobacter sphaeroides, Zymomonas mobilis, or Pseudomonas putida. In an exemplary embodiment, the bacterial cell is E. coli.

[0022] In some embodiments, bacterial cells express recombinant sucrose synthase enzyme. In some embodiments, bacterial cells expressing sucrose synthase enzyme are cultured in the presence of sucrose. In some embodiments, the sucrose synthase enzyme comprises an amino acid sequence having at least about 70% sequence identity with an amino acid sequence selected from SEQ ID NOs: 1-12. As shown in Figure 3, expression of sucrose synthase in bacterial cells results in a dramatic enhancement of glycosylation of substrates supplied throughout the cell. In various embodiments, the sucrose synthase enzyme comprises an amino acid sequence having at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity with an amino acid sequence selected from SEQ ID NOs: 1-12.

[0023] In some embodiments, the sucrose synthase enzyme comprises an amino acid sequence having sequence identity with SEQ ID NO: 2 of at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99%. In some embodiments, the sucrose synthase enzyme comprises an S11E or S11D substitution in the amino acid sequence of SEQ ID NO: 2.

[0024] In some embodiments, the sucrose synthase enzyme comprises an amino acid sequence having sequence identity with SEQ ID NO: 3 of at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99%. In some embodiments, the sucrose synthase enzyme comprises one or more amino acid substitutions of L637 (e.g., (L637M)) and T640 (e.g., T640V, T640L, T640I, or T640A) with respect to the amino acid sequence of SEQ ID NO: 3.

[0025] In some embodiments, the sucrose synthase enzyme comprises an amino acid sequence having sequence identity with SEQ ID NO: 5 of at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99%.

[0026] In some embodiments, the sucrose synthase enzyme comprises an amino acid sequence having sequence identity with SEQ ID NO: 6 of at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99%.

[0027] In some embodiments, the sucrose synthase enzyme comprises an amino acid sequence having sequence identity with SEQ ID NO: 7 of at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99%. In some embodiments, the sucrose synthase enzyme comprises an S11E or S11D substitution in the amino acid sequence of SEQ ID NO: 7.

[0028] In some embodiments, the sucrose synthase enzyme comprises an amino acid sequence having sequence identity with SEQ ID NO: 8 of at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99%. In some embodiments, the sucrose synthase enzyme comprises an S11E or S11D substitution in the amino acid sequence of SEQ ID NO: 8.

[0029] In some embodiments, the sucrose synthase enzyme comprises an amino acid sequence having sequence identity with SEQ ID NO: 9 of at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99%.

[0030] In some embodiments, the sucrose synthase enzyme comprises an amino acid sequence having sequence identity with SEQ ID NO: 10 of at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99%. In some embodiments, the sucrose synthase enzyme comprises an S11E or S11D substitution in the amino acid sequence of SEQ ID NO: 10.

[0031] In some embodiments, the sucrose synthase enzyme comprises an amino acid sequence having sequence identity with SEQ ID NO: 11 of at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99%.

[0032] Knowing the three-dimensional structure of an enzyme and the locations of its associated active site, substrate binding site, and other interaction sites facilitates the rational design of derivatives and can provide mechanistic insights into the phenotype of specific modifications. Plant sucrose synthase enzymes exhibit increased activity when the highly conserved S11 and analogue sites are phosphorylated. In some embodiments, sucrose synthase enzymes include S11E or S11D mutations, which mimic phosphorylation by placing a negative charge where an electrostatic phosphate load is found. Other modifications to sucrose synthase enzymes can be induced by publicly available structures, such as those described or referenced in Stein O. and Granot D., An Overview of Sucrose Synthases in Plants, Front Plant Sci. 2019;10:95.

[0033] Alternatively or additionally, bacterial cells may incorporate one or more genetic modifications that enhance the availability of UDP-sugars (e.g., UDP-glucose), thereby enhancing whole-cell biotransformation for glycosylation of desired substrates, as shown in Figures 1, 2, and 4. Wild-type UDP-glucose levels in exponentially growing E. coli are approximately 2.5 mM (Bennett BD, Kimball EH, Gao M, Osterhout R, Van dien SJ, Rabinowitz JD. Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. Nat Chem Biol. 2009;5(8):593-9). In some embodiments, genetic modifications to host cells are modified to increase UDP-glucose levels in exponentially growing cells (e.g., without recombinant expression of the UGT enzyme) to, for example, at least approximately 5 mM or at least approximately 10 mM.

[0034] In some embodiments, microbial cells have deletions, inactivations, or reduced activity or expression of genes encoding enzymes that consume UDP-glucose. For example, bacterial cells may have deletions, inactivations, or reduced activity or expression of one or more of ushA (UDP-glucose hydrolase) and / or galE, galT, galK, and galM (involved in UDP-galactose biosynthesis from UDP-glucose) or their orthologues in the bacterial species. In some embodiments, the galETKM gene is inactivated, deleted, or has substantially reduced expression or activity. Alternatively or additionally, bacterial cells may have deletions, inactivations, or reduced activity or expression of E. coli otsA (trehalose-6-phosphate synthase) or its orthologue in the bacterial species. Alternatively or additionally, microbial cells may have deletions, inactivations, or reduced activity or expression of E. coli ugd (UDP-glucose-6-dehydrogenase) or its orthologue in the bacterial species. Reducing or eliminating the activity of otsA and ugd can remove or reduce the UDP-glucose sink to trehalose or UDP-glucuronidate, respectively.

[0035] Other UDP-glucose sinks that can be reduced or removed include the removal or reduction of activity or expression of genes responsible for lipid glycosylation and LPS biosynthesis, as well as genes involved in undecaprenyl diphosphate (UPP) glycosylation. Genes involved in lipid glycosylation or LPS biosynthesis include E. coli waaG (lipopolysaccharide glucosyltransferase 1), E. coli waaO (UDP-D-glucose:(glucosyl)LPSα-1,3-glucosyltransferase), and E. coli waaJ (UDP-glucose:(glucosyl)LPSα-1,2-glucosyltransferase). Genes involved in the glycosylation of undecaprenyl diphosphate (UPP) include E. coli yfdG (a putative bactoprenol-binding glucose translocase), E. coli yfdH (bactoprenol glucosyltransferase), E. coli yfdI (serotype-specific glucosyltransferase), and E. coli wcaJ (undecaprenyl phosphate glucose phosphotransferase). Deletion, inactivation, or reduction of the activity or expression of one or more of these gene products (or their corresponding orthologs in bacterial cells) may increase the availability of UDP-glucose.

[0036] In these or other embodiments, the bacterial cells have a deletion, inactivation, or reduced activity or expression of a gene encoding an enzyme that consumes a UDP-glucose precursor. For example, in some embodiments, the bacterial cells have a deletion, inactivation, or reduced activity or expression of pgi (glucose-6-phosphate isomerase) or its ortholog in the bacterial species of the host cell.

[0037] In these or other embodiments, the cells have overexpression or increased activity of one or more genes encoding enzymes involved in the conversion of glucose-6-phosphate to UDP-glucose. For example, pgm (phosphoglucomutase) and / or galU (UTP-glucose-1-phosphate uridylyltransferase) (or its orthologue or derivative) may be overexpressed or modified to increase enzyme productivity. Alternatively or additionally, E. coli ycjU (β-phosphoglucomutase), which converts glucose-6-phosphate to glucose-1-phosphate, and Bifidobacterium bifidum ugpA, which converts glucose-1-phosphate to UDP-glucose, or orthologues or derivatives of these enzymes may be overexpressed or modified to increase enzyme productivity.

[0038] Alternatively or additionally, bacterial cells may have one or more genetic modifications that increase glucose transport. Such modifications may include increased expression or activity of E. coli galP (galactose:H+ cotransporter) and E. coli glk (glucokinase), or expression of Zymomonas mobilis glf and E. coli glk, or orthologues or modified derivatives of these genes.

[0039] Alternatively or additionally, microbial cells may have one or more genetic modifications that increase UTP production and recycling. Such modifications may include increased expression or activity of E. coli adk (adenylate kinase) or E. coli ndk (nucleoside diphosphate kinase), or orthologues or modified derivatives of these enzymes.

[0040] Alternatively or additionally, microbial cells may have one or more genetic modifications that increase UDP production. Such modifications include overexpression or increased activity of one or more of the following, including their orthologues or modified derivatives: E. coli upp (uracil phosphoribosyltransferase), E. coli dctA (C4 dicarboxylic acid / orotic acid:H+ symporter), E. coli pyrE (orotic acid phosphoribosyltransferase), E. coli pyrF (orotidine-5'-phosphate decarboxylase), E. coli pyrH (UMP kinase), and E. coli cmk (cytidylic acid kinase). For example, in some embodiments, microbial cells overexpress upp, pyrH, and cmk, or their orthologues or modified derivatives, or have increased activity of them. Alternatively, microbial cells overexpress dctA, pyre, pyrH, and cmk, or their orthologues or modified derivatives, or have increased activity of them.

[0041] Alternatively or additionally, microbial cells may have one or more genetic modifications that eliminate or reduce the regulation of glucose uptake. For example, microbial cells may have deletion, inactivation, or reduced expression of sgrS, a small regulatory RNA in E. coli.

[0042] Alternatively or additionally, microbial cells may have one or more genetic modifications that reduce glucose-1-phosphate dephosphorylation. Exemplary modifications include deletion, inactivation, or reduction of expression or activity of one or more of the following in bacterial cells: E. coli agp (glucose-1-phosphatase), E. coli yihX (α-D-glucose-1-phosphate phosphatase), E. coli ybiV (sugar phosphatase), E. coli yidA (sugar phosphatase), E. coli yigL (phosphate sugar phosphatase), and E. coli phoA (alkaline phosphatase), or their orthologues.

[0043] Alternatively or additionally, bacterial cells may have one or more genetic modifications that reduce the conversion of glucose-1-phosphate to TDP-glucose. Exemplary modifications include deletion, inactivation, or reduction of expression or activity of one or more E. coli rffH (dTDP-glucose pyrophosphorylase) and E. coli rfbA (dTDP-glucose pyrophosphorylase) or their orthologues in bacterial cells.

[0044] Alternatively or additionally, bacterial cells may have one or more genetic modifications that reduce the conversion of glucose-1-phosphate to ADP-glucose. Exemplary modifications include deletion, inactivation, or reduction of expression or activity of E. coli glgC (glucose-1-phosphate adenylyltransferase) or its ortholog in bacterial cells.

[0045] For example, in some embodiments, ushA (UDP-sugar diphosphatase) and galETKM or their orthologs are deleted, inactivated, or have reduced expression or activity; pgi (glucose-6-phosphate isomerase) or its orthologs are deleted, inactivated, or have reduced expression or activity; E. coli pgm (SEQ ID NO: 92) and / or ycjU (SEQ ID NO: 94) or their orthologs are overexpressed or derivatives with increased activity compared to the wild-type enzyme are expressed; and E. coli galU (SEQ ID NO: 93) and / or Bifidobacterium bifidum ugpA (SEQ ID NO: 95) or their orthologs are overexpressed or derivatives with increased activity compared to the wild-type enzyme are expressed.

[0046] In various embodiments in which the bacterial strain overexpresses E. coli pgm (SEQ ID NO: 92) and / or ycjU (SEQ ID NO: 94) or an ortholog, or expresses a derivative having increased activity compared to the wild-type enzyme; or overexpresses E. coli galU (SEQ ID NO: 93), or expresses Bifidobacterium bifidum ugpA (SEQ ID NO: 95) or its ortholog or derivative (e.g., with higher activity than the wild-type enzyme), the complementary gene may each contain an amino acid sequence that is identical to SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 93, or SEQ ID NO: 95 by at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 97%.

[0047] For example, in some embodiments, bacterial cells include overexpression of pgm or its ortholog or derivative (e.g., a derivative with higher activity than the wild-type enzyme), and optionally, galU or its ortholog or derivative (e.g., a derivative with higher activity than the wild-type enzyme). In further embodiments, bacterial cells have deletion, inactivation, or reduced activity or expression of one or more of ushA or its ortholog, and / or galE, galT, galK, and galM or their orthologs. For example, the galETKM gene or its ortholog may be inactivated, deleted, or have reduced expression or activity. In some embodiments, pgi (glucose-6-phosphate isomerase) or its ortholog may be deleted, inactivated, or have reduced expression or activity.

[0048] Alternatively or additionally, bacterial cells may have a deletion, inactivation, or reduced activity or expression of otsA (trehalose-6-phosphate synthase) or its ortholog, and / or otsB (trehalose-phosphate phosphatase) or its ortholog.

[0049] Alternatively or additionally, bacterial cells may have one or more deletions, inactivations, or reduced activity or expression of ugd (UDP-glucose-6-dehydrogenase) or its ortholog; rfaQ-GPSBIJ or its ortholog(s); yfdG-HI or its ortholog(s); wcaJ or its ortholog; and glgC or its ortholog.

[0050] In exemplary embodiments, bacterial cells have overexpression or increased activity or expression of one or more of the following enzymes: E. coli ycjU (β-phosphoglucomutase) (SEQ ID NO: 94) or its ortholog or derivative; Bifidobacterium bifidum ugpA (UTP-glucose-1-phosphate uridylyltransferase) (SEQ ID NO: 95) or its ortholog or derivative; E. coli adk (adenylate kinase) (SEQ ID NO: 96) or its ortholog or derivative; E. coli ndk (nucleoside diphosphate kinase) (SEQ ID NO: 97) or its ortholog or derivative; and E. coli cmk (cytidine monophosphate kinase) (SEQ ID NO: 98) or its ortholog or derivative. In various embodiments, derivative enzymes may be modified to have higher enzymatic activity than wild-type enzymes. Each complementary gene may contain an amino acid sequence that is at least approximately 50%, at least approximately 60%, at least approximately 70%, at least approximately 80%, at least approximately 90%, at least approximately 95%, or at least approximately 97% identical to SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, or SEQ ID NO: 98.

[0051] Other modifications to bacterial cells that improve the availability of UDP-sugars are described in US2020 / 0087692, which is incorporated herein by reference in whole.

[0052] In various embodiments, the substrate for glycosylation is provided as a plant extract or fraction thereof, or is produced synthetically or by a biosynthetic process. Exemplary substrates include a variety of secondary metabolites selected from terpenoids or terpenoid glycosides, flavonoids or flavonoid glycosides, cannabinoids or cannabinoid glycosides, polyketides or polyketide glycosides, stilbenoids or stilbenoid glycosides, and polyphenols or polyphenol glycosides. The plant extract can be fractionated or otherwise concentrated to obtain the desired substrate.

[0053] In some embodiments, the substrate comprises a terpenoid and / or terpenoid glycoside, e.g., steviol or steviol glycoside, or mogrol or mogrol glycoside ("mogroside"). In some embodiments, the substrate mainly has 0 to about 4 glycosyl groups, which may include glucosyl, galactosyl, mannosyl, xylosyl, and / or rhamnosyl groups. In various embodiments, the glycosyl group is mainly glucosyl. After whole-cell biotransformation, in various embodiments, the glycosylated product will have at least 4, at least 5, at least 6, or at least 7 glycosyl groups (e.g., glucosyl). In various embodiments, whole-cell biotransformation involves at least two glycosylation reactions of the substrate by bacterial cells. In some embodiments, whole-cell biotransformation results in a single glycosylation or deglycosylation of the substrate (in the case of a reverse reaction catalyzed by UGT).

[0054] In various embodiments, the substrate is provided as a stevia leaf extract or fraction thereof, in which the target substrate can be concentrated. For example, the stevia leaf extract may contain or be concentrated with one or more of steviol, stevioside, steviolbioside, rebaudioside A, dulcoside A, dulcoside B, rebaudioside C, and rebaudioside F. In some embodiments, at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 75% of the steviol glycosides in the extract or fraction thereof contains one or more of stevioside, steviolbioside, and rebaudioside A.

[0055] UGT enzymes and associated substrates (including plant extract fractions concentrated with the desired substrate) can be selected to produce the desired glycosylation product. In some embodiments, at least one UGT enzyme comprises an amino acid sequence having at least about 70% sequence identity with any one of SEQ ID NOs: 13-84 and 99. In various embodiments, at least one UGT enzyme comprises an amino acid sequence having at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 99% sequence identity with any one of SEQ ID NOs: 13-84 and 99. According to embodiments of this disclosure, the UGT enzyme is expressed without secretion or transport signaling and does not contain a membrane-anchored domain.

[0056] Knowing the three-dimensional structure of an enzyme and the locations of its associated active sites, substrate binding sites, and other interaction sites facilitates the rational design of derivatives and can provide mechanistic insights into the phenotypes of specific changes. Plant UGTs share highly conserved secondary and tertiary structures, although they exhibit relatively low amino acid sequence identity. (Osmani et al, Substrate specificity of plant UDP-dependent glycosyltransferases predicted from crystal structures and homology modeling, Phytochemistry 70(2009)325-347). The sugar acceptor and sugar donor substrate of UGTs are housed in a cleavage formed between the N-terminal and C-terminal domains. Several regions of the primary sequence contribute to the formation of the substrate binding pocket, which includes structurally conserved domains as well as loop regions that differ in both amino acid sequence and sequence length.

[0057] In some embodiments, the substrate is a terpenoid glycoside, and in some embodiments, it may include a steviol glycoside or mogroside. Numerous UGT enzymes having glycosyltransphasic activity to terpenoid or terpenoid glycoside scaffolds are described herein, including UGT enzymes defined in SEQ ID NOs: 13-39, 46, 54, 60, 71-84, and 99. See Tables 1, 8, and 9.

[0058] For example, in some embodiments, the glycosylation product is rebaudioside (steviol glycoside). In these embodiments, the UGT enzyme can perform one or more of the following: primary glycosylation at the C13 and / or C19 hydroxyl of the steviol core; 1-2 branched glycosylation of the primary glycosyl group at C13 and / or C19; and 1-3 branched glycosylation of the primary glycosyl group at C13 and / or C19. See Figure 21. In some embodiments, the UGT enzyme is selected from enzymes containing an amino acid sequence having at least about 70% sequence identity (or at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 97% sequence identity) of one of sequence numbers 13-32 and 84.

[0059] UGT enzymes for the glycosylation of steviol and steviol glycosides (including those for the biosynthesis of RebM) are disclosed in US2017 / 0332673 and 2020 / 0087692, which are incorporated herein by reference in their entirety. Exemplary UGT enzymes are listed in Table 1 below. TIFF2023550496000001.tif136165

[0060] In some embodiments, the glycosylation product is a mogroside. In various embodiments, the UGT enzyme can perform one or more of the following: primary glycosylation at the C3 and / or C24 hydroxyl of the mogrol core; 1-2 branched glycosylation of the primary glycosyl group at C3 and / or C24; and / or 1-6 branched glycosylation of the primary glycosyl group at C3 and / or C24. UGT enzymes useful for these embodiments are shown in Tables 8 and 9. In some embodiments, the UGT enzyme is selected from enzymes containing an amino acid sequence having at least about 70% sequence identity (or at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 97% sequence identity) of one of SEQ ID NOs: 13-17, 29, 33-39, 46, 54, 60, 71-80, and 82-84.

[0061] Changes in the amino acid sequence of an enzyme can alter its activity or eliminate any measurable effect. Silent changes, which do not produce measurable effects, are often conservative substitutions and small insertions or deletions on solvent-exposed surfaces, located away from the active site and substrate binding site. In contrast, enzyme activity is more likely to be affected by non-conservative substitutions, large insertions or deletions, and changes within the active site, substrate binding site, and embedded sites that are important for protein folding or conformation. Changes that alter enzyme activity can increase or decrease reaction rates, or increase or decrease affinity or specificity for particular substrates. For example, changes that increase the size of the substrate binding site may allow the enzyme to act on larger substrates, and changes that position catalytic amino acid side chains closer to the target site on the substrate may increase enzyme rate.

[0062] In some embodiments, “rational design” involves constructing a specific mutation in an enzyme. Rational design refers to incorporating knowledge about the enzyme or related enzymes, such as reaction thermodynamics and kinetics, three-dimensional structure, active site(s), substrate(s), and / or enzyme-substrate interactions, into the design of a specific mutation. Based on a rational design approach, a mutation can be created in an enzyme, which can then be screened for increased terpene or terpenoid production compared to control levels. In some embodiments, mutations can be rationally designed based on homology modeling. As used herein, “homologous modeling” refers to the process of constructing from an atomic-resolution model of a protein derived from its amino acid sequence and the three-dimensional structure of a related homologous protein.

[0063] The degree of amino acid sequence identity, or the proportion of sequence identity, can be determined by sequence alignment. Such alignment can be performed using several known algorithms, such as those described by Karlin and Altschul (Karlin & Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877), hmmalign (HMMER package), or the CLUSTAL algorithm (Thompson, JD, Higgins, DG & Gibson, TJ (1994) Nucleic Acids Res. 22, 4673-80). The degree of sequence identity (sequence matching) can be calculated, for example, using BLAST, BLAT, or BlastZ (or BlastX). Similar algorithms are incorporated into the BLASTN and BLASTP programs in Altschul et al (1990) J. Mol. Biol. 215:403-410. BLAST protein alignment can be performed using the BLASTP program (score = 50, word length = 3). For comparative purposes, gap alignment can be obtained using gap BLAST, as described in Altschul et al (1997) Nucleic Acids Res. 25:3389-3402. When using the BLAST and gap BLAST programs, the default parameters for each program are used.

[0064] UGT enzymes or other expressible enzymes may be incorporated into the chromosome of a microbial cell or expressed extrachromosomally. For example, UGT enzymes can be expressed from bacterial artificial chromosomes (BACs) or yeast artificial chromosomes (YACs).

[0065] The amino acid sequences of one or more UGT enzymes (or other expressing enzymes) may optionally include alanine inserted or substituted at position 2, which reduces intracellular turnover. In various embodiments, one or more UGT enzymes include an alanine amino acid residue inserted or substituted at position 2 to provide further stability in vivo.

[0066] Enzyme expression can be regulated to achieve optimal activity, for example, using gene modules (e.g., operons) or independent expression of the enzyme. For example, gene or operon expression can be regulated through the selection of promoters, such as inductive or constitutive promoters, having different intensities (e.g., strong, intermediate, or weak). Some non-limiting examples of promoters of different intensities include Trc, T5, and T7. Furthermore, gene or operon expression can be controlled by manipulating the copy number of the gene or operon within the cell. In some embodiments, cells express a single copy of each UGT enzyme. In some embodiments, gene or operon expression can be regulated by manipulating the order of genes within a module, with the first transcribed gene generally being expressed at a higher level. In some embodiments, gene or operon expression is regulated by the incorporation of one or more genes or operons into the chromosome.

[0067] Expression optimization can also be achieved by selecting appropriate promoters and ribosome binding sites. In some embodiments, this may include the selection of high-copy-number plasmids, or single, low-copy-number, or medium-copy-number plasmids. The transcription termination step can also be targeted for gene expression regulation by introducing or removing structures such as stem-loops.

[0068] Expression vectors containing all the elements necessary for expression are commercially available and known to those skilled in the art. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically modified by introducing heterologous DNA into them. To enable the expression of heterologous DNA within host cells, the heterologous DNA is placed under the operational control of its transcription elements.

[0069] In some embodiments, endogenous genes are edited, as opposed to gene complementation. Editing may modify endogenous promoters, ribosome-binding sequences, or other expression regulatory sequences, and / or, in some embodiments, modify trans- and / or cis-acting factors in gene regulation. Genome editing can be performed using CRISPR / Cas genome editing techniques or similar techniques using zinc finger nucleases and TALENs. In some embodiments, endogenous genes are replaced by homologous recombination.

[0070] In some embodiments, genes are at least partially overexpressed by controlling the gene copy number. The gene copy number can be conveniently controlled using plasmids with different copy numbers, but gene duplication and chromosomal integration can also be used. For example, the process of genetically stable tandem gene replication is described in US2011 / 0236927, which is incorporated herein by reference in its entirety.

[0071] In some embodiments, the glycosylation product includes RebM. In these embodiments, the UGT enzyme is capable of primary glycosylation of the C13 and C19 hydroxyls of the steviol core; 1-2 branched glycosylation of the primary glycosyl groups of C13 and C19; and 1-3 branched glycosylation of the primary glycosyl groups of C13 and C19. See Figure 21. In some embodiments, the UGT enzyme is selected from enzymes comprising one of SEQ ID NOs: 13-32 and 84 and an amino acid sequence having at least about 70% sequence identity (or at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 97% sequence identity). In such embodiments, the glycosylation product recovered in accordance with this disclosure is at least about 50% RebM, or at least about 75% RebM, or at least about 85% RebM, or at least about 90% RebM, or at least about 95% RebM, relative to the total steviol glycoside component.

[0072] In some embodiments, the glycosylation product comprises RebE and / or RebD. In such embodiments, bacterial cells may express one or more UGT enzymes capable of 1-2 glycosylation of the primary glycosyl groups of steviol C13 and C19. In some embodiments, the substrate for glycosylation comprises RebA and stevioside as the main components (e.g., at least about 20%, or at least about 30%, or at least about 50%, or at least about 70%) of the steviol glycoside composition of the substrate. In some embodiments, the UGT enzyme is selected from enzymes having at least about 70% sequence identity (or at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 97%) of one of SEQ ID NOs: 13-16 and 26-29. In such embodiments, the glycosylation product recovered in accordance with the Disclosure is at least about 50% RebE and / or RebD, or at least about 75% RebE and / or RebD, or at least about 85% RebE and / or RebD, or at least about 90% RebE and / or RebD, or at least about 95% RebE and / or RebD, relative to the total steviol glycoside component.

[0073] In some embodiments, the glycosylation product comprises RebB. In such embodiments, bacterial cells express one or more UGT enzymes capable of deglycosylating the primary glycosyl group of steviol C19. In some embodiments, the substrate for glycosylation comprises RebA as the main component (e.g., at least about 20%, or at least about 30%, or at least about 50%, or at least about 70% of the substrate's rebaudioside composition). In some embodiments, the UGT enzyme is selected from enzymes having at least about 70% sequence identity (or at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 97%) of one of SEQ ID NOs: 18, 30, 31, and 99. In some embodiments, bacterial cells express a UGT enzyme having at least about 70% sequence identity (or at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 97%) with SEQ ID NO: 31 or SEQ ID NO: 99. In such embodiments, the glycosylation product recovered according to this disclosure is at least about 50% RebB, or at least about 75% RebB, or at least about 85% RebB, or at least about 90% RebB, or at least about 95% RebB, relative to the total steviol glycoside component.

[0074] In some embodiments, the glycosylation product comprises RebI. In such embodiments, bacterial cells express one or more UGT enzymes capable of glycosylation of 1 to 3 primary glycosyl groups of steviol C19. In some embodiments, the substrate for glycosylation comprises RebA as the main component (e.g., at least about 20%, or at least about 30%, or at least about 50%, or at least about 70%, or at least about 80%) of the composition of steviol glycosides of the substrate. In some embodiments, the UGT enzyme is selected from enzymes having at least about 70% (or at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 97%) sequence identity with one of SEQ ID NOs: 19-25. In such embodiments, the glycosylation product recovered according to this disclosure is at least about 50% RebI, or at least about 75% RebI, or at least about 85% RebI, or at least about 90% RebI, or at least about 95% RebI, relative to the total steviol glycoside component.

[0075] In some embodiments, the substrate is provided as monk fruit extract or a fraction thereof, or as biosynthetically produced mogol or mogol glycoside. For example, the substrate may include one or more substrates selected from mogol, mog.IA, mog.IE, mog.II-A, mog.II-E, mog III, mog IVA, mog.IV, and siamenoside. The glycosylation product may include, for example, one or more of mog.IV, mog.IVA, mog.V, mog VI, isomog.V, and siamenoside. See Figure 18. In various embodiments, the UGT enzyme is capable of one or more of the following: primary glycosylation of the C3 and / or C24 hydroxyl group of the mogol core, as well as 1-2 branched glycosylation of the C3 and / or C24 primary glycosyl group; and 1-6 branched glycosylation of the C3 and / or C24 primary glycosyl group. In some embodiments, the glycosylation product is mog.V or siamenoside. In various embodiments, the UGT enzyme is selected from enzymes containing amino acid sequences having at least about 70% (or at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 97%) sequence identity with one of SEQ ID NOs: 13-17, 29, 33-39, 46, 54, 60, 71-80, and 82-84. See Tables 8 and 9. In various embodiments, the method results in at least about 40% conversion of the substrate to the glycosylation product (relative to the total mogol glycoside component of the recovered composition), or at least about 50% conversion of the substrate to the glycosylation product, or at least about 75% conversion of the substrate to the glycosylation product, or at least about 90% conversion of the substrate to the glycosylation product, or at least about 95% conversion of the substrate to the glycosylation product.

[0076] In various embodiments, bacterial cell biomass is generated by growth in a complex or minimal medium. The bacterial cells are then cultured in the presence of a substrate for glycosylation with one or more carbon sources. In some embodiments, the carbon sources include one or more of glucose, sucrose, fructose, xylose, and glycerol. In some embodiments, the carbon sources include sucrose, as well as one or more of glycerol and glucose. Generally, suitable carbon sources include C1-C6 carbon sources. Culture conditions can be selected from aerobic, microaerophilic, and anaerobic conditions. Culture can be carried out in a batch, continuous, or semi-continuous process. For example, in some embodiments, the method is carried out as a fed-batch process.

[0077] In some embodiments, the substrate is incubated with bacterial cells for about 72 hours or less, or about 48 hours or less. In certain embodiments, the substrate is incubated with bacterial cells for 1 to about 3 days, for example, using a stirred tank fermenter. In various embodiments, the glycoside product is recovered as described elsewhere in this specification. For example, recovery may include one or more of the following: lowering the pH of the culture to less than about pH 5 or raising the pH to greater than about pH 9, raising the temperature to at least about 50°C, and adding one or more glycoside dissolution accelerators, followed by removal of enzymes or biomass.

[0078] In other embodiments and settings, the present invention provides a modified UDP-dependent glycosyltransferase (UGT) enzyme having high productivity for glycosylation of substrates, including those comprising terpenoid glycoside substrates and relating to bacterial cells and methods described herein. In some embodiments, the modified UGT enzyme comprises an amino acid sequence having at least about 70% sequence identity with SEQ ID NO: 13 (or at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 97% sequence identity) and having one or more amino acid modifications that improve glycosylation activity toward terpenoid glycoside substrates (e.g., steviol glycoside substrates). In some embodiments, the amino acid modifications are V397S, V397C, G5N, S20E, S23D, R45Y, H59P, G94S, K97E, M150L, ​​I185F, A206P, G210E, Q237R, M250K, A251E, C252L, G259E, Q263Y, I287M, C28 The amino acid modification includes one or more amino acid substitutions (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, or 10) selected from 8F, V336I, F338L, D351E, F186I, F186M, F186T, L418F, A451T, A451L, T453K, T453R, V456S, V456W, V456T, V456M). See Table 2. Alternatively or additionally, the amino acid modification includes substitutions of 5 to 15 amino acids, mainly glycine and serine amino acids, at residues 270 to 281 of SEQ ID NO: 13. Alternatively or additionally, the amino acid modification includes, with respect to SEQ ID NO: 13, insertion of one or two amino acids at position 3 and / or addition of an amino acid to the C-terminus of SEQ ID NO: 13.

[0079] In some embodiments, the UGT enzyme has amino acid substitutions at positions 270-281 of SEQ ID NO: 13 by sequence GGSGGS (SEQ ID NO: 85). In these or other embodiments, the UGT enzyme has an Arg insertion at position 3 or an Ile-Arg insertion between positions 2 and 3 with respect to SEQ ID NO: 13. In these or other embodiments, the UGT enzyme includes one or more (or all) substitutions selected from G5N, F186T, and V397S with respect to SEQ ID NO: 13. An exemplary UGT enzyme of this embodiment includes the amino acid sequence of SEQ ID NO: 14. See Figure 5.

[0080] In yet another embodiment, the UGT enzyme has at least about 70% (or at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 97%) sequence identity with SEQ ID NO: 14 and includes an amino acid sequence having one or more amino acid modifications that improve glycosylation activity toward a terpenoid glycoside substrate (e.g., a steviol glycoside substrate). For example, the amino acid modifications for Sequence ID No. 14 are V395A, Q263Y, D269R, K97E, Q262E, H59P, G259E, M150L, ​​Y267H, T3R, V95Q, A238E, S308Q, Q237R, R45Y, E254D, L203I, S151R, S123D, D351E, T453M, G94T, T186M, V336I, L58S, F338L, F51W, C252L, M250D, A251E, C252V, A79P, W40 The amino acid substitution may include one or more (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid substitutions selected from 1F, S323A, A251E, A130D, S42E, H400Y, S266R, S23D, P56A, A206P, M250K, A143W, V456T, G94S, I427F, T186I, T453F, C252R, V38F, R45F, T37S, Q244K, L11I, I287M, V31P, T43D, and P39T. See Table 3. Alternatively or additionally, the amino acid modification may include deletion of residues 270-281 of SEQ ID NO: 14 using a 5-15 amino acid linker mainly consisting of glycine and serine amino acids. Alternatively or additionally, the UGT enzyme may include, with respect to SEQ ID NO: 14, the insertion of one or two amino acids at position 3 and / or the addition of an amino acid to the C-terminus of SEQ ID NO: 14.

[0081] In some embodiments, the UGT enzyme has substitutions of amino acids 270-281 in SEQ ID NO: 14 by a linker sequence of 6-12 amino acids mainly composed of Ser and Gly. In these or other embodiments, the UGT enzyme includes one or more substitutions (or all substitutions) selected from H59P, A238E, and L417F with respect to SEQ ID NO: 14. In these or other embodiments, the UGT enzyme includes an insertion or Arg-Arg between A2 and T3 in SEQ ID NO: 14. Exemplary UGT enzymes according to these embodiments include the amino acid sequence of SEQ ID NO: 15. See Figure 9.

[0082] In further embodiments, the UGT enzyme includes an amino acid sequence having at least about 70% (or at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 97%) sequence identity with SEQ ID NO: 15, and having one or more amino acid substitutions that enhance glycosylation activity to terpenoid glycoside substrates (e.g., steviol glycoside substrates). Such amino acid substitutions may be at positions selected from 125, 152, 153, and 442 with respect to SEQ ID NO: 15. In some embodiments, the UGT enzyme includes one or more (or all) amino acid substitutions selected from M152A, S153A, P442D, and S125V with respect to SEQ ID NO: 15. See Table 4. Exemplary UGT enzymes according to these embodiments include the amino acid sequence of SEQ ID NO: 16. See Figure 7.

[0083] In other embodiments and models, the present invention provides a UGT enzyme (including bacterial cells expressing it) for glycosylation of mogol or mogol glycoside substrates. In these embodiments, the method comprises contacting the substrate with the UGT enzyme in the presence of a UDP-sugar (e.g., UDP-glucose). The UGT enzyme may include an amino acid sequence selected from SEQ ID NOs: 84, 80, 46, 83, 82, 73, 72, 78, 54, 74, 75, 76, 13, 14, 15, 16, 29, and 79, and an amino acid sequence having at least about 80% (or at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or at least about 99%) sequence identity. See Tables 8 and 9.

[0084] In various embodiments, the substrate is brought into contact with a UGT enzyme containing an amino acid sequence having at least about 80% (or at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or at least about 99%) sequence identity with an amino acid sequence selected from SEQ ID NO: 84, SEQ ID NO: 80, SEQ ID NO: 83, SEQ ID NO: 73, SEQ ID NO: 72, SEQ ID NO: 54, and SEQ ID NO: 13.

[0085] In these embodiments, the mogol or mogol glycoside substrate may be provided as a plant extract or fraction thereof, such as monk fruit extract or fraction thereof. For example, the substrate may comprise (or be concentrated) one or more substrates selected from mogol, mog.IA, mog.IE, mog.II-A, mog.II-E, mog III, mog IVA, mog.IV, and siamenoside. In these embodiments, the glycosylation product may comprise one or more of mog.IV, mog.IVA, mog.V, mog.VI, isomog V, and siamenoside. For example, the UGT enzyme may be capable of primary glycosylation at the C3 and / or C24 hydroxyl group of the mogol core, and / or 1-2 and / or 1-6 branched glycosylation of the primary glycosyl group at C3 and / or C24. An exemplary product according to these embodiments is mog.V. Other mogroside products (including mog.IV, mog.VI, and siamenosides) can be prepared, and the UGT enzyme is selected based on its glycosylation activity.

[0086] In some embodiments relating to the production of mogrol glycosides, the substrate is cultured with microbial cells expressing UGT enzymes. Exemplary microbial cells include bacterial cells, e.g., species of Escherichia, Bacillus, Rhodobacter, Zymomonas, or Pseudomonas. Exemplary bacterial cells include Escherichia coli, Bacillus subtilis, Rhodobacter capsulatus, Rhodobacter sphaeroides, Zymomonas mobilis, or Pseudomonas putida. In some embodiments, the bacterial cell is E. coli. In various embodiments, the bacterial cell is modified for the whole-cell biotransformation process described herein, which has one or more genetic modifications that increase UDP-sugar availability, for example, as described elsewhere herein, and / or expresses sucrose synthase.

[0087] In yet another embodiment, the microbial cell is a yeast cell, which may be selected from the species Saccharomyces, Pichia, or Yarrowia, including Saccharomyces cerevisiae, Pichia pastoris, and Yarrowia lipolytica.

[0088] However, in yet another embodiment, the substrate is incubated with a cell lysate containing the UGT enzyme, or with a purified recombinant UGT enzyme according to a known method. UDP-sugars to support the glycosylation reaction can be added externally.

[0089] In various embodiments, the glycosylated product is recovered according to the methods described below. Such methods may include one or more of the following: lowering the pH of the reactant or culture to less than about pH 5 or raising the pH of the reactant or culture to greater than about pH 9, raising the temperature to at least about 50°C, and adding one or more glycoside dissolution accelerators, followed by removal of enzymes or biomass.

[0090] In some embodiments, the present invention provides a method for producing and recovering glycoside products. In such embodiments, the method comprises converting a substrate for glycosylation to a target glycoside product by enzymatic transfer of one or more sugar moieties in a cell-free reaction or in a microbial culture, which may optionally be done using methods such as UGT enzymes and / or bacterial cells as described herein. The method further comprises recovering the glycoside product from the reaction product or culture, which includes one or more of the following: lowering the pH of the reaction product or culture to less than about pH 5, raising the pH of the reaction product or culture to greater than about pH 9, raising the temperature to at least about 50°C, and adding one or more glycoside solubilizers, followed by removal of enzymes or biomass.

[0091] Conventionally, biomass removal, which removes large cell fragments and avoids further cell destruction that would complicate downstream purification, is the first step in recovery. However, according to some embodiments of the present invention, the culture material is highly viscous and difficult to process. For example, the efficiency of biomass removal by centrifugation can be limited by the physical properties of the collected culture material. By processing the culture material described herein before biomass or enzyme removal, it is possible to produce a product with desirable qualities, including high purity glycoside products, white color, easy solubilization, odorlessness, and high recovery rates. In particular, initial adjustment of the pH and temperature of the culture can alter the fluid properties of the broth, improving the efficiency of the disc stack separator for biomass removal. Furthermore, adjustment of pH and temperature substantially increases the solubility of the glycoside product and the resulting yield, thereby avoiding significant loss of the glycoside product in the solid phase.

[0092] In various embodiments, the glycosylation product is one or more terpenoid glycosides, such as RebM, RebE, RebD, RebB, and RebI (as described herein, for example). In some embodiments, the glycosylation product is RebM. In other embodiments, the glycosylation product includes one or more mog.IV, mog.IVA, mog.V, mog.VI, isomog.V, and siamenosides (as described herein). An exemplary mog.V product is mog.V.

[0093] In some embodiments, the enzymatic transfer occurs in a microbial culture, which comprises a microbial strain expressing one or more UGT enzymes (e.g., whole-cell biotransformation using a supplied substrate). In other embodiments, the microbial strain further expresses a biosynthetic pathway that produces a substrate for glycosylation (e.g., steviol or mogol) and expresses one or more UGT enzymes for glycosylation of the substrate. See, for example, U.S. Patent No. 10,463,062 and WO2019 / 169027 (these are incorporated herein by reference in their entirety). In various embodiments, the enzymatic transfer is by a microbial culture of a yeast strain selected from Saccharomyces, Pichia, or Yarrowia, including Saccharomyces cerevisiae, Pichia pastoris, and Yarrowia lipolytica. In other embodiments, the enzymatic transfer is by a microbial culture of bacterial cells described herein, including E. coli cells modified for whole-cell biotransformation (for example, including one or more genetic modifications expressing one or more sucrose synthase enzymes and / or improving UDP-sugar availability, as described herein). For example, the bacterial cells may include genetic modifications such as: ushA and galETKM or their orthologues being deleted, inactivated, or having reduced expression or activity; pgi or its orthologue being deleted, inactivated, or having reduced expression or activity; E. coli pgm (SEQ ID NO: 92) and / or ycjU (SEQ ID NO: 94) or its orthologue or derivative (e.g., a derivative with higher activity than the wild-type enzyme) being overexpressed; and / or E. coli galU (SEQ ID NO: 93) and / or Bifidobacterium bifidum ugpA (SEQ ID NO: 95) or its orthologue or derivative (e.g., a derivative with higher activity than the wild-type enzyme).

[0094] In some embodiments, the enzymatic transfer is carried out in a bioreactor having a volume of at least about 10,000 L, or at least about 50,000 L, or at least about 100,000 L, or at least about 150,000 L, or at least about 200,000 L, or at least about 500,000 L. In various embodiments, the culture material can be harvested in batch, continuous, or semi-continuous manner to recover the glycosides.

[0095] In some embodiments, the collected culture material is pH-adjusted to, for example, a pH in the range of about 2 to about 5. In some embodiments, the pH is adjusted to a pH in the range of about 2 to about 4, or a pH of about 2 to about 3.5, or a pH in the range of about 2.5 to about 4. In some embodiments, the pH is adjusted to about 2.5, about 3.0, or about 3.5. In yet other embodiments, the pH is adjusted to a basic pH range, for example, a pH in the range of about 9 to about 12, or a pH in the range of about 9.5 to about 12, or a pH in the range of about 10 to about 12 (for example, about 11, about 11.5, or about 12). In various embodiments, pH adjustment improves the solubility of glycosides and / or improves the physical properties of the collected material, and as a result, biomass and / or enzymes are more easily removed without causing significant loss to the product. pH adjustment may be by adding or titrating organic or inorganic acids or hydroxide ions according to known methods.

[0096] Alternatively or additionally, the temperature of the collected culture material is adjusted to a temperature of approximately 50°C to approximately 90°C, for example, approximately 50°C to approximately 80°C. For example, in some embodiments, the temperature is adjusted to a temperature in the range of approximately 55°C to approximately 75°C, or in the range of approximately 65°C to approximately 75°C. In some embodiments, the temperature is adjusted to approximately 70°C. In various embodiments, temperature adjustment improves the solubility of glycosides and / or improves the physical properties of the collected material, resulting in easier removal of biomass and / or enzymes without significant loss of product. In some embodiments, temperature adjustment is performed by transferring the reaction medium or culture to a preheated collection tank. In some embodiments, temperature adjustment is performed inline, for example, by passing through a holding loop on the way to the next unit operation.

[0097] In some embodiments, the collected reactants or cultures are transferred from the reaction tank to a sampling tank for pH and / or temperature adjustment, which may be done in the same sampling tank or in different sampling tanks. In some embodiments, pH and / or temperature adjustment is performed inline as a continuous unit operation. Temperature and pH adjustment may be performed in any order or simultaneously. In some embodiments, pH adjustment is performed before temperature adjustment. In other embodiments, temperature adjustment is performed before pH adjustment. In yet another embodiment, pH adjustment and temperature adjustment are performed substantially simultaneously.

[0098] Alternatively or additionally, the method includes adding one or more glycoside dissolution accelerators. Exemplary dissolution accelerators include, but are not limited to, chemical reagents having alcohol functional groups (including organic acids and polymers) and / or polar reagents (including those having ethers, esters, aldehydes, and ketone functional groups), particularly glycerol, 1,3-propanediol, polyvinyl alcohol, and polyethylene glycol. Other exemplary dissolution accelerators include organic acids, sugars, and polysaccharides. Other dissolution accelerators are described in US2020 / 0268026, which is incorporated herein by reference in whole. Improved glycoside solubility facilitates the removal of biomass and / or enzymes without significant product loss. Generally, dissolution accelerators can be added to the collected culture material in a range of about 0.1% to about 2% by weight, for example, in a range of about 0.1% to about 1% by weight (e.g., about 0.5% by weight).

[0099] Subsequently, the biomass and / or enzymes are removed by centrifugation, thereby preparing a clarified broth. An exemplary process for biomass removal involves using a disc stack centrifuge to separate the liquid and solid phases. The clarified broth (liquid phase) is recovered for further processing to purify the glycoside products. The separated biomass (solid phase) can be further reprocessed to recover the glycoside products or disposed of as waste.

[0100] In some embodiments, the glycoside is crystallized from the clarification broth. In some embodiments, the process includes one, two, or three crystallization steps. In some embodiments, the glycoside product is purified from the clarification broth using one or more processes selected from filtration, ion exchange, activated carbon, bentonite, affinity chromatography, and digestion, which can optionally be performed before crystallization and / or recrystallization. These processes can be selected to achieve high product purity, an attractive color (white in the case of RebM), easy solubilization, odorlessness, and high recovery. In some embodiments, the method uses affinity chromatography comprising, for example, one or more of styrene-divinylbenzene adsorption resins, strongly acidic cation exchange resins, weakly acidic cation exchange resins, strongly basic anion exchange resins, weakly basic anion exchange resins, and hydrophobic interaction resins. In yet another embodiment, the process uses simulated mobile bed chromatography as described in U.S. Patent No. 10,213,707 (which is incorporated herein by reference in its entirety). In further embodiments, the recovery process is non-chromatographic (i.e., without a chromatography step), which offers substantial cost advantages. For example, the recovery process after biomass removal consists essentially of, or may consist of, filtration and crystallization steps. In some embodiments, the recovery process uses an organic solvent (e.g., ethanol), while in other embodiments, the process uses an entirely aqueous solvent. In some embodiments, two crystallization steps are used.

[0101] In some embodiments, the recovery process may include one or more steps of tangential flow filtration (TFF). For example, a TFF with a filter with a pore size of about 5 kD can remove endotoxins, large proteins, and other cellular debris while also increasing the solubility of the final powder product. In some embodiments, before initial crystallization, the glycoside product is optionally purified by tangential flow filtration with a membrane pore size of about 5 kD. A TFF with a filter with a pore size of about 0.5 kD may also be used downstream to remove small molecule impurities and salts and / or to concentrate the mother liquor for recrystallization. In some embodiments, a TFF with a pore size of about 0.5 kD is used before recrystallization.

[0102] In any case, the crystallization step may include one or more of the following: static crystallization, stirred crystallization, and evaporative crystallization. For example, the crystallization step may include a stationary phase followed by a stirred phase to control the crystal morphology. The stationary phase can grow large crystals with a high degree of crystalline domains. The crystallization process may include crystal seeding, or, in some embodiments, may not include crystal seeding (i.e., crystals form spontaneously). In various embodiments, the crystallization solvent includes water or water / ethanol. An exemplary crystallization solvent is water (optionally containing about 5% to about 50% by volume of ethanol, or about 25% to about 50% by volume of ethanol (e.g., about 30% to about 40% by volume of ethanol)). In some embodiments, after seeding crystals in the stationary phase, the stirred phase will cause the crystals to grow rapidly and increase the degree of amorphous domains. Using this process, the resulting crystals may have good final solubility and high purity of the glycoside product, which may facilitate recovery and washing.

[0103] In various embodiments, prior to recrystallization, the glycoside product is resolubilized in a solvent (not limited to water and / or ethanol), which may be done by lowering the pH of the solvent and the solution or suspension of the glycoside product to less than about pH 5, or raising the pH of the solution or suspension to greater than about pH 9, heating to at least about 50°C, and adding one or more glycoside solubilizers. Alternatively, target values ​​for pH, temperature, and glycoside solubilizer concentration can be used for biomass removal. For example, the pH of the solution or suspension of the glycoside product may be adjusted to a range of about 2 to about 5. In other embodiments, the pH is adjusted to a basic pH range, e.g., a pH in the range of about 9 to about 12, or a pH in the range of about 9.5 or about 10 to about 12. pH adjustment may be done by adding or titrating organic or inorganic acids or hydroxide ions according to known methods. In yet another embodiment, recrystallization is carried out at a pH of about 4 to about 12. Alternatively or additionally, the temperature of the solution or suspension is adjusted to a temperature of about 50°C to about 90°C, for example, about 50°C to about 80°C. An exemplary recrystallization solvent is water (optionally containing about 5% to about 50% by volume of ethanol, or about 25% to about 50% by volume of ethanol (e.g., about 30% to about 40% by volume of ethanol)). Alternatively or additionally, a dissolution accelerator may be added to the solution / suspension in the range of about 0.1% to about 2% by weight, for example, in the range of about 0.1% to about 1% by weight (e.g., about 0.5% by weight), as described. An example of a dissolution accelerator is glycerol.

[0104] In some embodiments, after crystallization, the resulting crystals are isolated using, for example, a basket centrifuge or a belt filter, thereby isolating the glycoside wet cake (e.g., a steviol glycoside or mogrol glycoside wet cake). Washing in the basket centrifuge step may involve washing with water, or alternatively, other rinsing (e.g., cold water / ethanol) may be used. In some embodiments, the cake is dissolved and recrystallized. The recrystallized wet cake can then be optionally dried using a belt dryer, paddle dryer, or spray dryer. The dry cake can be crushed and packaged.

[0105] Before recrystallization, the glycoside solution (e.g., RebM and other steviol glycosides) can be filtered to remove impurities. In some embodiments, the filter may be about 0.2 microns in size. Alternatively, other pore sizes such as about 0.45 microns and about 1.2 microns can be used. According to embodiments, the filter material can be selected to remove further impurities, for example, by adsorption. For example, hydrophilic materials such as polyethersulfone (PES) have advantages over hydrophobic materials such as polypropylene. Other exemplary hydrophilic filter materials include nylon, cellulose acetate, cellulose nitrate, and hydrophobic materials that are typically functionalized to yield hydrophilic properties (e.g., PTFE or PVDF coated with fluoroalkyl-terminated polyethylene glycol).

[0106] In various embodiments, the recovery process yields a high-purity composition of the target glycoside. For example, in some embodiments, the target glycoside product is at least about 75% by weight of the recovered composition. In some embodiments, the target glycoside product is at least about 80% by weight, or at least about 90% by weight, or at least about 95% by weight of the recovered composition. In exemplary embodiments, the yield of the glycosylated product is at least about 25 grams of product (g / L) per liter of culture or reactant, or at least about 50 g / L, or at least about 75 g / L, or at least about 100 g / L, or at least about 125 g / L, or at least about 150 g / L, or at least about 200 g / L.

[0107] In some embodiments, the present invention provides a method for producing products comprising glycosylated products such as steviol glycoside or mogol glycoside (e.g., RebM or mog.V). The method involves incorporating the glycoside product (produced according to this disclosure) into a product, such as a food, beverage, oral care product, sweetener, flavoring, or other product. Purified glycosides prepared according to the present invention may be used in a variety of products, including, but are not limited to, foods, beverages, texturers (e.g., starch, fiber, gum, fats and fat mimics, and emulsifiers), pharmaceutical compositions, tobacco products, nutritional supplement compositions, oral hygiene compositions, and cosmetic compositions. Non-limiting examples of flavors that can be used in combination with glycosides include lime, lemon, orange, fruit, banana, grape, pear, pineapple, mango, bitter almond, cola, cinnamon, sugar, cotton candy, and vanilla flavors. Other non-limiting examples of food ingredients include flavorings, acidulants, and amino acids, colorants, fillers, modified starch, gum, texturizers, preservatives, antioxidants, emulsifiers, stabilizers, thickeners, and gelling agents.

[0108] In some embodiments, the present invention provides a method for producing a sweetener product comprising a plurality of high-intensity sweeteners, the plurality comprising two or more of the following: steviol glycosides (e.g., RebM, RebE, RebD, RebI, or RebB), mogrosides (e.g., mog.IV, mog.IVA, mog.V, mog.VI, or isomog.V), sucralose, aspartame, neotame, advantame, acesulfame potassium, saccharin, sugar alcohols (e.g., erythritol or xylitol), tagatose, cyclamate, neohesperidin dihydrochalcone, gnetifolin E, and / or piceatannol 4'-O-β-D-glucopyranoside. The method may further include incorporating the sweetener product into foods, beverages, oral care products, sweeteners, flavorings, or other products containing the above.

[0109] Target glycosides, such as RebM or mog.V, and sweetener compositions containing them can be used in combination with various bioactive substances or functional ingredients. Functional ingredients are generally classified into categories such as carotenoids, dietary fiber, fatty acids, saponins, antioxidants, nutritional supplements, flavonoids, isothiocyanates, phenols, plant sterols and stanols (phytosterols and phytostanols); polyols; prebiotics, probiotics; phytoestrogens; soy proteins; sulfides / thiols; amino acids; proteins; vitamins; and minerals. Functional ingredients may also be classified based on their health benefits, such as cardiovascular, cholesterol-lowering, and anti-inflammatory properties.

[0110] Furthermore, targeted glycosides such as RebM and mog.V, as well as the sweetener compositions obtained according to the present invention, can be applied as high-intensity sweeteners to produce zero-calorie, low-calorie, or diabetic beverages and foods with improved taste characteristics. They can also be used in beverages, foods, pharmaceuticals, and other products where sugar cannot be used. In addition, the sweetener compositions can be used not only as sweeteners for beverages, foods, and other products intended for human consumption, but also as improved animal feeds and feed sweeteners.

[0111] Examples of products in which target glycosides and sweetener compositions may be used include: alcoholic beverages such as vodka, wine, beer, spirits, and sake; natural juices; soft drinks; carbonated soft drinks; diet drinks; zero-calorie drinks; low-calorie drinks and foods; yogurt drinks; instant juices; instant coffee; powdered instant beverages; canned products; syrups; miso; soy sauce; vinegar; dressings; mayonnaise; ketchup; curry; soup; instant bouillon; powdered soy sauce; powdered vinegar; and biscuit dough. This includes, but is not limited to, the following: rice biscuits; crackers; bread; chocolate; caramel; candy; chewing gum; jelly; pudding; preserved fruits and vegetables; fresh cream; jam; marmalade; flour paste; powdered milk; ice cream; sherbet; bottled vegetables and fruits; canned and boiled beans; canned meats and foods; agricultural vegetable products; seafood; ham; sausages; fish ham; fish sausages; fish paste; fried fish products; dried seafood products; frozen foods; preserved seaweed; preserved meat; tobacco; pharmaceuticals; and many other items.

[0112] Conventional methods, such as mixing, kneading, dissolving, pickling, immersion, filtration, spraying, atomizing, injection, and other methods, may be used in the manufacture of products, such as food, beverages, pharmaceuticals, cosmetics, table products, and chewing gum.

[0113] As used herein, the term "approximately" means within ±10% of the relevant figure.

[0114] Other aspects and embodiments of the present invention will become apparent from the following examples. [Examples]

[0115] Example 1: Modification of biotransformation chassis strain The bioconversion (glycosylation) of steviol glycoside intermediates using a modified E. coli strain expressing the UGT enzyme is described in US2020 / 0087692, which is incorporated herein by reference. US2020 / 0087692 describes bacterial genetic modification to increase the spontaneous flux to UDP-glucose, a key substrate of the UGT enzyme. A flux greater than the spontaneous flux to UDP-glucose allows for improved UGT performance by increasing the amount of substrate available for UGT. The genetic modification gives the cell the ability to convert the supplied substrate into glycosylation products (including, but not limited to, rebaudiosides and mogrosides). Other substrates for glycosylation are described herein. Genetic modifications include the deletion or inactivation of enzymes that consume UDP-glucose (ushA, galETKM); the deletion or inactivation of enzymes that consume glucose-6-phosphate (G6P), a precursor of UDP-glucose (e.g., pgi); and the overexpression of enzymes that convert G6P to UDP-glucose via glucose-1-phosphate (G1P) (e.g., pgm, galU). E. coli strains with modified ΔushA, ΔgalETKM, Δpgi, and complementation of pgm and galU will be referred to as "chassis strains" below.

[0116] Additional chromosomal modifications were tested to improve bioconversion compared to the chassis strain. Figure 1 shows the improvement in steviol glycoside bioconversion with two additional chromosomal modifications. The improvement factor refers to total steviol glycoside conversion. Stevia leaf extract, sucrose, and glucose were supplied to bioconversion strains expressing the UGT enzymes of SEQ ID NOs. 15 and 25, and the sucrose synthase of SEQ ID NO. 11. Bioconversion was performed at 37°C for 48 hours. Data were quantified by reverse-phase LC DAD to quantify steviol glycoside conversion. Deletion of otsA and otsB (shown as 1 in Figure 1) showed improved steviol glycoside bioconversion compared to the chassis strain. Furthermore, overexpression of ugpA (shown as 2 in Figure 1) provided a further improvement in total steviol glycoside bioconversion.

[0117] Bioconversion was tested by overexpressing other bacterial genes and comparing them to chassis strains expressing UGT enzymes of SEQ ID NOs. 14 and 24. Figure 2 shows the improvement in steviol glycoside bioconversion from a series of overexpressed genes complemented on plasmids. The improvement factor refers to total steviol glycoside conversion. Stevia leaf extract and glucose were supplied to the bioconverting strains. Bioconversion was performed at 37°C for 48 hours. Data were quantified by reverse-phase LC DAD to quantify steviol glycoside conversion. As shown, overall glycosylation was improved by several gene complements, including E. coli pgm (SEQ ID NO: 92), galU (SEQ ID NO: 93), pgm-galU (SEQ ID NOs. 92 and 93), ugpA (SEQ ID NO: 95), ycjU (SEQ ID NO: 94), adk (SEQ ID NO: 96), ndk (SEQ ID NO: 97), and cmk (SEQ ID NO: 98).

[0118] We created strains expressing candidate sucrose synthase enzymes. This may improve UDP-glucose availability when sucrose is supplied. Sucrose synthase expression allows for the splitting of sucrose into fructose and glucose. Glucose can then be collected for UDP-glucose biosynthesis. However, when grown on either glycerol or glucose as a carbon source, the cells exhibit similar growth and UDP-glucose availability. Figure 3 shows the improved steviol glycoside bioconversion from complemented sucrose synthase in bioconversion chassis strains expressing the UGT enzymes of SEQ ID NOs. 15 and 25. The genes were complemented on plasmids. The improvement factor relates to total steviol glycoside conversion. Stevia leaf extract, sucrose, and glucose were supplied to the bioconversion strains. Bioconversion was performed at 37°C for 48 hours. Data were quantified by reverse-phase LC DAD to quantify steviol glycoside conversion. Several sucrose synthase enzymes, including those represented by SEQ ID NOs: 2, 3, 5, 6, 7, 8, 9, 10, and 11, resulted in a dramatic improvement in glycosylation.

[0119] Figure 4 shows the improvement in steviol glycoside bioconversion by bioconversion chassis strains expressing the UGT enzymes of SEQ ID NO: 14 and SEQ ID NO: 24, each containing various gene knockouts. The improvement factor refers to total steviol glycoside conversion. Stevia leaf extract and glucose were supplied to the bioconversion strains. Bioconversion was carried out at 37°C for 48 hours. The data were quantified by reverse-phase LC-DAD to quantify steviol glycoside conversion. Several gene knockouts were confirmed to improve bioconversion.

[0120] Example 2: UGT modification and generation of target steviol glycoside The UGT enzyme, known as MbUGT1,2, is described in U.S. Patent No. 10,743,567, which is incorporated herein by reference. A modified version of MbUGT1,2 (SEQ ID NO: 13) is described in US2020 / 0087692, which is incorporated herein by reference in its entirety. Furthermore, the UGT enzyme of SEQ ID NO: 13 was modified to improve the activity of steviol glycoside bioconversion. Figure 5 shows the improvement in steviol glycoside bioconversion by the modified version of SEQ ID NO: 14. The improvement factor is related to the steviol glycoside conversion rate (%) of the parent UGT enzyme (SEQ ID NO: 13). SEQ ID NO: 14 has the following mutations from SEQ ID NO: 13: G5N, F186T, V397S. Stevia leaf extract and glucose were supplied to a bioconverting strain. Bioconversion was carried out at 37°C for 48 hours. The conversion of steviol glycoside was quantified by reverse-phase LC DAD.

[0121] Table 2 shows the improvement in the bioconversion of steviol glycosides to the UGT enzyme of Sequence ID No. 13 from individual mutations. The improvement factor (FI) is related to the steviol glycoside conversion rate (%). TIFF2023550496000002.tif233165TIFF2023550496000003.tif58165

[0122] Figure 6 shows the improved bioconversion of steviol glycoside by a further modified version, SEQ ID NO: 15. The improvement factor is related to the steviol glycoside conversion rate (%) of the parent UGT enzyme of SEQ ID NO: 14. The UGT enzyme of SEQ ID NO: 15 has the following mutations from SEQ ID NO: 14: ins_A2_T3_RR, H59P, A238E, L417F. Stevia leaf extract and glucose were supplied to the bioconverting strain. Bioconversion was carried out at 37°C for 48 hours. The conversion of steviol glycoside was quantified by reverse-phase LC DAD.

[0123] Table 3 shows the improvement in the bioconversion of steviol glycosides to the UGT enzyme of Sequence ID No. 14 from individual mutations. The improvement factor (FI) is related to the steviol glycoside conversion rate (%). TIFF2023550496000004.tif98165TIFF2023550496000005.tif233165TIFF2023550496000006.tif121165TIFF2023550496000007.tif65165

[0124] Figure 7 shows the improved bioconversion of steviol glycoside by a further modified version, SEQ ID NO: 16. The improvement factor is related to the steviol glycoside conversion rate (%) of the parent UGT enzyme of SEQ ID NO: 15. SEQ ID NO: 16 has the following mutations from SEQ ID NO: 15: M152A, S153A. Stevia leaf extract and glucose were supplied to the bioconverting strain. Bioconversion was carried out at 37°C for 48 hours. The conversion of steviol glycoside was quantified by reverse-phase LC DAD.

[0125] Table 4 shows the improvement in steviol glycoside bioconversion from individual mutations to Sequence ID No. 15. The improvement factor (FI) is related to the steviol glycoside conversion rate (%). TIFF2023550496000008.tif135165

[0126] In addition to the generation of RebM with the co-expression of four UGT enzymes (see Figure 21), in various embodiments, other target steviol glycosides can be generated by the expression of fewer UGTs and / or by utilizing specific rebaudiosides as substrates. For example, certain stevia leaf extracts may contain large amounts of RebA and steviosides. Expression of a 1-2 branched UGT enzyme (e.g., one of SEQ ID NOs: 13-16) will result in the generation of a mixture of RebE and RebD, depending on the rebaudioside content of the extract. Expression of a 1-3 branched UGT enzyme (e.g., SEQ ID NOs: 19-25) will substantially generate RebI. Furthermore, expression of UGTC19 favorably facilitates deglycosylation to steviol biosides and RebB.

[0127] Figure 8 shows the bioconversion of stevia leaf extract to a mixture of RebE and RebD using the UGT enzyme of SEQ ID NO: 15, and to RebI using the UGT enzyme of SEQ ID NO: 25. Stevia leaf extract (mainly containing stevioside and RebA), sucrose, and glucose were supplied to the bioconversion strain. Bioconversion was carried out at 37°C for 48 hours. The conversion of steviol glycosides was quantified by reverse-phase LC-DAD.

[0128] Figure 9 shows the bioconversion of stevia leaf extract to a mixture of RebB and steviol bioside using the UGT enzymes of SEQ ID NO: 31 and SEQ ID NO: 99. Stevia leaf extract, UDP, and glucose were supplied to the bioconverting strain. Bioconversion was carried out at 37°C for 48 hours. The conversion of steviol glycoside was quantified by reverse-phase LC-DAD.

[0129] Example 3: Recovery of steviol glycoside Conventionally, in order to enable the recovery and purification of steviol glycosides (or other glycoside products), biomass (in the case of fermentation or whole-cell / lysate bioconversion processes) or enzymes (in the case of bioconversion by purified enzymes) would first be removed from the culture. Conventionally, in order to minimize the destruction of microbial cells, it has been preferred to remove biomass as the first step of recovery, as cell debris (both large and small molecules) would otherwise complicate the purification process. A conventional process for recovering steviol glycosides is summarized in Figure 10. However, according to embodiments of the present invention, the culture broth produced by the bioconverting strain has a very high viscosity, which presents challenges in the removal of biomass and the recovery of steviol glycosides.

[0130] This problem can be significantly mitigated by adjusting the temperature and pH before biomass removal, and / or by adding glycoside dissolution accelerators. For example, these treatments can reduce the viscosity of the culture material, allowing for protein precipitation and glycoside solubilization, which facilitates subsequent separation and recovery from the biomass. The process outlined in Figure 11 can yield a final product (e.g., RebM) containing 95% or more steviol glycoside. For example, lowering the pH (from an initial pH of approximately 7) to a range of approximately 2–4 significantly increases the solubility of RebM. Alternatively, increasing the pH (from an initial pH of approximately 7) to above pH 11 can also increase solubility. With pH adjustment and dissolution accelerators, it is possible to achieve concentrations of over 100 g / L or over 150 g / L of high-purity steviol glycoside according to this disclosure. Exemplary dissolution accelerators include glycerol (e.g., approximately 0.5 wt%) and 1,3-propanediol (e.g., approximately 0.5 wt%). In addition to those described herein, other dissolution accelerators include polyvinyl alcohol, polyethylene glycol, and polypropylene glycol.

[0131] Figure 12 shows the effect of various treatments on the separation of biomass from aqueous broth after centrifugation. Pellet density and supernatant clarity serve as indicators of the ease of biomass removal. In summary, 30 ml of fermentation broth was subjected to the following treatments, either individually or in combination: heating at 70°C for 30 minutes, acidification to pH 3.78, or addition of 15% v / v ethanol. The broth was then centrifuged at 3000 rpm for 5 minutes to measure the separation efficiency. The results show that heating and acidification have a positive effect on separation. Tube No. 8, which showed the best separation, was heated to 70°C and adjusted to pH 3.78. Tube No. 7, which included pH adjustment to 3.78 with the addition of ethanol, also showed good separation.

[0132] Table 5 shows the effects of heating (70°C, 30 minutes) and acidification (pH 3.6) on the processing time required for biomass removal. In summary, treated and untreated fermentation broth were passed through a GEA Westfalia SB7 separator to test biomass removal. The untreated broth required three separate passes through the SB7 at a processing time of 0.44 min / L, followed by tangential flow filtration (TFF) at a processing time of 2.2 min / L, in order to ensure sufficient biomass separation in the downstream steps. With heating and acidification, efficient biomass separation became possible with only one pass through the SB7, and the processing time was reduced by more than eight times. TIFF2023550496000009.tif50165

[0133] Table 6 shows the effects of heating and acidification on the quantification and recovery of RebM. In summary, the RebM concentration in aqueous broth was measured before and after treatment using both heating (70°C, 15 minutes) and acidification (pH 2.5). The treatment improved RebM recovery by 120–173% compared to the untreated state (an average improvement of 140% across seven independent samples). TIFF2023550496000010.tif51165

[0134] Table 7 shows the effect of heating combined with the addition of acids or bases and / or small molecule enhancers on the solubility of RebM. Fermentation broth was maintained at a constant temperature of 70°C and subjected to the various treatments described in Table 7. RebM was gradually added while constantly stirring, and the maximum solubility of RebM was measured. Acidification of the culture medium showed an increase in RebM solubility, similar to the addition of small molecule enhancers (glycerol, 1,3-propanediol). In some cases, the addition of enhancers and changes in pH (addition of bases) further increased the solubility of RebM. TIFF2023550496000011.tif58165

[0135] The processes described herein can produce products with desirable qualities, including glycoside (e.g., RebM or mog.V) purity of 95% or more, attractive white color, easy solubilization, odorlessness, and high recovery rate. In particular, adjusting the initial pH and temperature of the culture can alter the fluid properties of the broth, improving the efficiency of the disc stack separator for biomass removal. Furthermore, adjusting the pH and temperature substantially increases the solubility of the glycoside and the resulting yield (thus avoiding substantial loss of the product in the solid phase).

[0136] The process may involve one or more crystallization steps. The crystallization process may include a stationary phase, a subsequent stirred phase, and optionally, an evaporated phase, to control the crystal morphology. The stationary phase can grow large crystals with a high degree of crystalline domains. Crystallization may involve a crystal seeding process or use a system without crystal seeding (i.e., crystals form spontaneously). For example, using a crystal seeding process, crystals will be seeded in the stationary phase, and then rapidly grow in the stirred phase, increasing the degree of amorphous domains. Using this process, the resulting crystals may ultimately have good solubility. The resulting crystals will have high purity steviol glycoside (e.g., RebM), making recovery and washing easier. In the case of recrystallization, exemplary recrystallization solution systems may contain water, or in some embodiments, ethanol (e.g., 1:2 EtOH:H2O). In some embodiments, the recrystallization solution further contains glycerol (e.g., up to 2%). The pH of the solution used for recrystallization can vary, for example, from about 4.0 to about 12.0.

[0137] The solution can be filtered before recrystallization. Furthermore, the choice of filter material can significantly affect the quality of the final product. For example, Figure 13 compares the use of hydrophobic filter materials, e.g., polypropylene (PP), and relatively hydrophilic materials, e.g., polyethersulfone (PES), for filtering the solution before recrystallization (both with a pore size of 0.2 microns). The RebM final product (over 98%) is dissolved in propylene glycol at a concentration of 10 wt%. As shown in Figure 13, using a PP filter results in a fairly turbid solution (left side), while using a PES filter results in a clear solution (right side). Accordingly, PES filter materials and similar hydrophilic materials likely offer greater advantages in terms of impurity adsorption.

[0138] Understanding the thermodynamic and kinetic properties of crystallization systems is crucial for the proper design of industrial processes. For example, thermodynamic solubility represents the maximum concentration (saturation or solubility) that a solute can reach at a given temperature. The region above this solubility curve (see, for example, Figure 14) is supersaturated, and the region below is unsaturated. For crystallization to proceed, the solution must be supersaturated. One way to achieve supersaturation is to reduce the temperature of the saturated solution. However, in this situation, crystallization does not start immediately; rather, the system enters a metastable zone of supersaturated space with a given width. In this zone, there is no spontaneous nucleation, but crystallization can be initiated by adding a seed crystal. If no seed is added during cooling, the system will reach the edge of the metastable region, and beyond this point, spontaneous nucleation will occur. The higher the degree of supersaturation, the faster the nucleation rate will be. This has a significant impact on grain size and crystal growth rate. Therefore, knowing the solubility and the width of the metastable region makes it possible to design industrial crystallization processes that have a desirable crystal size distribution (CSD) and proceed at a practical rate. In the case of seedless crystallization, the solution must reach the edge of the metastable zone and slightly exceed it in order to begin crystallization without the adverse effects of excessive spontaneous nucleation (e.g., this results in the formation of very small crystals). As the process progresses, the concentration will return to the metastable region, but thereafter, supersaturation must be maintained throughout the crystallization process (by cooling, evaporation, etc.). In the case of seeded crystallization, it is important not to exceed the metastable region in order to avoid spontaneous nucleation, and the seed must be added so that the seed crystal begins nucleation without dissolving after the solution has saturated. In both seeded and seedless cases, understanding the thermodynamics and kinetics of the system makes it possible to design the rate of ascent (or evaporation rate) and nucleation point of the crystallization process.

[0139] To understand the solubility of RebM in various solvent systems and investigate the effects of solubility enhancement, we conducted research that enabled seeding and temperature reduction strategies for crystal formation and growth. In these studies, we used the Crystal 16 system (Crystalline Series) from Technobis Crystallization Systems to induce a clear point (as a substitute for solubility) during temperature increase and a cloud point (as a substitute for metastable region width) during temperature decrease. Various solvent systems were evaluated. TIFF2023550496000012.tif67165

[0140] Figure 14 shows the solubility (lower curve) and metastable limit curve (upper curve) that define the width of the metastable region, determined for RebM in water (pH 7.0, 0% glycerol), enabling control of crystal growth in this solvent system.

[0141] Figures 15A and 15B show the solubility (lower curve) and metastable limit curve (upper curve) that define the metastable zone width, determined for RebM in 67% water / 33% ethanol at pH 7, enabling control of crystal growth in this solvent system. Figure 15A is for 0% glycerol, while Figure 15B contains 0.5% glycerol.

[0142] Figures 16A and 16B show the solubility (lower curve) and metastable limit curve (upper curve) that define the metastable zone width for RebM in 67% water / 33% ethanol at pH 11, enabling control of crystal growth in this solvent system. Figure 16A is for 0% glycerol, while Figure 16B contains 0.5% glycerol.

[0143] In some embodiments, the recovery process may include one or more steps of tangential flow filtration (TFF). For example, a TFF with a filter with a pore size of approximately 5 kD can remove endotoxins, large proteins, and other cellular debris while also increasing the solubility of the final powder product. A TFF with a filter with a pore size of approximately 0.5 kD may also be used downstream to remove small molecule impurities and salts and / or to concentrate the mother liquor for recrystallization.

[0144] Washing in the basket-type centrifugal separation step may involve washing with water, or alternatively, other rinsing methods may be used. For example, cold water / ethanol (e.g., 15% ethanol) may improve cake quality. The mother liquor may be used as washing water or reprocessed.

[0145] Other processes that can be used include activated carbon treatment, bentonite treatment, ion exchange chromatography, and concentration by evaporation. In particular, activated carbon treatment after dissolving the wet cake in EtOH:H2O can improve the color of the final product.

[0146] Example 4: Bioconversion of mogrol or mogrol glycoside precursor The modified bacterial strains described herein can be used for glycosylation of various substrates, including terpenoid glycosides, but are not limited to these applications. In some embodiments, the present invention identifies active UGT enzymes on mogrol or mogroside scaffolds. Glycosylation pathways for generating various mogrosides are presented in Figure 22. Figures 17A and 17B show the bioconversion of mogrol to mogroside intermediates. Modified E. coli strains (chassis strains) expressing UGT enzymes were incubated with mogrol in 96-well plates. After 48 hours, product formation was tested. Reported values ​​were above the blank vector control. Products were measured by LC-MS / MS using standard materials. As shown in Figure 17A, both enzyme 1 (SEQ ID NO: 71) and enzyme 2 (SEQ ID NO: 33) UGT enzymes primarily produced Mog.IA from mogrol, with smaller amounts of Mog.IE and / or Mog.IIE formed. Figure 17B shows the bioconversion of mogrol to mogroside-IA using modified E. coli strains expressing enzyme 1 (SEQ ID NO: 71), enzyme 3 (SEQ ID NO: 33), enzyme 4 (SEQ ID NO: 82), and enzyme 5 (SEQ ID NO: 83).

[0147] Figures 18A and 18B illustrate the bioconversion of Mog.IA (Figure 18A) or Mog.IE (Figure 18B) to Mog.IIE. In the experiment, genetically modified E. coli chassis strains expressing the UGT enzyme, SEQ ID NO: 84, SEQ ID NO: 71, or SEQ ID NO: 33 were incubated at 37°C in fermentation medium containing Mog.IA (Figure 18A) or Mog.IE (Figure 18B) in a 96-well plate. After 48 hours, product formation was tested. The product was measured by LC-MS / MS using a standard substance. Mog.IIE levels above the blank vector control were calculated. As shown in Figure 18A, SEQ ID NO: 84 and SEQ ID NO: 71 were able to catalyze the bioconversion of Mog.IA to Mog.IIE. Similarly, as shown in Figure 18B, SEQ ID NO: 84, SEQ ID NO: 71, and SEQ ID NO: 33, they were able to catalyze the bioconversion of Mog.IE to Mog.IIE.

[0148] Figure 19 shows the production of Mog.III or siamenoside from Mog.II-E. In the experiment, modified E. coli strains expressing the UGT enzymes SEQ ID NO: 72, SEQ ID NO: 54, or SEQ ID NO: 13 were grown in fermentation medium containing Mog.II-E at 37°C for 48 hours. The products were quantified by LC-MS / MS using standards for each compound. As shown in Figure 19, all strains were capable of catalyzing the bioconversion of Mog.IIE to Mog.III. In addition, the enzyme SEQ ID NO: 13 also showed the production of a considerable amount of siamenoside.

[0149] Figure 20 shows the production of Mog.II-A2. Mog.IE was supplied in vitro. In the experiment, a modified E. coli strain (chassis strain) expressing the UGT enzyme SEQ ID NO: 73 was incubated at 37°C for 48 hours. The products were quantified by LC-MS / MS using standards for each compound. As shown in Figure 20, SEQ ID NO: 73 can catalyze the bioconversion of Mog.IE to Mog.II-A2.

[0150] Table 8 summarizes the primary glycosylation reactions observed with C3 and C24 hydroxyls of mogrol. Specifically, mogrol was supplied to cells expressing various UGT enzymes. The reaction mixture was incubated at 37°C for 48 hours. The products were quantified by LC-MS / MS using standards for each compound.

[0151] TIFF2023550496000013.tif139165

[0152] A summary of the branched glycosylation reaction is presented in Table 9. Mog.IIE or Mog.IE was supplied to cells expressing various UGT enzymes. The reaction mixture was incubated at 37°C for 48 hours. The products were quantified by LC-MS / MS using standards for each compound. "Indirect" evidence indicates that substrate consumption was observed. TIFF2023550496000014.tif167165

[0153] Embodiments of the present invention will now be defined with reference to the attached claims. array Sucrose synthase enzyme Sequence ID 1: Solanum tuberosum (StSus1) MAERVLTRVHSLERVDATLAAHRNEILLFLSRIESHGKGILKPHELLAEFDAIRQDDKNKLNEHAFEELLKSTQEAIVLPPWVALAIRLRPGVWEYIRVNVNALVVEELSVPEYLQFKEELVDGASNGNFVLELDFEPFTASFPKPTLTKSIGNGVEFLNRHLSAKMFHDKESMTPLLEFLRAHHYKGKTMMLNDRIQNS NTLQNVLRKAEEYLIMLPPETPYFEFEHKFQEIGLEKGWGDTAERVLEMVCMLLDLLEAPDSCTLEKFLGRIPMVFNVVILSPHGYFAQENVLGYPDTGGQVVYILDQVPALEREMLKRIKEQGLDIIPRILIVTRLLPDAVGTTCGQRIEKVYGAEHSHILRVPFRTEKGIVRKWISRFEVWPYMETFIEDVAKEISAEL QAKPDLIIGNYSEGNLAASLLAHKLGVTQCTIAHALEKTKYPDSDIYWKKFDEKYHFSSQFTADLIAMNHTDFIITSTFQEIAGSKDTVGQYESHMAFTMPGLYRVVHGINVFDPKFNIVSPGADINLYFSYSETEKRLTAFHPEIDELLYSDVENDEHLCVLKDRTKPILFTMARLDRVKNLTGLVEWYAKNPRLRGLVN LVVVGGDRRKESKDLEEQAEMKKMYELIETHNLNGQFRWISSQMNRVRNGELYRYIADTKGAFVQPAFYEAFGLTVVEAMTCGLPTFATNHGGPAEIIVHGKSGFHIDPYHGEQAADLLADFFEKCKKDPSHWETISMGGLKRIEEKYTWQIYSESLLTLAAVYGFWKHVSKLDRLEIRRYLEMFYALKYRKMAEAVPLAAE sequence number 2:Solanum tuberosum(StSus2) MAERVLTRVHSLRERLDATLAAHRNEILLFLSRIESHGKGILKPHQLLAEFESIHKEDKDKLNDHAFEEVLKSTQEAIVLPPWVALAIRLRPGVWEYVRVNVNALIVEELTVPEFLQFKEELVNGTSNDNFVLELDFEPFTASFPKPTLTKSIGNGVEFLNRHLSAKMFHDKESMTPLLEFLRVHHYKGKTMMLNDRIQNLYTLQKVLRKAEEYLTTLSPETSYSAFEHKFQEIGLERGWGDTAERVLEMICMLLDLLEAPDSCTLEKFLGRIPMVFNVVILSPHGYFAQENVLGYPDTGGQVVYILDQVPALEREMLKRIKEQGLDIKPRILIVTRLPDAVGTTCGQRLEKVFGTEHSHILRVPFRTEKGIVRKWISRFEVWPYMETFIEDVGKEITAEL QAKPDLIIGNYSEGNLAASLLAHKLGVTQCTIAHALEKTKYPDSIYLNKFDEKYHFSAQFTADLIAMNHTDFIITSTFQEIAGSKDTVGQYESHMAFTMPGLYRVVHGIDVFDKPFNIVSPGADVNLYFPYSEKEKRLTTFHPEIEDLLFSDVENEEHLCVLKDRNKPIIFTMARLDRWKNLTGLVEWYAKNPRLRELVN LVVVGGDRRKESKDLEEQAEMKKMYELIKTHNLNGQFRWISSQMNRVRNGELYRYIADTRGAFVQPAFYEAFGLTVVEAMSCGLPTFATNQGGPAEIIVHGKSGFQIDPYHGEQAADLLADFEKCKKVDPSHWEAISEGGLKRIQEKYTWQIYSDRLLTLAAVYGFWKHVSKLDRLEIRRYLEMFYALKFRKLAQLVPLAVE sequence number 3:Solanum tuberosum(StSus2_S11E) MAERVLTRVHELRERLDATLAAHRNEILLFLSRIESHGKGILKPHQLLAEFESIHKEDKDKLNDHAFEEVLKSTQEAIVLPPWVALAIRLRPGVWEYVRVNVNALIVEELTVPEFLQFKEELVNGTSNDNFVLELDFEPFTASFPKPTLTKSIGNGVEFLNRHLSAKMFHDKESMTPLLEFLRVHHYKGKTMMLNDRIQNLYTLQKVLRKAEEYLTTLSPETSYSAFEHKFQEIGLERGWGDTAERVLEMICMLLDLLEAPDSCTLEKFLGRIPMVFNVVILSPHGYFAQENVLGYPDTGGQVVYILDQVPALEREMLKRIKEQGLDIKPRILIVTRLLPDAVGTTCGQRLEKVFGTEHSHILRVPFRTEKGIVRKWISRFEVWPYMETFIEDVGKEITAELQAKPDLIIGNYSEGNLAASLLAHKLGVTQCTIAHALEKTKYPDSDIYLNKFDEKYHFSAQFTADLIAMNHTDFIITSTFQEIAGSKDTVGQYESHMAFTMPGLYRVVHGIDVFDPKFNIVSPGADVNLYFPYSEKEKRLTTFHPEIEDLLFSDVENEEHLCVLKDRNKPIIFTMARLDRVKNLTGLVEWYAKNPRLRELVNLVVVGGDRRKESKDLEEQAEMKKMYELIKTHNLNGQFRWISSQMNRVRNGELYRYIADTRGAFVQPAFYEAFGLTVVEAMSCGLPTFATNQGGPAEIIVHGKSGFQIDPYHGEQAADLLADFFEKCKVDPSHWEAISEGGLKRIQEKYTWQIYSDRLLTLAAVYGFWKHVSKLDRLEIRRYLEMFYALKFRKLAQLVPLAVE Accession number 4: Acidithiobacillus caldus (AcSuSy) MAIEALRQQLLDDPRSWYAFLRHLVASQRDSWLYTDLQRACADFREQLPEGYAEGIGPLEDFVAHTQEVIFRDPWMVFAWRPRPGRWIYVRIHREQLALEELSTDAYLQAKEGIVGLGAEGEAVLTVDFRDFRPVSRRLRDESTIGDGLTHLNRRLAGRIFSDLAAGRSQILEFLSLHRLDGQNLMLSNGNTDFDSLR QTVQYLGTLPRETPWAEIREDMRRRGFAPGWGNTAGRVRETMRLLMDLLDSPSPAALESFLDRIPMISRILIVSIHGWFAQDKVLGRPDTGGQVVYILDQARALEREMRNRLRQQGVDVEPRILIATRLIPESDGTTCDQRLEPVVGAENVQILRVPFRYPDGRIHPHWISRFKIWPWLERYAQDLEREVLAELGSRPD LIIGNYSDGNLVATLLSERLGVTQCNIAHALEKSKYLYSDLHWRDHEQDHHFACQFTADLIAMNAADIIVTSTYQEIAGNDREIGQYEGHQDYTLPGLYRVENGIDVFDSKFNIVSPGADPRFYFSYARTEERPSFLEPEIESLLFGREPGADRRGVLEDRQKPLLLSMARMDRIKNLSGLAELYGRSSRLRGLANLV IIGGHVDVGNSRDAEEREEIRRMHEIMDHYQLDGQLRWVGALLDKTVAGELYRVVADGRGVFVQPALFEEAFGLTVIEAMSSGLPVFATRFGGPLEIIEDGVSGFHIDPNDHEATAERLADFLEAARERPKYWLEISDAALARVAERYTWERYAERLMTIARIFGFWRFVLDRESQVMERYLQMFRHLQWRPLAHAVPME Sequence ID 5: Acidithiobacillus caldus (AcSuSy_L637M-T640V) MAIEALRQQLLDDPRSWYAFLRHLVASQRDSWLYTDLQRACADFREQLPEGYAEGIGPLEDFVAHTQEVIFRDPWMVFAWRPRPRGRWIYVRIHREQLALEELSTDAYLQAKEGIVGLGAEGEAVLTVDFRDFRPVSRRLRDESTIGDGLTHLNRRLAGRIFSDLAAGRSQILEFLSLHRLDGQNLMLSNGNTDFDSLR QTVQYLGTLPRETPWAEIREDMRRRGFAPGWGNTAGRVRETMRLLMDLLDSPSPAALESFLDRIPMISRILIVSIHGWFAQDKVLGRPDTGGQVVYYILDQARALEREMNRLRQQGVDVEPRILIATRLIPESDGTTTCDQRLEPVVGAENVQILRVPFRYPDGRIHPHWISRFKIWPWLERYAQDLEREVLAELGSRPD LIIGNYSDGNLVATLLSERLGVTQCNIAHALEKSKYLYSDLHWRDHEQDHHFACQFTADLIAMNAADIIVTSTYQEIAGNDREIGQYEGHQDYTLPGLYRVENGIDVFDSKFNIVSPGADPRFYFSYARTEERSFLEPEIESLLFGREPGADRRGVLEDRQKPLLLSMARMDRIKNLSGLAELYGRSSRLRGLANLVIIGGHVDVGNSRDAEEREEIRRMHEIMDHYQLDGQLRWVGALMDKVVAGELYRVVADGRGVFVQPALFEAFGLTVIEAMSSGLPVFATRFGGPLEIIEDGVSGFHIDPNDHEATAERLADFLEAARERPKYWLEISDAALARVAERYTWERYAERLMTIARIFGFWRFVLDRESQVMERYLQMFRHLQWRPLAHAVPME sequence number 6:Arabidopsis thaliana(AtSus1) MANAERMITRVHSQRERLNETLVSERNEVLALLSRVEAKGKGILQQNQIIAEFEALPEQTRKKLEGGPFFDLLKSTQEAIVLPPWVALAVRPRPGVWEYLRVNLHALVVEELQPAEFLHFKEELVDGVKNGNFTLELDFEPFNASIPRPTTLHKYIGNGVDFLNRHLSAKLFHDKESLLPLLKFLRLHSHQGKNLMLSEKIQNLNTLQHTLRKAEEYLAELKSETLYEEFEAKFEEIGLERGWGDNAERVLDMIRLLDLEAPDPCTLETFLGRVPMVFNVVILSPHGYFAQDNVLGYPDTGQVVYILDQVRALEIEMLQRIKQQGLNIKPRILILTRLPDAVGTTCGERLERVYDSEYCDILRVPFRTEKGIVRKWISRFEVWPYLETYTEDAAVELSKEL NGKPDLIIGNYSDGNLVASLLAHKLGVTQCTIAHALEKTKYPDSDIYWKKLDDKYHFSCQFTADIFAMNHTDFIITSTFQEIAGSKETVGQYESHTAFTLPGLYRVVHGIDVFDKPFNIVSPGADMSIYFPYTEEKRRLTKFHSEIEELLYSDVENKEHLCVLKDKKKPILFTMARLDRVKNLSGLVEWYGKNTRLRELL VVVGGDRRKESKDNEEKAEMKKMYDLIEEYKLNGQFRWISSQMDRVRNGELYRYICDTKGAFVQPALYAEAFGLTVVEAMTCGLPTFATCKGPAEIIVHGKSGFHIDPYHGDQAADTLADFTKCKEDPSHWDEISKGGLQRIEEKYTWQIYSQRLLTLTGVYGFWKHVSNLDRLEARRYLEMFYALKYRPLAQAVPLAQDD sequence number 7:Arabidopsis thaliana(AtSus3) MANPKLTRVLSTRDRVQDTLSAHRNELVALLSRYVDQGKGILQPHNLIDELESVIGDDETKKSLSDGPFGEILKSAMEAIVVPPFVALAVRPRPGVWEYVRVNVFELSVEQLTVSEYLRFKEELVDGPNSDPFCLELDFEPFNANVPRPSRSSSIGNGVQFLNRHLSSVMFRNKDCLEPLLDFLRVHKYKGHPLMLNDRIQSISRLQIQLSKAEDHISKLSQETPFSEFEYALQGMGFEKGWGDTAGRVLEMMHLLSDILQAPDPSSLEKFLGMVPMVFNVVILSPHGYFGQANVLGLPDTGGQVVYILDQVRALETEMLLRIKRQGLDISPSILIVTRLIPDAKGTTCNQRLERVSGTEHTHILRVPFRSEKGILRKWISRFDVWPYLENYAQDAASEIVGELQGVPDFIIGNYSDGNLVASLMAHRMGVTQCTIAHALEKTKYPDSDIYWKDFDNKYHFSCQFTADLIAMNNADFIITSTYQEIAGTKNTVGQYESHGAFTLPGLYRVVHGIDVFDPKFNIVSPGADMTIYFPYSEETRRLTALHGSIEEMLYSPDQTDEHVGTLSDRSKPILFSMARLDKVKNISGLVEMYSKNTKLRELVNLVVIAGNIDVNKSKDREEIVEIEKMHNLMKNYKLDGQFRWITAQTNRARNGELYRYIADTRGAFAQPAFYEAFGLTVVEAMTCGLPTFATCHGGPAEIIEHGLSGFHIDPYHPEQAGNIMADFFERCKEDPNHWKKVSDAGLQRIYERYTWKIYSERLMTLAGVYGFWKYVSKLERRETRRYLEMFYILKFRDLVKTVPSTADD Accession number 8: Vigna radiate (VrSS1) MATDRLTRVHSLRERLDETLSANRNEILALLSRIEGKGKGILQHHQVIAEFEEIPEESRQKLTDGAFGEVLRSTQEAIVLPPWVALAVRPRPGVWEYLRVNVHALVVEVLQPAEYLRFKEELVDGSSNGNFVLELDFEPFTASFPRPTLNKSIGNGVQFLNRHLSAKLFHDKESLHPLLEFLRLHSVKGKTLMLNDRIQNPDALQHVLRKAEEYLGTVPPETPYSAFEHKFQEIGLERGWGDNAERVLESIQLLLDLLEAPDPCTLETFLGRIPMVFNVVILSPHGYFAQDNVLGYPDTGGQVVYILDQVRALENEMLHRIKQQGLDIVPRILIITRLLPDAVGTTCGQRLEKVFGTEHSHILRVPFRTENGIVRKWISRFEVWPYLETYTEDVAHELAKELQGKPDLIVGNYSDGNIVASLLAHKLGVTQCTIAHALEKTKYPESDIYWKKLEERYHFSCQFTADLFAMNHTDFIITSTFQEIAGSKDTVGQYESHTAFTLPGLYRVVHGIDVFDPKFNIVSPGADQTIYFPHTETSRRLTSFHTEIEELLYSSVENEEHICVLKDRSKPIIFTMARLDRVKNITGLVEWYGKNAKLRELVNLVVVAGDRRKESKDLEEKAEMKKMYSLIETYKLNGQFRWISSQMNRVRNGELYRVIADTKGAFVQPAVYEAFGLTVVEAMTCGLPTFATCNGGPAEIIVHGKSGFHIDPYHGDRAADLLVEFFEKVKVDPSHWDKISQAGLQRIEEKYTWQIYSQRLLTLTGVYGFWKHVSNLDRRESRRYLEMFYALKYRKLAESVPLAVE Sequence number 9: Vigna radiate (VrSS1_S11E) MATDRLTRVHELRERLDETLSARNNEILALLSRIEGKGKGILQHHQVIAEFEEIPEESRQKLTDGAFGEVLRSTQEAIVLPPWVALAVRPRPGVWEYLRVNVHALVVEVLQPAEYLRFKEELVDGSSNGNFVLELDFEPFTASFPRPTLNKSIGNGVQFLNRHLSAKLFHDKESLHPLLEFLRLHSVKGKTLMLNDRIQNP DALQHVLRKAEEYLGTVPPETPYSAFEHKFQEIGLERGWGDNAERVLESIQLLLDLLEAPDPCTLETFLGRIPMVFNVVILSPHGYFAQDNVLGYPDTGGQVVYILDQVRALENEMLHRIKQQGLDIVPRILIITRLLPDAVGTTCGQRLEKVFGTEHSHILRVPFRTENGIVRKWISRFEVWPYLETYTEDVAHELAKEL QGKPDLIVGNYSDGNIVASLLAHKLGVTQCTIAHALEKTKYPESDIYWKKLEERYHFSCQFTADLFAMNHTDFIITSTFQEIAGSKDTVGQYESHTAFTLPGLYRVVHGIDVFDPKFNIVSPGADQTIYFPHTETSRRLTSFHTEIEELLYSSVENEEHICVLKDRSKPIIFTMARLDVRVKNITGLVEWYGKNAKLRELVNLVVVAGDRRKESKDLEEKAEMKKMYSLIETYKLNGQFRWISSQMNRVRNGLEYRVIADTKGAFVQPAVYEAFGLTVVEAMTCGLPTFATCNGGPAEIIVHGKSGFHIDPYHGDRAADLLVEFFEKVKVDPSHWDKISQAGLQRIEEKYTWQIYSQRLLTLTGVYGFWKHVSNLDRRESRRYLEMFYALKYRKLAESVPLAVE SEQ ID NO:10:Glycine Max(GmSS) MATDRLTRVHSLRERLDETLTANRNEILALLSRIEAKGKGILQHHQVIAEFEEIPEENRQKLTDGAFGEVLRSTQEAIVLPPWVALAVRPRPGVWEYLRVNHALVVEELQPAEYLHFKEELVDGSSNGNFVLELDFEPFNAAFPRPTLNKSIGNGVQFLNRHLSAKLFHDKESLHPLLEFLRLHSVKGKTLMLNDRIQNP DALQHVLRKAEEYLGTVPPETPYSEFEHKFQEIGLERGWGDNAERVLESIQLLLDLLEAPDPCTLETFLGRIPMVFNVVILSPHGYFAQDNVLGYPDTGGQVVYILDQVRALENEMLHRIKQQGLDIVPRILIITRLLPDAVGTTCGQRLEKVFGTEHSHILRVPFRTEKGIVRKWISRFEVWPYLETYTEDVAHELAKEL QGKPDLIVGNYSDGNIVASLLAHKLGVTQCTIAHALEKTKYPESDIYWKKLEERYHFSCQFTADLFAMNHTDFIITSTFQEIAGSKDTVGQYESHTAFTLPGLYRVVHGIDVFDPKFNIVSPGADQTIYFPHTETSRRLTSFHPEIEELLYSSVENEEHICVLKDRSKPIIFTMARLDVRVKNITGLVEWYGKNAKLRELVNLVVVAGDRRKESKDLEEKAEMKKMYGLIETYKLNGQFRWISSQMNRVRNGLEYRVICDTRGAFVQPAVYEAFGLTVVEAMTCGLPTFATCNGGPAEIIVHGKSGFHIDPYHGDRAADLLVDFFEKCKLDPTHWDKISKAGLQRIEEKYTWQIYSQRLLTLGVYGFWKHVSNLDRRESRRYLEMFYALKYRKLAESVPLAAE sequence number 11:Glycine Max(GmSS_S11E) MATDRLTRVHELRERLDETLTANRNEILALLSRIEAKGKGILQHHQVIAEFEEIPEENRQKLTDGAFGEVLRSTQEAIVLPPWVALAVRPRPGVWEYLRVNVHALVVEELQPAEYLHFKEELVDGSSNGNFVLELDFEPFNAAFPRPTLNKSIGNGVQFLNRHLSAKLFHDKESLHPLLEFLRLHSVKGKTLMLNDRIQNPDALQHVLRKAEEYLGTVPPETPYSEFEHKFQEIGLERGWGDNAERVLESIQLLLDLLEAPDPCTLETFLGRIPMVFNVVILSPHGYFAQDNVLGYPDTGGQVVYILDQVRALENEMLHRIKQQGLDIVPRILIITRLLPDAVGTTCGQRLEKVFGTEHSHILRVPFRTEKGIVRKWISRFEVWPYLETYTEDVAHELAKELQGKPDLIVGNYSDGNIVASLLAHKLGVTQCTIAHALEKTKYPESDIYWKKLEERYHFSCQFTADLFAMNHTDFIITSTFQEIAGSKDTVGQYESHTAFTLPGLYRVVHGIDVFDPKFNIVSPGADQTIYFPHTETSRRLTSFHPEIEELLYSSVENEEHICVLKDRSKPIIFTMARLDRVKNITGLVEWYGKNAKLRELVNLVVVAGDRRKESKDLEEKAEMKKMYGLIETYKLNGQFRWISSQMNRVRNGELYRVICDTRGAFVQPAVYEAFGLTVVEAMTCGLPTFATCNGGPAEIIVHGKSGFHIDPYHGDRAADLLVDFFEKCKLDPTHWDKISKAGLQRIEEKYTWQIYSQRLLTLTGVYGFWKHVSNLDRRESRRYLEMFYALKYRKLAESVPLAAE Accession number 12: Anabaena sp. (AsSusA) MASELMQAILDSEEKHDLRGFISELRQQDKNYLLRNDILNVYAEYCSKCQKPETSYKFSNLSKLIYYTQEIIPEDSNFCFIIRPKIAAQEVYRLTADLDVEPMTVQELLDLRDRLVNKFHPYEGDILELDFGPFYDYTPTIRDPKNIGKGVQYLNRYLSSKLFQDSQQWLESLFNFLRLHNYNGIQLLINHQIQSQQQLSQQVKNALNFVSDRPNDEPYEQFRLQLQTMGFEPGWGNTASRVRDTLNILDELIDSPDPQTLEAFISRIPMIFRIVLVSAHGWFGQEGVLGRPDTGGQVVYVLDQAKNLEKQLQEDAILAGLEVLNVQPKVIILTRLIPNSDGTLCNQRLEKVYGTENAWILRVPLREFNPKMTQNWISRFEFWPYLETFAIDSERELLAEFQGRPDLIVGNYTDGNLVAFLLTRRMKVTQCNIAHALEKSKYLFSNLYWQDLEEKYHFSLQFTADLIAMNAANFVISSTYQEIVGTPDSIGQYESYKCFTMPELYHVVNGIELFSPKFNVVPPGVNENSYFPYTQTQNRIESDRDRLEEMLFTLEDSSQIFGKLDDPNKRPIFSMARLDRIKNLTGLAECFGQSQELQERCNLILVAGKLRIEESEDNEEKDEIVKLYRIIDEYNLHGKIRWLGVRLSKNDSGEIYRVICDRQGIFVQPALFEAFGLTILESMISGLPTFATQFGGPLEIIQDKINGFYINPTHLEETATKILDFVTKCEQNPNYWNIISEKAIDRVYSTYTWKIHTTKLLTLARIYGFWNFTSKEKREDLLRYLESLFYLIYKPRAQQLLEQHKYR Uridine diphosphate-dependent glycosyltransferase (UGT) SEQ ID NO: 13: Synthesis (MbUGT1,2.2) MATKGSSGMSLAERFWLTLSRSSLVVGRSCVEFEPETVPLLSTLRGKPITFLGLMPPLHEGRREDGEDATVRWLDAQPAKSVVYVALGSEVPLGVEKVHELALGLELAGTRFLWALRKPTGVSDADLLPAGFEERTRGRGVVATRWVPQMSILAHAAVGAFLTHCGWNSTIEGLMFGHPLIMLPIFGDQGPNARLIEAKNAGLQVARNDDGGSDFDREGVAAAIRAVAVEEE SSKVFQAKAKKLQEIVADMACHERYIDGFIQQLRSYKDDSGYSSSYAAAAGMHVVICPWLAFGHLLPCLDLAQRLASRGHRVSFVSTPRNISRLPPVRPLAPLVAFVALPLPRVEGLPDGAESTNDVPHDRPDMVELHRRAFDGLAAPFSEFLGTACADWVIVDVFHHWAAAAAALEHKVPCAMMLLGSAEMIASIADERLEHAETESPAAAGQGRPAAAPTFEVARMKLIR sequent number 14: gössét(MbUGT1,2.3) MATKNSSGMSLAERFWLTLSRSSLVVGRSCVEFEPETVPLLSTLRGKPITFLGLMPPLHEGRREDGEDATVRWLDAQPAKSVVYVALGSEVPLGVEKVHELALGLELAGTRFLWALRKPTGVSDADLLPAGFEERTRGRGVVATRWVPQMSILAHAAVGAFLTHCGWNSTIEGLMFGHPLIMLPITDGDQGPNARLIEAKNAGLQVARNDDGSFDREGVAAAIRAVAVEEE SSKVFQAKAKKLQEIVADMACHERYIDGFIQQLRSYKDDSGYSSSYAAAAGMHVVICPWLAFGHLLPCLDLAQRLASRGHRVSFVSTPRNISRLPPVRPLAPLVAFVALPLPRVEGLPDGAESTNDVPHDRPDMVELHRRAFDGLAAPFSEFLGTACADWVIVDSFHHWAAAAAALEHKVPCAMMLLGSAEMIASIADERLEHAETESPAAAGQGRPAAAPTFEVARMKLIR Sequence ID 15: Synthesis (MbUGT1,2.4) MARRTKNSSGMSLAERFWLTLSRSSLVVGRSCVEFEPETVPLLSTLRGKPITFLGLMPPLPEGRREDGEDATVRWLDAQPAKSVVYVALGSEVPLGVEKVHELALGLELAGTRFLW ALRKPTGVSDADLLPAGFEERTRGRGVVATRWVPQMSILAHAAVGAFLTHCGWNSTIEGLMFGPHPLIMLPITGDQGPNARLIEAKNAGLQVARNDGDGSFDREGVAAAIRAVAVEE ESSKVFQEKAKKLQEIVADMACHERYIDGFIQQLRSYKDDSGYSSSYAAAAGMHVVICPWLAFGHLLPCLDLAQRLASRGHRVSFVSTPRNISRLPPVRPALAPLVAFVALPLPRV EGLPDGAESTNDVPHDRPDMVELHRRAFDGLAAPFSEFLGTACADWVIVDSFHHWAAAAALEHKVPCAMMFLGSAEMIASIADERLEHAETESPAAAGQGRPAAAPTFEVARMKLIR Sequence ID 16: Synthesis (MbUGT1,2.5) MARRTKNSSGMSLAERFWLTLSRSSLVVGRSCVEFEPETVPLLSTLRGKPITFLGLMPPLPEGRREDGEDATVRWLDAQPAKSVVYVALGSEVPLGVEKVHELALGLELAGTRFLWALRKPTGVSDADLLPAGFEERTRGRGVVATRWVPQAAILAHAAVGAFLTHCGWNSTIEGLMFGHPLIMLPITGDQGPNARLIEAKNAGLQVARNDGDGSFDREGVAAIRAVAVEE ESSKVFQEKAKKLQEIVADMACHERYIDGFIQQLRSYKDDSGYSSSYAAAAGMHVVICPWLAFGHLLPCLDLAQRLASRGHRVSFVSTPRNISRLPPVRPLAPLVAFVALPLPRVEGLPDGAESTNDVPHDRPDMVELHRRAFDGLAAPFSEFLGTACADWVIVDSFHHWAAAAAALEHKVPCAMMFLGSAEMIASIADERLEHAETESPAAAGQGRPAAAPTFEVARMKLIR SEQ ID NO:17:SrUGT85C2(Stevia rebaudiana) MDAMATTEKKPHVIFIPFPAQSHIKAMLKLAQLLHHKGLQITFVNTDFHIHNQFLESSGPHCLDGAPGFRFETIPDGVSHSPEASIPIRESLLRSIETNFLDRFIDLVTKLPDPPTCIISDGFLSVFTIDAAKKLGIPVMMYWTLAACGFMGFYHIHSLIEKGFAPLKDASYLTNGYLDTVIDWVPGMEGIRLKDFPLDWSTDLNDKVLMFTTEAPQRSHKVSHIFHTFDELEPSIIKTL SLRYNHIYTIGPLQLLLDQIPEEKKQTGITSLHGYSLVKEEPECFQWLQSKEPNSVVYVNFGSTTVMSLEDMTEFGWGLANSNHYFLWIIRSNLVIGENAVLPPELEEHIKKRGFIASWCSQEKVLKHPSVGGFLTHCGWGSTIESLSAGVPMICWPYSWDQLTNCRYICKEWEVGLEMGTKVKRDEVKRLVQELMGEGGHKMRNKAKDWKEKARIAIAPNGSSSLNIDKMVKEITVLARN sequence number 18:SrUGT74G1(Stevia rebaudiana) MAEQQKIKKSPHVLLIPFPLQGHINPFIQFGKRLISKGVKTTLVTTIHTLNSTLNHSNTTTTSIEIQAISDGCDEGGFMSAGESYLETFKQVGSKSLADLIKKLQSEGTTIDAIIYDSMTEWVLDVAIEFGIDGGSFFTQACVVNSLYYHVHKGLISLPLGETVSVPGFPVLQRWETPLILQNHEQIQSPWSQMLFGQFANIDQARWVFTNSFYKLEEEVIEWTRKIWNL KVIGPTLPSMYLDKRLDDDKDNGFNLYKANHECMNWLDDKPKESVVYVAFGSLVKHGPEQVEEITRALIDSDVNFLWVIKHKEEGKLPENLSEVIKTGKGLIWAWCKQLDVLAHESVGCFVTHCGFNSTLEAISLGVPVAMPQFSDQTTNAKLLDEILGVGVRVKADENGIVRRGNLASCIKMIMEEERGVIIRKNAVKWKDLAKVAHGSSDNDIVEFVSELIKA sequence number 19:SrUGT76G1(Stevia rebaudiana) MENKTETTVRRRRRIILFPPVPFQGHINPILQLANVLYSKGFSITIFHTFNNKPKTSNYPHFTFRFILDNDPQDERISNLPTHGPLAGMRIPIINEHGADELRRELELLMLASEEDEEEVSCLITDALWYFAQSVADSLNRRLVLMTSSLFNFHAHVSLPQFDELGYLDPDDKTRLEEQASGFPMLKVKDIKSAYSNWQILKEILGKMIKQTKASSGVIWNSFKELEESE LETVIREIPAPSFLIPLPKHLTASSSSLLHDRTVFQWLDQQPPSSVLYVSFGSTSEVDEKDFLEIARGLVDSKQSFLWVVRPGFVKGSTWVEPLPDGFLGERGRIVKWVPQQEVLAHGAIGAFWTHSGWNSTLESVCEGVPMIFSDFGLDQPLNARYMSDVLKVGVYLENGWERGEIANAIRVMVDEEGEYIRQNARVLKQKADVSLMKGGSSYESLVSYSSL Sequence ID 20: Synthesis (MbUGT1-3) MANWQILKEILGKMIKQTKASSGVIWNSFKELEESELETVIREIPAPSFLIPLPKHLTASSSSLLDHDRTVFQWLDQQPPSSVLYVSFGSTSEVDEKDFLEIARGLVDSKQSFL WVVRPGFVKGSTWVEPLPDGFLGERGRIVKWVPQQEVLAHGAIGAFWTHSGWNSTLESVCEGVPMIFSDFGLDQPLNARYMSDVLKVGVYLENGWERGEIANAIRRVMVDEEGEY IRQNARVLKQKADVSLMKGGSSYESLESLVSYISSLENKTETTVRRRRRIILFPVPFQGHINPILQLANVLYSKGFSITIFHTNFNKPKTSNYPHFTFRFILDNDPQDERISNLP THGPLAGMRIPIINEHGADELRRELELLMLASEEDEEVSCLITDALWYFAQSVADSLNLRRLVLMTSSLFNFHAHVSLPQFDELGYLDPDDKTRLEEQASGFPMLKVKDIKSAYS Sequence ID 21: UGT76G1_L200A (Stevia rebaudiana, L200A) MAENKTETTVRRRRRIILFPVPFQGHINPILQLANVLYSKGFSITIFHTNFNKPKTSNYPHFTFRFILDNDPQDERISNLPTHGPLAGMRIPIINEHGADELRRELELLMLASE EDEEVSCLITDALWYFAQSVADSLNLRRLVLMTSSLFNFHAHVSLPQFDELGYLDPDDKTRLEEQASGFPMLKVKDIKSAYSNWQIAKEILGKMIKQTKASSGVIWNSFKELEES ELETVIREIPAPSFLIPLPKHLTASSSSLLDHDRTVFQWLDQQPPSSVLYVSFGSTSEVDEKDFLEIARGLVDSKQSFLWVVRPGFVKGSTWVEPLPDGFLGERGRIVKWVPQQE VLAHGAIGAFWTHSGWNSTLESVCEGVPMIFSDFGLDQPLNARYMSDVLKVGVYLENGWERGEIANAAIRRVMVDEEGEYIRQNARVLKQKADVSLMKGGSSYESLESLVSYISSL Sequence ID 22: Synthesis (MbUGT1-3_0) MAKQSFLWVVRPGFVKGSTWVEPLPDGFLGERGRIVKWVPQQEVLAHGAIGAFWTHSGWNSTLESVCEGVPMIFSDFGLDQPLNARYMSDVLKVGVYLENGWERGEIANAIRRV MVDEEGEYIRQNARVLKQKADVSLMKGGSSYESLESLVSYISSLENKTETTVRRRRRIILFPVPFQGHINPILQLANVLYSKGFSITIFHTNFNKPKTSNYPHFTFRFILDDNDPQ DERISNLPTHGPLAGMRIPIINEHGADELRRELELLMLASEEDEEVSCLITDALWYFAQSVADSLNLRRLVLMTSSLFNFHAHVSLPQFDELGYLDPDDKTRLEEQASGFPMLKV KDIKSAYSNWQIAKEILGKMIKQTKASSGVIWNSFKELEESELETVIREIPAPSFLIPLPKHLTASSSSLLDHDRTVFQWLDQQPPSSVLYVSFGSTSEVDEKDFLEIARGLVDS Sequence ID 23: Synthesis (MbUGT1-3_1) MAFLWVVRPGFVKGSTWVEPLPDGFLGERGRIVKWVPQQEVLAHGAIGAFWTHGGWNSTLESVCEGVPMIFSDFGLDQPLNARYMSDVLKVGVYLENGWERGEIANAIRRLMVD EEGEYIRQNARVLKQKADVSLMKGGSSYESLESLVSYISSLGSGGSGGSGRRRRIILFPVPFQGHINPMLQLANVLYSKGFSITIFHTNFNKPKTSNYPHFTFRFILDNDPQDER ISNLPTHGPLAGMRIPIINEHGADELRRELELLMLASEEDEEVSCLITDALWYFAQSVADSLNLRRLVLMTSSLFNFHAHVSLPQFDELGYLDPDDKTRLEEQASGFPMLKVKD IKSAYSNWQIAKEILGKMIKQTKASSGVIWNSFKELEESELETVIREIPAPSFLIPLPKHLTASSSSLLDHDRTVFQWLDQQPPSSVLYVSFGSTSEVDEKDFLEIARGLVDSQS Sequence ID 24: Synthesis (MbUGT1-3_2) MAFLWVVRPGFVKGSTWVEPLPDGFLGERGRIVKWVPQQEVLAHGAIGAFWTHGGWNSTLESVCEGVPMIFSDFGLDQPLNARYMSDVLKVGVYLENGWERGEIANAIRRLMV DEEGEYIRQNARVLKQKADVSLMKGGSSYESLESLVSYISSLGSGGSGRRRRIILFPPVPFQGHINPMLQLANVLYSKGFSITIFHTNFNKPKTSNYPHFTFRFILDNDPQDERI SNLPTHGPLAGMRIPIINEHGADELRRELELQMLASEEDEEVSCLITDALWYFAQSVADSLNLPRLVLMTSSLFNFHAHVSLPQFDELGYLDPDDKTRLEEQASGFPMLKVKDI KSAYSNWQIAKEILGKMIKQTKASSGVIWNSFKELEESELETVIREIPAPSFLIPLPKHLTASSSSLLEHDRTVFQWLDQQPPSSVLYVSFGSTSEVDEKDFLEIARGLVDSQS Sequence ID 25: Synthesis (MbUGT1-3_3) MAFLWVVRPGFVKGSTWVEPLPDGFLGERGRIVKWVPQQEVLAHGAIGAFWTHGGWNSTLESVCEGVPMIFQDFGLDQPLNARYMSDVLKVGVYLENGWERGEIANAIRRL MVDEEGEYIRQNARVLKQKADVSLMKGGSSYESLESLVSYISSLGSGGSGRRRRIILFPPVFQGHINPMLQLANVLYSKGFSITIFHTNFNKPKTSNYPHFTFRFILDNDNPQ DHGPLAGMRIPIINEHGADELRRELELQMLASEEDEEVSCLITDALWYFAQSVADSLNLPRLVLMTSSLFNFHCHVSLPQFDELGYLDPDDKTRLEEQASGFPMLKVKDIKS AFSNWQIAKEILGKMIKQTKASSGVIWNSFKELEESELETVIREIPAPSFLIPLPKHLTASSSSLLEHDRTVFQWLDQQPPSSVIYVSFGSTSEVDEKDFLEIARGLVDSQS SEQ ID NO:26:SrUGT91D1(Stevia rebaudiana) MYNVTYHQNSKAMATSDSIVDDRKQLHVATFPWLAFGHILPFLQLSKLIAEKGHKVSFLSTTRNIQRLSSHISPLINVVQLTLPVRQELPEDAEATTDVHPEDIQYLKKAVDGLQPEVTRFLEQHSPDWIIYDFTHYWLPSIAASLGISRAYFCVITPWTIAYLAPSSDAMINDSDGRTTVEDLTTPPPKWFPFPTKVCWRKHDLARMEPYEAPGISDGYRMGMVFKGSDCLLFKCYHEFGTQ WLPLLETLHQVPVVPGLLPPEIPGDEKDETWVSIKKWLDGKQKGSVVYVALGSEALVSQTEVVELALGLELSGLPFVWAYRKPKGPAKSDSVELPDGFVERTRDRGLVWTSWAPQLRILSHESVCGFLTHCGSGSIVEGLMFGHPLIMLPIFCDQPLNARLLEDKQVGIEIPRNEEDGCLTKESVARSVVVENEGEIYKANARALSKIYNDTKVEKEYVSQFVDYLEKNARAVAIDHES SEQ ID NO:27:SrUGT91D2(Stevia rebaudiana) MATSDSIVDDRKQLHVATFPWLAFGHILPYLQLSKLIAEKGHKVSFLSTTRNIQRLSSHISPLINVVQLTLPRVQELPEDAEATTDVHPEDIPYLKKASDGGLPEVTRFLEQHSPDWIIYDYTHYWLPSIASLGISRAHFSVTTPWAIAYMGPSADAMINGSDGRTTVEDLTTPPKWFPFPTKVCWRKHDLARLVPYKAPGISDGYRMGLVLKGSDLLSKCYHEFGTQWLPLLE TLHQVPVVPGLLPPEVPGDETKETWVSIKKWLDGKQKGSVVYVALGSEVLVSQTEVVELALGLELSGLPFVWAYRKPKGPAKSDSVELPDGFVERTRDRGLVWTSWAPQLRILSHESVCGFLTHCGSGSIVEGLMFGHPLIMLPIFGDQPLNARLLEDKQVGIEIPRNEEDGCLTKESVARSVVVKEGEIYKANARELSKIYNDTKVEKEYVSQFVDYLEKNTRAVAIDHES sequence number 28:SrUGT91D2e(Stevia rebaudiana) MATSDSIVDDRKQLHVATFPWLAFGHILPYLQLSKLIAEKGHKVSFLSTTRNIQRLSSHISPLINVVQLTLPRVQELPEDAEATTDVHPEDIPYLKKASDGGLPEVTRFLEQHSPDWIIYDYTHYWLPSIASLGISRAHFSVTTPWAIAYMGPSADAMINGSDGRTTVEDLTTPPKWFPFPTKVCWRKHDLARLVPYKAPGISDGYRMGLVLKGSDLLSKCYHEFGTQWLPLLE TLHQVPVVPGLLPPEIPGDEKDETWVSIKKWLDGKQKGSVVYVALGSEVLVSQTEVVELALGLELSGLPFVWAYRKPKGPAKSDSVELPDGFVERTRDRGLVWTSWAPQLRILSHESVCGFLTHCGSGSIVEGLMFGHPLIMLPIFGDQPLNARLLEDKQVGIEIPRNEEDGCLTKESVARSLRSVVVEKEGEIYKANARELSKIYNDTKVEKEYVSQFVDYLEKNARAVIDHES SEQ ID NO:29:OsUGT1-2(Oryza sativa) MDSGYSSSYAAAAGMHVVICPWLAFGHLLPCLDLAQRLASRGHRVSFVSTPRNISRLPPVRRPALAPLVAFVALPLPRVEGLPDGAESTNDVPHDRPDMVELHRRAFDGLAAPFSEFLGTACADWVIVDVFHHWAAAAAALEHKVPCAMMLLGSAHMIASIADRRLERAETESPAAAGQGRPAAAPTFEVARMKLIRTKGSSGMSLAERFSLTLSRSSLVVGRSCVEFEPETV PLLSTLRGKPITFLGLMPPLHEGRREDGEDATVRWLDAQPAKSVVYVALGSEVPLGVEKVHELALGLELAGTRFLWALRKPTGVSDADLLPAGFEERTRGRGVVATRWVPQMSILAHAAVGAFLTHCGWNSTIEGLMFGHPLIMLPIFDGDQGPNARLIEAKNAGLQVARNDGDGSFDREGVAAIRAVAVEEESSKVFQAKAKKLQEIVADMACHERYIDGFIQQLRSYKD sequence number 30: gössé(MbUGTC19) MAECMNWLDDKPKESVVYVAFGSLVKHGPEQVEEITRALIDSDVNFLWVIKHKEEGKLPENLSEVIKTKGLIWAWCKQLDVLAHESVGCVTHCGFNSTLEAISLWGVPVAMPQFSDQTTNAKLLDEILGVGVRVKADENGIVRGNLASCIKMIMEEERGVIIRKNAVKWKDLAKVAVHEGSSDNDIVEFVSELIKAGSGEQQKIKKSPHLIPPLQGHINPFIQF GKRLISKGVKTTLVTTIHTNLNSTLNHSNTTTTSIEIQAISDGCDEGGFMSAGESYLETFKQVGSKSLADLIKKLQSEGTTIADAIIYDSMTEWVLDVAIEFGIDGGSFFTQACVVNSLYYHVHKGLISLPLGETVSVPGFPVLQRWETPLILQNHEQIQSPWSQMLFGQFANIDQARWVFTNSFYKLEEEVIEWTRKIWNLKVIGPTLPSMYLDKRLDDDKDNGFNLYKANHH Sequence ID 31: Synthesis (MbUGTC19-2) MANHHECMNWLDDKPKESVVYVAFGSLVKHGPEQVEEITRALIDSDVNFLWVIKHKEEGKLPENLSEVIKTGKGLIVAWCKQLDVLAHESVGCFVTHCGFNSTLEAISLGVPVVA MPQFSDQTTNAKLLDEILGVGVRVKADENGIVRRGNLASCIKMIMEEERGVIIRKNAVKWKDLAKVAVHEGGSSSDNDIVEFVSELIKAGSGEQQKIKKSPHVLLIPFPLQGHINPF IQFGKRLISKGVKTTLVTTIHTLNSTLNHSNTTTTSIEIQAISDGCDEGGFMSAGESYLETFKQVGSKSLADLIKKLQSEGTTIDAIIYDSMTEWVLDVAIEFGIDGGSFFTQACV VNSLYYHVHKGLISLPLGETVSVPGFPVLQRWETPLILQNHEQIQSPWSQMLFGQFANIDQARWVFTNSFYKLEEEVIEWTRKIWNLKVIGPTLPSMYLDKRLDDDKDNGFNLYKA Sequence ID 32: MbUGTC13 (Stevia rebaudiana UGT85C2, P215T) MADAMATTEKKPHVIFIPFPAQSHIKAMLKLAQLLHHKGLQITFVNTDFHIHNQFLESSGPHCLDGAPGFRFETIPDGVSHSPEASIPIRESLLRSIETNFLDRFIDLVTKLPDPPTCIISDGFLSVFTIDAAKKLGIPVMMYWTLAACGFMGFYHIHSLIEKGFAPLKDASYLTNGYLDTVIDWVPGMEGIRLKDFPLDWSTDLNDKVLMFTTEATQRSHKVSHIFHTFDELEPSIIKTL SLRYNHIYTIGPLLLDQIPEEKKQTGITSLHGYSLVKEEPECFQWLQSKEPNSVVYVNFGSTTVMSLEDMTEFGWGLANSNHYFLWIIRSNLVIGENAVLPPLEEEHIKKRGFIASWCSQEKVLKHPSVGGFLTHCGWGSTIESLSAGVPMICWPYSWDQLTNCRYICKEWEVGLEMGTKVKRDEVKRLVQELMGEGGHKMRNKAKDWKEKARIAIAPNGSSSLNIDKMVKEITVLARN SEQ ID NO:33:SgUGT720-269-1(Siraitia grosvenorii) MEDRNAMDMSRIKYRPQPLRPASMVQPRVLLFPFPALGHVKPFLSLAELLSDAGIDVVFLSTEYNHRRISNTEALASRFPTLHFETIPDGLPPNESRALADGPLYFSMREGTKPRFRQLIQSLNDGRWPITCIITDIMLSSPIEVAEEFGIPVIAFCPCSARYLSIHFFIPKLVEEGQIPYADDDPIGEIQGVPLFEGLLRRNHLPGSWSDKSADISFSHGLINQTLAAGRASALILNTFDELEAPFLTHLSSIFNKIYTIGPLHALSKSRLGDSSSSASALSGFWKEDRACMSWLDCQPPRSVVFVSFGSTMKMKADELREFWYGLVSSGKPFLCVLRSDVVSGGEAAELIEQMAEEEGAGGKLGMVVEWAAQEKVLSHPAVGGFLTHCGWNSTVESIAAGVPMMCWPILGDQPSNATWIDRVWKIGVERNNREWDRLTVEKMVRALMEGQKRVEIQRSMEKLSKLANEKVVRGINLHPTISLKKDTPTTSEHPRHEFENMRGMNYEMLVGNAIKSPTLTKK Accession number 34: SgUGT94-289-3 (Siraitia grosvenorii) MTIFFSVEILVLGIAEFAAIAMDAAQQGDTTTILMLPWLGYGHLSAFLELAKSLSRRNFHIYFCSTSVNLDAIKPKLPSSFSDSIQFVELHLPSSPEFPPHLHTTNGLPPTLMPALHQAFSMAAQHFESILQTLAPHLLIYDSLQPWAPRVASSLKIPAINFNTTGVFVISQGLHPIHYPHSKFPFSEFVLHNHWKAMYSTADGASTERTRKRGEAFLYCLHASCSVILINSFRELEGKYMDYLSVLLNKKVVPVGPLVYEPNQDGEDEGYSSIKNWLDKKEPSSTVFVSFGSEYFPSKEEMEEIAHGLEASEVNFIWVVRFPQGDNTSGIEDALPKGFLERAGERGMVVKGWAPQAKILKHWSTGGFVSHCGWNSVMESMMFGVPIIGVPMHVDQPFNAGLVEEAGVGVEAKRDPDGKIQRDEVAKLIKEVVVEKTREDVRKKAREMSEILRSKGEEKFDEMVAEISLLLKI Accession number 35: SgUGT74-345-2 (Siraitia grosvenorii) MDETTVNGGRRASDVVVFAFPRHGHMSPMLQFSKRLVSKGLRVTFLITTSATESLRLNLPPSSSLDLQVISDVPESNDIATLEGYLRSFKATVSKTLADFIDGIGNPPKFIVYDSVMPWVQEVARGRGLDAAPFFTQSSAVNHILNHVYGGSLSIPAPENTAVSLPSMPVLQAEDLPAFPDDPEVVMNFMTSQFSNFQDAKWIFFNTFDQLECKKQSQVVNWMADRWPIKTVGPTIPSAYLDDGRLEDDRAFGLNLLKPEDGKNTRQWQWLDSKDTASVLYISFGSLAILQEEQVKELAYFLKDTNLSFLWVLRDSELQKLPHNFVQETSHRGLVVNWCSQLQVLSHRAVSCFVTHCGWNSTLEALSLGVPMVAIPQWVDQTTNAKFVADVWRVGVRVKKKDERIVTKEELEASIRQVVQGEGRNEFKHNAIKWKKLAKEAVDEGGSSDKNIEEFVKTIA Sequence number 36: SgUGT75-281-2 (Siraitia grosvenorii) MGDNGDGGEKKELKENVKKKGELGRQAIGEGYINPSLQLARLRLISLGVNVTFATTVLAGRRMKNKTHQTATTPGLSFATFSDGFDDETLKPNDGLTHYFSELRRCGSESLTHLITSAANEGRPITFVIYSLLLSWAADIASTYDIPSALFFAQPATVLALYFYYFHGYGDTICSKLQDPSSYIELPGLPLLTSQDMPSFSPSGPHAFILPPMREQAEFLGRQSQPKVLVNTFDALEADALRA IDKLKMLAIGPLIPSALLGGNDSSDASFCGDLFQVSSEDYIEWLNSKPDSSVVYISVGSICVLSDEQEDELVHALLNSGHTFLWVKRSKENNEGVKQETDEEKLKKLEEQGKMVSWCRQVEVLKHPALGCFLTHCGWNSTIESLVSGLPVVAFPQQIDQATNAKLIEDVWKTGVRVKANTEGIVEREEIRRCLDLVMGSRDGQKEEIERNAKKWKELARQAIGEGGSSDSNLKTFLWEIDLEIS SEQ ID NO:37:SgUGT720-269-4(Siraitia grosvenorii) MAEQAHDLLHVLLFPFPAEGHIKPFLCLAELLCNAGFHVTFLNTDYNHRRLHNLHLLAARFPSLHFESISDGLPPDQPRDILDPKFFISICQVTKPLFRELLLSYKRISSVQTGRPPITCVITDVIFRFPIDVAEELDIPVFSFCTFSARFMFLYFWIPKLIEDGQLPYPNGNINQKLYGVAPEAEGLLRCKDLPGHWAFADELKDDQLNFVDQTTASSRSSGLILNTFDDLEAPFLGRLSTIFKKIYAVGPIHSLLNSHHCGLWKEDHSCLAWLDSRAAKSVVFVSFGSLVKITSRQLMEFWHGLLNSGKSFLFVLRSDVVEGDDEKQVVKEIYETKAEGKWLVVGWAPQEKVLAHEAVGGFLTHSGWNSILESIAAGVPMISCPKIGDQSSNCTWISKVWKIGLEMEDRYDRVSVETMVRSIMEQEGEKMQKTIAELAKQAKYKVSKDGTSYQNLECLIQDIKKLNQIEGFINNPNFSDLLRV Accession number 38: SgUGT94-289-2 (Siraitia grosvenorii) MDAQQGHTTTILLMLPWVGYGHLLPFLELAKSLSRRKLFHIYFCSTSVSLDAIKKPLPPSISSDDSIQLVELRLPSSPELPPHLHTTNGLPSHLMPALHQAFVMAAQHFQVILQTLAPHLLIYDILQPWAPQVASSLNIPAINFSTTGASMLSRTHLHPTHYPSSKFPISEFVLHNHWRAMYTTADGALTEEGHKIEETLANCLHTSCGVLVNSFRELETKYIDYLSVLLNKKVPV GPLVYEPNQEGEDEGYSSIKNWLDKKEPSSTVFVSFGTEYFPSKEEMEEIAYGLELSEVNFIWVLRFPQGDSTSTIEDALPKGFLERAGERAMVVKGWAPQAKILKHWSTGGLVSHCGWNSMMEGMMFGVPIIAVPMHLDQPFNAGLVEEAGVGVEAKRDSDGKIQREEVAKSIKEVVIEKTREDVRKKAREMDTKHGPTYFSRSKVSSFGRLYKINRPTTLTVGRFWSKQIKMKRE SEQ ID NO:39:SgUGT94-289-1 (Siraitia grosvenorii) MDAQRGHTTTILMFPWLGYGHLSAFLELAKSLSRRNFHIYFCSTSVNLDAIKPKLPSSSSDSIQLVELCLPSSPDQLPPHLHTTNALPPHLMPTLHQAFSMAAQHFAAILHTLAPHLLIYDSFQPWAPQLASSLNIPAINFNTTGASVLTRMLHATHYPSSKPFISEFVLHDYWKAMYSAAGGAVTKKDHKIGETLANCLHASCSVILINSFRELEEKYMDYLSV LLNKKVVPVGPLVYEPNQDGEDEGYSSIKNWLDKKEPSSTVFVSFGSEYFPSKEEMEEIAHGLASEVHFIWVVRFPQGDNTSAIEDALPKGFLERVGERGMVVKGWAPQAKILKHWSTGGFVSHCGWNSVMESMMFGVPIIGVPMHLDQPFNAGLAEEAGVGVEAKRDPDGKIQRDEVAKLIKEVVVEKTREDVRKKAREMSEILRSKGEMDEMVAAISLFLKI sequence number 40:McUGT1(Momordica charantia) MAQPQTQARVLVFPYPTVGHIKPFLSLAELLADGGLDVVFLSTEYNHRRIPNLEALASRFPTLHFDTIPDGLPIDKPRVIIGGELYTSMRDGVKQRLRQVLQSYNDGSSPITCVICDVMLSGPIEAAEEELGIPVVTFCPYSARYLCAHFVMPKLIEEGQIPFTDGNLAGEIQGVPLFGGLLRRDHLPGFWFVKSLSDEVWSHAFLNQTLAVGRTSALIINTLDELEAPFLAHLSST FDKIYPIGPLDALSKSRLGDSSSSSTVLTAFWKEDQACMSWLDSQPPKSVIFVSFGSTMRMTADKLVEFWGHGLVNSGTRFLCVLRSDIVEGGGAADLIKQVGETGNGIVVEWAAQEKVLAHRAVGGFLTHCGWNSTMESIAAGVPMMCWQIYGDQMINATWIGKVWKIGERDDKWDRSTVEKMIKELMEGEGAIQRSMEKFSKLANDKVVKGGTSFENLELIVEYLKKLKPSN sequence number 41:McUGT2(Momordica charantia) MAQPRVLLFPFPAMGHVKPFLSLAELLSDAGVEVVFLSTEYNHRRIPDIGALAARFPTLHFETIPDGLPDQPRVLADGHLYFSMLDGTKPRFRQLIQSLNGNPRPITCIINDVMLSSPIEVAEEFGIPVIAFCPCSARFLSVHFFMPNFIEEAQIPYTDENPMGKIEEATVFEGLLRRKDLPGLWCAKSSNISFSHRFINQTIAAGRASALILNTFDELESPFLNHLSSIFP KIYCIGPLNALSRSRLGKSSSSSLASAGFWKEDQAYMSWLESQPPRSVIFVSFGSTMKMEAWKLAEFWYGLVNGSPFLFVFRPDVINSGDAAEVMEGRGRGMVVEWASQEKVLAHPAVGGFLTHCGWNSTVESIVAGVPMMCCPIVADQLSNATWIHKVWKIGIEGDEKWDRSTVEMMIKELMESQKGTEIRTSIEMLSKLANEKVVKGGTSLNNFELLVEDIKTLRRPYT sequence number 42:McUGT3(Momordica charantia) MEQSDSNSDDHQHHVLLFPPFAKGHIKPFLCLAQLLCGAGLQVTFLNTDHNHRRIDDRHRRLLATQFPMLHFKSISDGLPDHPRDLLDGCLIASMRRVTESLFRQLLLSYNGYGNGTNNVSNSGRRPPISCVITDVIFSFPVEVAEELGIPVFSFATFSARFLYFWIPKLIQEGQLPFPDGKTNQELYPGAEGIIRCKDLPGSWSVEAVAKNDPMNFVKQTLASSRSSGLILNTFE DLEAPFVTHLSNTFDKIYTIGPIHSLLGTSHCGLWKEDYACLAWLDARPRKSVVFVSFGSLVKTTSRELMELWHGLVSSGKSFLLVLRSDVVEGEDEEQVVKEILESNGEGKWLVVGWAPQEEVLAHEAIGGFLTHSGWNSTMESIAAGVPMVCWPKIGDQPSNCTWVSRVWKVGLEMEERYDRSTVAMARSMMEQEGKEMERRIAELAKRVKYRVGKDGESYRNLESLIRDIKTSSN sequence number 43:McUGT4(Momordica charantia) MDAHQQAEHTTTILMLPWVGYGHLTAYLELAKALSRRNFHIYYCSTPVNIESIKKPLTIPCSSIQFVELHLPSSDDLPPNLHTTNGLPSHLMPTLHQAFSAAAPLFEEILQTLCPHLLIYDSLQPWAPKIASSLKIPALNFNTSGVSVIAQALHAIHHPDSKFPLSDFILHNYWKSTYTTADGGASEKTRRAREAFLYCLNSSGNAILINTFRELEGEYIDYLSL LLNKKVIPIGPLVYEPNQDEDQDEEYRSIKNWLDKKEPCSTVFVSFGSEYFPSNEEMEEIAPGLEESGANFIWVVRFPKLENRNGIIEGGLERAGERGMVIKEWAPQARILRHGSIGGFVSHCGWNSVMESIICGVPVIGVPMRVDQPYNAGLVEEAGVGVEAKRDPDGKIQRHEVSKLIKQVVVEKTRDDVRKKVAQMSEILRRKGDEKIDEMVALISLLPKG sequence number 44:McUGT5(Momordica charantia) MDARQQAEHTTTILMLPWVGYGHLSAYLELAKALSRRNFHIYYCSTPVNIESIKKPLTIPCSSIQFVELHLPFSDDLPPNLHTTNGLPSHLMPALHQAFSAAAPLFEAILQTLCPHLLIYDSLQPWAPQIASSLKIPALNFNTTGVSVIARALHTIHHPDSKFPLSEIVLHNYWKATHATADGANPEKFRRDLEALLCCLHSSCNAILINTFRELEGEYIDYLSL LLNKKVTPIGPLVYEPNQDEEQDEEYRSIKNWLDKKEPYSTIFVSFGSEYFPSNEEMEEIARGLEESGANFIWVVRFHKLENGNGITEEGLLERAGERGMVIQGWAPQARILRHGSIGGFVSHCGWNSVMESIICGVPVIGVPMGLDQPYNAGLVEEAGVGVEAKRDPDGKIQRHEVSKLIKQVVVEKTRDDVRKKVAQMSEILRRKGDEKIDEMVALISLLKG sequence number 45(Cucumis sativus) MGLSPTDHVLLFPPAKGHIKPFFCLAHLCLCNAGLRVTFLSTEHHHQKLHNLTHLAAQIPSLHFQSISDGLSLDHPRNLLDGQLFKSMPQVTKPLFRQLLLSYKDGTSPITCVITDLILRFPMDVAQELDIPVFCFSTFSARFLFLYFSIPKLLEDGQIPYPEGNSNQVLHGIPGAEGLLRCKDLPGYWSVEAVANYNPMNFVNQTIATSKSHGLILNTFDELEVPFITNLSKIYKKVYTIGPIHSLLKKSVQTQYEFWKEDHSCLAWLDSQPPRSVMFVSGFGSIVKLKSSQLKEFWNGLVDSGKAFLLVLRSDALVEETGEEDEKQKELVIKEIMETKEEGRWVIVNWAPQEKVLEHKAIGGFLTHSGWNSTLESVAVGVPMVSWPQIGDQPSNATWLSKVWKIGVEMEDSYDRSTVESKVRSIMEHEDKKMENAIVELAKRVDDRVSKEGTSYQNLQRLIEDIEGFKLN sequence number 46:CmaUGT1(Cucurbita maxima) MELSHTHHVLLFPFPAKGHIKPFFSLAQLLCNAGLRVTFLNTDHHHRRIHDLNRLAAQLPTLHFDSVSDGLPPDEPRNVFDGKLYESIRQVTSSLFRELLVSYNNGTSSGRPPITCVITDVMFRFPIDIAEELGIPVFTFSTFSARFLFLIFWIPKLLEDGQLRYPEQELHGVPGAEGLIRWKDLPGFWSVEDVADWDPMNFVNQTLATSRSSGLILNTFDELEAPFLTSLSKIYKKIYSLGPINSLLKNFQSQPQYNLWKEDHSCMAWLDSQPRKSVVFVSFGSVVKLTSRQLMEFWNGLVNSGMPFLLVLRSDVIEAGEEVVREIMERKAEGRWVIVSWAPQEEVLAHDAVGGFLTHSGWNSTLESLAAGVPMISWPQIGDQTSNSTWISKVWRIGLQLEDGFDSSTIETMVRSIMDQTMEKTVAELAERAKNRASKNGTSYRNFQTLIQDITNIIETHI Accession number 47: (Prunus persica) MAMKQPHVIIFPFPLQGHMKPLLCLAELLCHAGLHVTYVNTHHNHQRLANRQALSTHFPTLHFESISDGLPEDDPRTLNSQLLIALKTSIRPHFRELLKTISLKAESNDTLVPPPSCIMTDGLVTFAFDVAEELGLPILSFNVPCPRYLWTCLCLPKLIENGQLPFQDDDMNVEITGVPGMEGLLHRQDLPGFCRVKQADHPSLQFAINETQTLKRASALILDTVYELDAPCISHMALMFPKIYTLGPLHALLNSQIGDMSRGLASHGSLWKSDLNCMTWLDSQPSKSIIYVSFGTLVHLTRAQVIEFWYGLVNSGHPFLWVMRSDITSGDHQIPAELENGTKERGCIVDWVSQEEVLAHKSVGGFLTHSGWNSTLESIVAGLPMICWPKLGDHYIISSTVCRQWKIGLQLNENCDRSNIESMVQTLMGSKREEIQSSMDAISKLSRDSVAEGGSSHNNLEQLIEYIRNLQHQN sequence number 48: (Theobroma cacao) MRQPHVLVLFPPAQGHIKPMLCLAELLCQAGLRVTFLNTHHSHRRLNNLQDLSTRFPTLHFESVSDGLPEDHPRNLVHFMHLVHSIKNVTKPLLRDLLTSLSLKTDPPVSCIADGILSFAIDVAEELQIKVIIFRTISSSCCLWSYLVCVPKLIQQGELQFSDSDMGQKVSSVPEMKGSLRLHDRPYSFGLKQLEDPNFQFFVSETQAMTRASAVIFNTFDSLEAPVLSQMIPL LPKVYTIGPHLARKARLGDLSQHSSFNGNLREADHNCITWLDSQPLRSVVYVSFGSHVVLTSEELLEFWHGLVNSGKRFLWVLRPDIIAGEKDHNQIIAREPDLGTKEKGLLVDWAPQEEVLAHPSVGGFLTHCGWNSTLESMVAGVPMLCWPKLPDQLVNSSCVSEVWKIGLDLKDMCDRSTVEKMVRALMEDRREEVMRSVDGISKLARESVSHGGSSSNLEMLIQELET SEQ ID NO:49:CmaUGT2(Cucurbita maxima) MDAQKAVDTPPTTVLMLPWIGYGHLSAYLELAKALSRRNFHVYFCSTPVNLDSIKPNLIPPPSSSIQFVDLHLPSSPELPPHLHTTNGLPSHLKPTLHQAFSAAAQHFEAILQTLSPHLLIYDSLQPWAPRIASSLNIPAINFNTTAVSIIAHALHSVHYPDSKFPFSDFVLHDYWKAKYTTADGATSEKIRRGAEAFLYCLNASCDVLVNSFRELEGEYMDYLSVL LKKKVVSVGPLVYEPSEGEEDEEYWRIKKWLDEKEALSTVLVSFGSEYFPSKEEMEEIAHGLEESEANFIWVVRFPKGEESCRGIEALPKGFVERAGERAMVVKKWAPQGKILKHGSIGGFVSHCGWNSVLESIRFGPVIGVPMHLDQPYNAGLLEEAGIGVEAKRDADGKIQRDQVASLIKRVVVEKTREDIWKTVREMREVLRRRRDDMIDEMVAEISVVLKI sequence no.50:CmoUGT2(Cucurbita moschata) MDAQKAVDTPPTTVLMLPWIGYGHLSAYLELAKALSRRNFHVYFCSTPVNLDSIKPNLIPPPSIQFVDLHLPSSPELPPHLHTTNGLPSHLKPTLHQAFSAAAQHFEAILQTLSPHLLIYDSLQPWAPRIASSLNIPAINFNTTAVSIIAHALHSVHYPDSKFPFSDFVLHDYWKAKYTTADGATSEKTRRGVEAFLYCLNASCVLVNSFRELEGEYMDYLSVLL KKKVVSVGPLVYEPSEGEEDEEEYWRIKKWLDEKEALSTVLVSFGSEYFPPPKEEMEEIAHGLEESEANFIWVVRFPKGESSSRGIEEALPKGFVERAGERAMVVKKWAPQGKILKHGSIGGFVSHCGWNSVLESIRFGVPVIGAPMHLDQPYNAGLLEEAGIGVEAKRDADGKIQRDQVASLIKQVVVEKTREDIWKKVREMREVLRRRRDDDMMIDEMVAVISVVLKI SEQ ID NO:51:CmaUGT3(Cucurbita maxima) MSSNLFLKISIPFGRLRDSALNCSVFHCKLHLAIAIAMDAQQAANKSPTATTIFMLPWAGYGHLSAYLELAKALSTRNFHIYFCSTPVSLASIKPRLIPSCSSIQFVELHLPSSDEFPPHLHTTNGLPSRLVPTFHQAFSEAAQTFEAFLQTLRPHLLIYDSLQPWAPRIASSLNIPAINFFTAGAFAVSHVLRAFHYPDSQFPSSDFVLHSRWKIKNTTAESPTQAKLPKIGEAIGYCLNASRGV ILTNSFRELEGKYIDYLSVILKKRVFPIGPLVYQPNQDEEDEDYSRIKNWLDRKEASSTVLVSFGSEFFLSKEETEAIAHGLEQSEANFIWGIRFPKGAKKNAIEALPEGFLERAGRAMVVEEWVPQGKILKHGSIGGFVSHCGWNSAMESIVCGVPIIGPMQVDQPFNAGILEEAGVGVEAKRDSDGKIQRDEVAKLIKEVVVERTREDIRNKLEKINEILRSRREEKLDELATEISLLSRN SEQ ID NO:52:CmoUGT3(Cucurbita moschata) MDAQQAANKSPTASTIFMLPWVGYGHLSAYLELAKALSTRNFHVYFCSTPVSLASIKPRLIPSCSSIQFVELHLPSSDEFPPHLHTTNGLPAHLVPTIHQAFAAAAQTFEAFLQTLRPHLLIYDSLQPWAPRIASSLNIPAINFFTAGAFAVSHVLRAFHYPDSKFPSSDFVLHSRWKIKNTTAESPTQVKIPKIGEAIGYCLNASRGVILTNSFRELEGKYIDYLS VILKKRVLPIGPLVYQPNQDEEDEDYSRIKNWLDRKEASSTVLVSFGSEFFLSKEETEAIAHGLEQSEANFIWGIRFPKGAKKNAIEELPEGFLERVGGRAMVVEEWVPQGKILKHGNIGGFVSHCGWNSAMESIMCGVPVIGIPMQVDQPFNAGILEEAGVGVEAKRDSDGKIQRDEVAKLIKEVVVERTREDIRNKLEEINEILRTRREEKLDELATEISLLCKN SEQ ID NO: 53: (Corchorus capsularis) MDSKQKKMSVLMFPWLAYGHISPFLELAKKLSKRNFHTFFFSTPINLNSIKSKLSKPYAQSIQFVELHLPSLPDLPPHYHTTNGLPPHLMNTLKKAFDMSSLQFSKILKTLNPDLLVYDFIQPWAPLLALSNKIPAVHFLCTSAAMSSFSVHAFKKPCEDFPFPNIYVHGNFMNAKFNNMENCSSDDSISDQDRVLQCFERSTKIILVKTFEELEGKFMDYLSVLLNKKIV PTGPLTQDPNEDEGDDDERTKLLLEWLNKKSSKSSTVFVSFGSEYFLSKEEREEIAYGLELSKVNFIWVIRFPLGENKTNLEEALPQGFLQRVSERGLVVENWAPQAKILQHSSIGGFVSHCGWSSVMESLKFGVPIIAIPMHLDQPLNARLVVDVGVGLEVIRNHGSLEREEIKLIKEVVLGNGNNDGEIVRRKAREMSNHIKKKGEKDMDELVELMLICKMKPNSCHLS Accession number 54: (Ziziphus jujube) MMERQRSIKVLMFPWLAHGHISPFLELAKRLTDRNFQIYFCSTPVNLTSVKPKLSQKYSSSIKLVELHLPSLPDLPPHYHTTNGLALNLIPTLKKAFDMSSSSFSTILSTIKPDLLIYDFLQPWAPQLASCMNIPAVNFLSAGASMVSFVLHSIKYNGDDHDDEFLTTELHLSDSMEAKFAEMTESSPDEHIDRAVTCLERSNSLILIKSFRELEGKYLDYLSLSFAKKVVPIGPLVAQDTNPEDDSMDIINWLDKKEKSSTVFVSFGSEYYLTNEEMEEIAYGLELSKVNFIWVVRFPLGQKMAVEEALPKGFLERVGEKGMVVEDWAPQMKILGHSSIGGFVSHCGWSSLMESLKLGVPIIAMPMQLDQPINAKLVERSGVGLEVKRDKNGRIEREYLAKVIREIVVEKARQDIEKKAREMSNIITEKGEEEIDNVVEELAKLCGM Accession number 55: (Vitis vinifera) MDARQSDGISVLMFPWLAHGHISPFLQLAKKLSKRNFSIYFCSTPVNLDPIKGKLSESYSLSIQLVKLHLPSLPELPPQYHTTNGLPPHLMPTLKMAFDMASPNFSNILKTLHPDLLIYDFLQPWAPAAASSLNIPAVQFLSTGATLQSFLAHRHRKPGIEFPFQEIHLPDYEIGRLNRFLEPSAGRISDRDRANQCLERSSRFSLIKTFREIEAKYLDYVSDLTKKKMVTVGPLLQDPEDEDEATDIVEWLNKKCEASAVFVSFGSEYFVSKEEMEEIAHGLELSNVDFIWVVRFPMGEKIRLEDALPPGFLHRLGDRGMVVEGWAPQRKILGHSSIGGFVSHCGWSSVMEGMKFGVPIIAMPMHLDQPINAKLVEAVGVGREVKRDENRKLEREEIAKVIKEVVGEKNGENVRRKARELSETLRKKGDEEIDVVVEELKQLCSY Sequence number 56: (Juglans regia) MDTARKRIRVVMLPWLAHGHISPFLELSKKLAKRNFHIYFCSTPVNLSSIKPKLSGKYSRSIQLVELHLPSLPELPPQYHTTKGLPPHLNATLKRAFDMAGPHFSNILKTLSPDLLIYDFLQPWAPAIAASQNIPAINFLSTGAAMTSFVLHAMKKPGDEFPFPEIHLDECMKTRFVDLPEDHSPSDDHNHISDKDRALKCFERSSGFVMMKTFEELEGKYINFLSHLMQKKIVPVGPLVQNPVRGDHEKAKTLEWLDKRKQSSAVFVSFGTEYFLSKEEMEEIAYGLELSNVNFIWVVRFPEGEKVKLEEALPEGFLQRVGEKGMVVEGWAPQAKILMHPSIGGFVSHCGWSSVMESIDFGVPIVAIPMQLDQPVNAKVVEQAGVGVEVKRDRDGKLEREEVATVIREVVMGNIGESVRKKEREMRDNIRKKGEEKMDGVAQELVQLYGNGIKNV Accession number 57: (Hevea brasiliensis) METLQRRKISVLMFPWLAHGHLSPFLELSKKLNKRNFHVYFCSTPVNLDSIKPKLSAEYSFSIQLVELHLPSSPELPLHYHTTNGLPPHLMKNLKNAFDMASSSFFNILKTLKPDLLIYDFIQPWAPALASSLNIPAVNFLCTSMAMSCFGLHLNNQEAKFPFPGIYPRDYMRMKVFGALESSSNDIKDGERAGRCMDQSFHLILAKTFRELEGKYIDYLSVKLMKKIVPVGPLVQDPIFEDDEKIMDHHQVIKWLEKKERLSTVFVSFGTEYFLSTEEMEEIAYGLELSKAHFIWVVRFPTGEKINLEESLPKRYLERVQERGKIVEGWAPQQKILRHSSIGGFVSHCGWSSIMESMKFGVPIIAMPMNLDQPVNSRIVEDAGVGIEVRRNKSGELEREEIAKTIRKVVVEKDGKNVSRKAREMSDTIRKKGEEEIDGVVDELLQLCDVKTNYLQ Accession number 58: (Manihot esculenta) MATAQTRKISVLMFPWLAHGHLSPFLELSKKLANRNFHVYFCSTPVNLDSIKPKLSPEYHFSIQFVELHLPSSPELPSHYHTTNGLPPHLMKTLKKAFDMASSSFFNILKTLNPDLLIYDFLQPWAPALASSLNIPAVNLCSSMAMSCFGLNLNKNKEIKFLFPEIYPRDYMEMKLFRVFESSSNQIKDGERAGRCIDQSFHVILAKTFRELEGKYYVSVKCNKKIV PVGPLVEDTIHEDDEKTMDHHHHHHDEVIKWLEKKERSTTVFVSFGSEYFLSKEEMEEIAHGLELSKVNFIWVVRFPKGECINLEESLPEGYLERIQERGKIVEGWAPQRKILGHSSIGGFVSHCGWSSIMESMKLGVPIIAMPMNLDQPINSRIVEAAGVGIEVSRNQSGELEREEMAKTIRKVVVEREGVYVRRKAREMSDVLRKKGEEIDGVDELVQLCDMKTNYL SEQ ID NO:59:(Cephalotus follicularis) MDLKRRSIRVLMLPWLAHGHISPFLELAKKLTNRNFLIYFCSTPINLNSIKPKLSSKYSFSIQLVELHLPSLPELPPHYHTTNGLPLHLMNTLKTAFDMASPFLNILKTLKPDLLICDHLQPWAPSLASSLNIPAIIFPTNSAIMMAFSLHHAKNPGEEFPFPSININDDMVKSINFLHSASNGLTDMDRVLQCLERSSNTMLLKTFRQLEAKYVDYSSALLKKK IVLAGPLVQVPDNEDEKIEIIKWLDSRGQSSTVFVSFGSEYFLSKEEREDIAHGLELSKVNFIWVVRFPVGEKVKLEEALPNGFAERIGERGLVVEGWAPQAMILSHSSIGGFVSHCGWSSMMESMKFGVPIIAMPMHIDQPLNARLVEDVGVGLEIKRNKDGRFEREELARVIKEVLVYKNGDAVRSKAREMSEHIKKNGDQEIDGVADALVKLCEMKTNSLNQD Accession number 60: UGT_1,6 (Coffea Arabica) MENHATFNVLMLPWLAHGHVSPYLELAKKLTARNFNVYLCSSPATLSSVRSKLTEKFSQSIHLVELHLPKLPELPAEYHTTNGLPPHLMPTLKDAFDMAKPNFCNVLKSLKPDLLIYDLLQPWAPEAASAFNIPAVVFISSSATMTSFGLHFFKNPGTKYPYGNAIFYRDYESVFVENLTRRDRDTYRVINCMERSSKIILIKGFNEIEGKYFDYFSCLTGKKVVPVGPLVQDPVLDDEDCRIMQWLNKKEKGSTVFVSFGSEYFLSKKDMEEIAHGLEVSNVDFIWVVRFPKGENIVIEETLPKGFFERVGERGLVVNGWAPQAKILTHPNVGGFVSHCGWNSVMESMKFGLPIIAMPMHLDQPINARLIEEVGAGVEVLRDSKGKLHRERMAETINKVMKEASGESVRKKARELQEKLELKGDEEIDDVVKELVQLCATKNKRNGLHYY Accession number 61: CmoUGT1 (Cucurbita moschata) MELSPTHHLLLFPFPAKGHIKPFFSLAQLLCNAGARVTFLNTDHHHRRIHDLDRLAAQLPTLHFDSVSDGLPPDESRNVFDGKLYESIRQVTSSLFRELLVSYNNGTSSGRPPITCVITDCMFRFPIDIAEELGIPVFTFSTFSARFLFLFFWIPKLLEDGQLRYPEQELHGVPGAEGLIRCKDLPGFLSDEDVAHWKPINFVNQILATSRSSGLILNTFDELEAPFLTSLSKIYKKIYSLGPINSLLKNFQSQPQYNLWKEDHSCMAWLDSQPPKSVVFVSFGSVVKLTNRQLVEFWNGLVNSGKPFLLVLRSDVIEAGEEVVRENMERKAEGRWMIVSWAPQEEVLAHDAVGGFLTHSGWNSTLESLAAGVPMISWTQIGDQTSNSTWVSKVWRIGLQLEDGFDSFTIETMVRSVMDQTMEKTVAELAERAKNRASKNGTSYRNFQTLIQDITNIIETH Accession number 62: (Arabidopsis thaliana) MGSISEMVFETCPSPNPPIHVMLVSFQGQGHVNPLLRLGKLIASKGLLVTFVTTELWGKKMRQANKIVDGELKPVGSGSIRFEFFDEEWAEDDDRRADFSLYIAHLESVGIREVSKLVRRYEEANEPVSCLINNPFIPWVCHVAEEFNIPCAVLWVQSCACFSAYYHYQDGSVSFPTETEPELDVKLPCVPVLKNDEIPSFLHPSSRFTGFRQAILGQFKNLSKSFCVLIDSFDSLEREVIDYMSSLCPVKTVGPLFKVARTVTSDVSGDICKSTDKCLEWLDSRPKSSVVYYSFGTVAYLKQEQIEEIAHGVLKSGLSFWVIRPPPHDLKVETHVLPQELKESSAKGGMIVDWCPQEQVLSHPSVACFVTHCGWNSTMESLSSGVPVVCCPQWGDQVTDAVYLIDVFKTGVRLGRGATEERVVPREEVAEKLLEATVGEKAEELRKNALKWKAEAEAAVAPGGSSSDKNFREFVEKLGAGVTKTKDNGY sequence number63:(Arabidopsis thaliana) MGSHVAQKQHVVCVPYPAQGHINPMMKVAKLLYAKGFHITFVNTVYNHNRLLRSRGPNAVDGLPSFRFESIPDGLPETDVDVTQDIPTLCESTMKHCLAPFKELLRQINARDDVPPVSCIVSDGCMSFTLDAAEELGVPEVLFWTTSACGFLAYLYYYRFIEKGLSPIKDESYLTKEHLDTKIDWIPSMKNLRLKDIPSFIRTTNPDDIMLNFIIREADRAKRASAIILNTFDDLEHDVIQSMKSIVPPVYSIGPLHLLEKQESGEYSEIGRTGSNLWREETECLDWLNTKARNSVVYVNFGSITVLSAKQLVEFAWGLAATGKEFLWVIRPDLVAGDEAMVPPEFLTATADRRMLASWCPQEKVLSHPAIGGFLTHCGWNSTLESLCGGVPMVCWPFFAEQQTNCKFSRDEWEVGIEIGGDVKREEVEAVVRELMDEEKGKNMREKAEEWRRLANEATEHKHGSSKLNFEMLVNKVLLGE Sequence number 64: ClUGT1 (Columba livia) MIHCGKKHICAFVTCILISASILMYSWKDPQLQNNITRKIFQATSALPASQLCRGKPAQNVITALEDNRTFIISPYFDDRESKVTRVIGIVHHEDVKQLYCWFCCQPDGKIYVARAKIDVHSDRFGFPYGAADIVCLEPENCNPTHVSIHQSPHANIDQLPSFKIKNRKSETFSVDFTVCISAMFGNYNNVLQFIQSVEMYKILGVQKVVIYKNNCSQLMEKVLKFYMEEGTVEIIPWPINSHLKVSTKWHFSMDAKDIGYYGQITALNDCIYRNMQRSKFVVLNDADEIILPLKHLDWKAMMSSLQEQNPGAGIFLFENHIFPKTVSTPVFNISSWNRVPGVNILQHVHREPDRKEVFNPKKMIIDPRQVVQTSVHSVLRAYGNSVNVPADVALVYHCRVPLQEELPRESLIRDTALWRYNSSLITNVNKVLHQTVL Sequence ID 65: (Haemophilus ducreyi) MPTLTVAMIVKNEAQDLAECLKTVDGWVDEIVIVDSGSTDDTLKIATQFNAKVYVNSDWQGFGPQRQFAQQYVTSDYVLWLDADERVTPELKASILQAVQHNQKNTVYKVSRLSEIFGKEIRYSGW YPDYVVRLYPTYLAKYGDELVHEKVHYPADSRVEKLQGDLLHFTYKNIHHYLVKSASYAKAWAMQRAKAGKKASLLDGVTHAIACFLKMYLFKAGFLDGKQGFLLAVLSAHSTFVKYADLWDRTRS Sequence ID 66: (Neisseria gonorrhoeae) MKKVSVLIVAKNEANHIRECIESCRFDKEVIVIDDHSADNTAEIAEGLGAKVFRRHLNGDFGAQKTFAIEQAGGEWVFLIDADERCTPELSDEISKIVRTGDYAAYFVERRNLFPNHPATHGAMRP DSVCRLMPKKGGSVQGKVHETVQTPYPERRLKHFMYHYTYDNWEQYFNKFNKYTSISAEKYREQGKPVSFVRDIILRPIWGFFKIYILNKGFLDGKMGWIMSVNHSYYTMIKYVKLYYLYKSGGKF Sequence ID 67: (Rhizobium meliloti, strain 1021) MPNETLHIDIGVCTYRRPELAETLRSLAAMNVPERARLRVIVADNAEPSARALVEGLRPEMPFDILYVHCPHSNISARNCCLDNSTGDFLAFLDDDETVSGDWLTRLLETARTTGAAAVLGPVRAHYGPTAPRWMRSGDFHSTLPVWAKGEI RTGYTCNALLRRDAASLLGRRFKLSLGKSGGEDTDFFTGMHCAGGTIAFSPEAWVHEPVPENRASLAWLAKRRFRSGQTHGRLLAEKAHGLRQAWNIALAGAKSGFCATAAVLCFPSAARRNRFALRAVLHAGVISGLLGLKEIEQYGAREVTSA sequence number 68: (Rhizobium radiobacter) MCRCGRAVRSRPVCRPGQLVVRRSPRPRSRNHSRCRPLRLSVFPRPHRRVRHHCQRDLRWEPGRWIAVRWKAARSHRRRCPFPPRQLVWPVRERHRDAGDRRNQRERRRRDAYHEISEPKFRTRKRTESFWMNKAITVIVWLLVSLCVLAIITMPVSLQTHLVATAISLILLATIKSFNGQGAWRLVALGFGTAIVLRYVYWRTTSTLPPVNQL ENFIPGFLLYLAEMYSVVMLGLSLVIVSMPLPSRKTRPGSPDYRPTVDVFVPSYNEDAELLANTLAAAKNMDYPADRFTVWLLDDGGSVQKRNAANIVEAQAAQRRHEELKKLCEDLDVRYLTRERNVHAKAGNLNNGLAHSTGELVTVFDADHAPARDFLLETVGYFDEDPRLFLVQTPHFVNPDPIERNLRTFETMPSENEMFYGIIQRGLD KWNGAFFCGSAAVLRREALQDSDGFSGVSITEDCETALALHSRGWNSVYVDKPLIAGLQPATFASFIGQRSRWAQGMMQILIFRQPLFKRGLSFTQRLCYMSSTLFWLFPPFPRTIFLFAPLFYLFFDLQIFVASGGEFLAYTAAYMLVNLMMQNYLYGSFRWPWISELYEYVQTVHLLPAVVSVIFNPGKPTFKVTAKDESIAEARLSEISRPFF VIFALLLVAMAFAVWRIYSEPYKADVTLVVGGWNLLNLIFAGCAlgVVSERGDKSASRRITVKRRCEVQLGGSDTWVPASIDNVSVHGLLINIFDSATNIEKGATAIVKVKPHSEGVPETMPLNVVRTVRGEGFVSIGCTFSPQRAVDHRLIADLIFANSEQWSEFQRVRRKKPGLIRGTAIFLAIALFQTQRGLYYLVRARRPAPKSAKPVGAVK sequence number 69: (Streptococcus agalactiae) MIKKIEKDLISVIVPIYNVEDYLVECIESLIVQTYRNIEILLINDGSTDNCATIAKEFSERDCRVIYIEKSNGGLSEARNYGIYHSKGKYLTFVDSDDKVSSDYIANLYNAIQKHDSSIAIGGYLEFYERHNSIRNYEYLDKVIPVEEALLNMYDIK TYGSIFITAWGKLFHKSIFNDLEFALNKYHEDEFFNYKAYLKANSITYIDKPLYHYRIRVGSIMNNSDNVIIARKKLDVLSALDERIKLITSLRKYSVFLQKTEIFYVNQYFRTKKFLKQQSVMFKEDNYIDAYRMYGRLLRKVKLVDKLKLIKNRFF sequence number 70 (Streptococcus pneumonia) MYTFILMLLDFFQNHDFHFFMLFVFILIRWAVIYFHAVRYKSYSCSVSDEKLFSSVIIPVVDEPLNLFESVLNRISRHKPSEIIVVINGPKNERLVKLCHDFNEKLENNMTPIQCYYTPVPGKRNAIRVGLEHVDSQSDITVLVDSDTVWTPRTLSELLKPFVCDKKIGGVTTRQKILDPERNLVTMFANLEIRAEGTMKAMSVT GKVGCLPGRTIAFRNIVERVYTKFIEETFMGFKEVSDRSLTNLTLKKGYKTVMQDTSSVVYDTAPTSWKKFIRQQLRWAEGSQYNNLKMTPWMIRNAPLMFFIYFTDMILPMLLISFGVNIFLLKILNITTIVYTASWWEIILYVLLGMIFSFGGRNFKAMSRMKWYYVFLIPVFIIVLSIIMCPIRLLGLMRCSDDLGWGTRNLTE sequence number 71: AtUGT73C3 (Arabidopsis thaliana) MATEKTHQFHPSLHFVLFPFMAQGHMIPMIDIARLLAQRGVTITIVTTPHNAARFKNVLNRAIESGLAINILHVKFPYQEFGLPEGKENIDSLDSTELMVPFFKAVNLLEDPVMKLMEEMKPRPSCLISDWCLPYTSIIAKNFNIPKIVFHGMGCFNLLCMHVLRRNLEILENVKSDEEYFLVPSFPDRVEFTKLQLPVKANASGDWKEIMDEMVKAEYTSYGVIVNTFQELEPPYVKDYKEAMDGKVWSIGPVSLCNKAGADKAERGSKAAIDQDECLQWLDSKEEGSVLYVCLGSICNLPLSQLKELGLGLEESRRSFIWVIRGSEKYKELFEWMLESGFEERIKERGLLIKGWAPQVLILSHPSVGGFLTHCGWNSTLEGITSGIPLITWPLFGDQFCNQKLVVQVLKAGVSAGVEEVMKWGEEDKIGVLVDKEGVKKAVEELMGDSDDAKERRRRVKELGELAHKAVEKGGSSHSNITLLLQDIMQLAQFKN Accession number 72: HvUGT B1 (Hordeum vulgare subsp. Vulgare) MAQAESERMRVVMFPWLAHGHINPYLELAKRLIASASGDHHLDVVVHLVSTPANLAPLAHHQTDRLRLVELHLPSLPDLPPALHTTKGLPARLMPVLKRACDLAAPRFGALLDELCPDILVYDFIQPWAPLEAEARGVPAFHFATCGAAATAFFIHCLKTDRPPSAFPFESISLGGVDEDAKYTALVTVREDSTALVAERDRLPLSLERSSGFVAVKSSADIERKYMEYLSQLLGKEIIPTGPLLVDSGGSEEQRDGGRIMRWLDGEEPGSVVFVSFGSEYFMSEHQMAQMARGLELSGVPFLWVVRFPNAEDDARGAARSMPPGFEPELGLVVEGWAPQRRILSHPSCGAFLTHCGWSSVLESMAAGVPMVALPLHIDQPLNANLAVELGAAAARVKQERFGEFTAEEVARAVRAAVKGKEGEAARRRARELQEVVARNNGNDGQIATLLQRMARLCGKDQAVPN Sequence number 73: HvUGT_B3 (Hordeum vulgare subsp. Vulgare) MAEANDGGKMHVVMLPWLAFGHVLPFTEFAKRVARQGHRVTLLSAPRNTRRLIDIPPGLAGLIRVVHVPLPRVDGLPPEHAEATIDLPSDHLRPCLRRAFDAAFERELSRLLQEEAKPDWVLVDYASYWAPTAAARHGVPCAFLSLFGAAALSFFGTPETLLGIGRHAKTEPAHLTVVPEYVPFPTTVAYRGYEARELFEPGMVPDDSGVSEGYRFAKTIEGCQLVGIRSSSSEFEPEWLRLLGELYRKPVIVPGLFPPAPQDDVAGHEATLRWLDGQAPSSVVYAAFGSEVKLTGAQLQRIALGLEASGLPFIWAFRAPTSTETGASGGLPEGFEERLAGRGVVCRGWVPQVKFLAHASVGGFLTHAGWNSIAEGLAHGVRLVLLPLVFEQGLNARNIVDKNIGVEVARDEQDGSFAAGDIAAALRRVMVEDEGEGFGAKVKELAKVFGDDEVNDQCVREFLMHLSDHSKKNQGQD sequence number 74:CcUGT_1,6(Coffea canephora) MAENHATFNVLMLPWLAHGHVSPYLELAMKLTARNFNVYLCSSPATLSSVRSKLTEKFSQSIHLVELHLPKLPELPAEYHTTNGLPPHLMPTLKDAFDMAKPNFCNVLKSLKPDLLIYDLLQPWAPEAASAFNIPAVVFISSSATMTSFGLHFFKNPGTKYPYGNTIFYRDYESVFVENLKKRDRDTYRVNCMERSSKIILIKGFKEIEGKYFDYFSCLTGKKVV PVGPLVQDPVLDDEDCRIMQWLNKKEKGSTVFVSFGSEYFLSKEDMEEIAHGLELSNVDFIWVVRFPKGENIVIEETLPKGFFERVGERGLVVNGWAPQAKILTHPNVGGFVSHCGWNSVMESMKFGLPIVAMPMHLDQPINARLIEEVGAGVEVLRDSKGKLHRERMAETINKVTKEASGEPARKKARELQEKLELKGDEEIDDVVKELVQLCATKNKRNGLHCYN SEQ ID NO:75:CeUGT_1,6(Coffea eugenioides) MAENHATFNVLMLPWLAHGHVSPYLELAKKLTARNFNVYLCSSPATLSSVRSKLTEKFSQSIHLVELHLPKLPELPAEYHTTNGLPPHLMPTLKDAFDMAEPNFCNVLKSLKPDLLIYDLLQPWAPEAASAFNIPAVVFISSSATMTSFGLHFFKNPGTKYPYGNTIFYRDYESVFVENLKRRDRDTYRVVNCMERSSKIILIKGFKEIEGKYFDYFSCLTGKKVV PVGPLVQDPVLDDEDCRIMQWLNKKEKGSTVFVSFGSEYFLSKEDMEEIAHGLELSNVDFIWVVRFPKGENIVIEETLPKGFFERVGERGLVVNGWAPQAKILTHPNVGGFVSHCGWNSVMESMKFGLPIIAMPMHLDQPINARLIEEVGAGVEVLRDSKGKLHRERMAETINKVTKEASGESVRKKARELQEKLELKGDEEIDDVKELVQLCATKNKRNGLHYN Accession number 76: CeUGT_1,6.2 (Coffea eugenioides) MAENHATFNVLMLPWLAHGHVSPYLELAKKLTARNFNVYLCSSPATLSSVRSKLTEKFSQSIHLVELHLPKLPELPAEYHTTNGLPPHLMPTLKDAFDMAKPNFCNVLKSLKPDLLIYDLLQPWAPEAASAFNIPAVVFISSSATMTSFGLHFFKNPGTKYPYGNAIFYRDYESVFVENLTRRDRDTYRVINCMERSSKIILIKGFNEIEGKYFDYFSCLTGKKVVPVGPLVQDPVLDDEDCEIMQWLNKKEKVSTVFVSFGSEYFLSKKDMEEIAHGLELSNVDFIWVVRFPKGENIVIEETLPKGFFERVGERGLVVNGWAPQAKILTHPNVGGFVSHCGWNSVMESMKFGLPIIAMPMHLDQPINARLIEEVGAGVEVLRDSKGKLHRERMAETINKVMKEASGESVRKKARELQEKMDLKGDEEIDDVVKELVQLCATKNKRNGLHYY Accession number 77: SgUGT94-289-3.2 (Siraitia grosvenorii) MADAAQQGDTTTILMLPWLGYGHLSAFLELAKSLSRRNFHIYFCSTSVNLDAIKPKLPSSFSDSIQFVELHLPSSPEFPPHLHTTNGLPPTLMPALHQAFSMAAQHFESILQTLAPHLLIYDSLQPWAPRVASSLKIPAINFNTTGVFVISQGLHPIHYPHSKFPFSEFVLHNHWKAMYSTADGASTERTRKRGEAFLYCLHASCSVILINSFRELEGKYMDYLSVLLNKKVVPVGPLVYEPNQDGEDEGYSSIKNWLDKKEPSSTVFVSFGSEYFPSKEEMEEIAHGLEASEVNFIWVVRFPQGDNTSGIEDALPKGFLERAGERGMVVKGWAPQAKILKHWSTGGFVSHCGWNSVMESMMFGVPIIGVPMHVDQPFNAGLVEEAGVGVEAKRDPDGKIQRDEVAKLIKEVVVEKTREDVRKKAREMSEILRSKGEEKFDEMVAEISLLLKI Accession number 78: OsJUGT_1,6 (Oryza sativa) (OsJUGT_1,6) MAQAERERLRVLMFPWLAHGHINPYLELATRLTTTSSSQIDVVVHLVSTPVNLAAVAHRRTDRISLVELHLPELPGLPPALHTTKHLPPRLMPALKRACDLAAPAFGALLDELSPDVVLYDFIQPWAPLEAAARGVPAVHFSTCSAAATAFFLHFLDGGGGGGGRGAFPFEAISLGGAEEDARYTMLTCRDDGTALLPKGERLPLSFARSSEFVAVKTCVEIESKYMDYLSKLVGKEIIPCGPLLVDSGDVSAGSEADGVMRWLDGQEPGSVVLVSFGSEYFMTEKQLAEMARGLELSGAAFVWVVRFPQQSPDGDEDDHGAAAARAMPPGFAPARGLVVEGWAPQRRVLSHRSCGAFLTHCGWSSVMESMSAGVPMVALPLHIDQPVGANLAAELGVAARVRQERFGEFEAEEVARAVRAVMRGGEALRRRATELREVVARRDAECDEQIGALLHRMARLCGKGTGRAAQLGH Accession number 79: PgUGT94_B1 (Panax ginseng) MADNQNGRISIALLPFLAHGHISPFFELAKQLAKRNCNVFLCSTPINLSSIKDKDSSASIKLVELHLPSSPDLPPHYHTTNGLPSHLMLPLRNAFETAGPTFSEILKTLNPDLLIYDFNPSWAPEIASSHNIPAVYFLTTAAASSSIGLHAFKNPGEKYPFPDFYDNSNITPEPPSADNMKLLHDFIACFERSCDIILIKSFRELEGKYIDLLSTLSDKTLVPVGPLVQDPMGHNEDPKTEQIINWLDKRAESTVVFVCFGSEYFLSNEELEEVAIGLEISTVNFIWAVRLIEGEKKGILPEGFVQRVGDRGLVVEGWAPQARILGHSSTGGFVSHCGWSSIAESMKFGVPVIAMARHLDQPLNGKLAAEVGVGMEVVRDENGKYKREGIAEVIRKVVVEKSGEVIRRKARELSEKMKEKGEQEIDRALEELVQICKKKKDEQ Sequence ID 80: SrUGT73E1, has any His tag (Stevia rebaudiana) MAHHHHHHVGTGSNDDDDKSPDPNWASTSELVFIPSPGAGHLPPTVELAKLLLHRDQRLSVTIIVMNLWLGPKHNTEARPCVPSLRFVDIPCDESTMALISPNTFISAFVEHHKPRVRDIVRGI IESDSVRLAGFVLDMFCMPMSDVANEFGVPSYNYFTSGAATLGLMFHLQWKRDHEGYDATELKNSDTELSVPSYVNPVPAKVLPEVVLDKEGGSKMFLDLAERIRESKGIIVNSCQAIERHALEY LSSNNNGIPPVFPVGPILNLENKKDDAKTDEIMRWLNEQPESSVVFLCFGSMGSFNEKQVKEIAVAIERSGHRFLWSLRRPTPKEKIEFPKEYENLEEVLPEGFLKRTSSIGKVIGWAPQMAVLS HPSVGGFVSHCGWNSTLESMWCGVPMAAWPLYAEQTLNAFLLVVELGLAAEIRMDYRTDTKAGYDGGMEVTVEEIEEDGIRKLMSDGEIRNKVKDVKEKSRAAVVEGGSSYASIGKFIEHVSNVTI Sequence ID 81: (Camelina sativa) MASEKTLQVHPPLHFVLFFPMAQGHMIPMVDIARLLAQRGATVTIVTTRYNAGRFENVLSRAVESGLPINIVHVKFPYEEVGLPKGKENIDSLDSMELMVPFFKAVNMLQDPVVKLMEEMSRPSCIISDLLLPYTSKIAKFNIPKIVFHGISFCCLLCVHVLRRNLEILTNLKSDKEYFLVPSFPDRVEFTKPQVTVETNASGDWKEFLDEMVEAEDTSYGVIINTFEELEPAYVKDYKDARAGN VWSIGPVSLCNKAGVDKAERGNKATIDQDECLKWLDSKEEGSVLYVCLGSICNLPLVQLKELGLGLEESQRPFIWVIRGWEKYNELSEWMVESGFEERIRERGLLIRGWAPQVLILSHPSVGGFLTHCGWNSTVEGITSGVPLITWPLFGDQFCNQTLVVQVLKAGVSVGVEVMKWGEEEKVLVDKEGVKKAVEDLMGESDDAKERTKRVKEGLAHKAVEEGGSSNITLFQDIRQVQSV sequence number 82:UGT73F24(Glycyrrhiza uralensis(UGT73F24) MADVAEEQPLKIYFIPYLAAGHMIPLCDIATLFASRGHHVTIITTPSNAQTLRESHHFRVQTIQFPSQEVGLPAGVQNLTAVTNLDDSYKIYHATMLLRKHIEDFVERDPDCIVADFLFPWVDDVATKLHIPRLVFTNGFTLFTICAMESHKAHPLPVDAASGSFVIPDFPHHVTINSTPPKRTKEFVDPLLTEAFKSHGFLINSFVELDGEECVEHYERITGGHKAWHLGPAFLVHRTAQDRGEKSVVSTQECLSWLDSKRDNSVLYICFGTICYFPDKQLYEIASAIEASGHEFIWVVPEKRGNADESEEEKEKWLPKGFEERNNGKKGMIIRGWAPQVAILGHPAVGGFLTHCGWNSTVEAVSAGVPMITWPVHSDQYFNEKLITQVRGIGVEVGAEEWIVTAFRETEKLVGRDRIERAVRRVMDGGGDEAVQIRRRARELGEMARQAVQEGGSSHTNTALINDLKRWRDSKQLN SEQ ID NO:83:UGT73C33(Glycyrrhiza uralensis) MAVFQANQPHFVLFPLMAQGHIIPMIDARLLAQRGAIVTPTPKNASRFTSVLSRAVSSGLQIRLVHLHFPSKEAGLPEGCENLDMVASHDMICNIFQAIRMLQKQAEELFETLTPKPSCIISDFCIPWTTQVAEKHHIPRISFHGFSCFCCLHCMLKIHTSKVLEGITSESEYFTVPGIPDQIQVTKQQVPMPIDEMKEFGEQMRDAEIRSYGVIINTFEELEKAYVNDYKKERNGKVWCIG PVSLCNKDGLDKAQRGNKASISEHHCLEWLDLQQPNSVIYVCLGSLCNLTPPQLMELALGLEATKRPFIWVIREGNKFEELEKWISEEGFEERIKGRGLIIRGWAPQVLILSHPSIGGFLTHCGWNSTLEGVTAGVPMVTWPLFADQFLNEKLVTQVLRIGVSLGVDVPLKWGEEEKVGVQVKKEGIEKAICMVMDEGEESKERREKLESMAKRAVEKDGSSHLNMTMLIQDIMQQSSSKVET SEQ ID NO:84:UGT85C1(Stevia rebaudiana) MDQMAKIDEKKPHVVFIFPPAQSHIKCMLKLARILHQKGLYITFINTDTNHERLVASGGTQWLENAPGFWFKTVPDGFGSAKDDGVKPTDALRELMDYLKTNFFDLFLDLVLKLEVPATCIICDGCMTFANTIRAAEKNLIPVILFWTMAACGFMAFYQAKVLKEKEIVPVKDETYLTNGYLDMEIDWIPGMKRIRLRDLPEFILATKQNYFAFEFLFETAQLADKVSHMIIHTFEELEAS LVSEIKSIFPNVYTIGPLQLLLNKITQKETNNDSYSLWKEEPECVEWLNSKEPNSVVYVNFGSLAVMSLQDLVEFGWGLVNSNHYFLWIIRANLIDGKPAVMPQELKEAMNEKGFVGSWCSQEEVLNHPAVGGFLTHCGWGSIIESLSAGVPMLGWPSIGDQRANCRQMCKEWEVGMEIGKNVKRDEVEKLVRLMEGLEGERMRKKALEWKKSATLATCCNGSSLDVEKLANEIKKLSRN sequence number 99:At75D1 (Arabidopsis thaliana) MANNNSNSPTGPHFLFVTFPAQGHINPSLELAKRLAGTISGARVTFAASISAYNRRMFSTENVPETLIFATYSDGHDDGFKSSAYSDKSRQDATGNFMSEMRRRGKETLTELIEDNRK QNRPFTCVVYTILLTWVAELAREFHLPSALLWVQPVTVFSIFYHYFNGYEDAISEMANTPSSSIKLPSLPLLTVRDIPSFIVSSNVYAFLLPAFREQIDSLKEEINPKILINTFQELEP EAMSSVPDNFKIVPVGPLLTLRTDFSSRGEYIEWLDTKADSSVLYVSFGTLAVLSKKQLVELCKALIQSRRPFLWVITDKSYRNKEDEQEKEEDCISSFREELDEIGMVVSWCDQFRV LNHRSIGCFVTHCGWNSTLESLVSGVPVVAFPQWNDQMMNAKLLEDCWKTGVRVMEKKEEEGVVVVDSEEIRRCIEEVMEDKAEEFRGNATRWKDLAEAAVREGGGSSFNHLKAFVDEHM Linker Sequence ID 85: GGSGGS(L6) Sequence ID 86: GGSGGSG(L7) Sequence ID 87: GGSGGSGG (L8) Sequence ID 88: GGSGGSGGS(L9) Sequence ID 89: GGSGGSGGSG(L10) Sequence ID 90: GGSGGSGGSGG (L11) Sequence ID 91: GGSGGSGGSGGS(L12) Complementary enzymes Sequence ID 92: E.coli pgm MAIHNRAGQPAQQSDLINVAQLTAQYYVLKPEAGNAEHAVKFGTSGHRGSAARHSFNEPHILAIAQAIAEERAKNGITGPCYVGKDTHALSEPAFISVLEVLAANGVDVIVQENNGFTPTPAVSNAILVHNKGGPLADGIVITPSHNPPEDGGIKYNPPNGGPADTNVTKVVEDRANALLADGLKGVKRISLDEAMASGHVKEQDLVQPFVEGLADIVDMAAIQKAGLTLGVDPLGGSGIEYWKRIGEYYNLNLTIVNDQVDQTFRFMHLDK DGAIRMDCSSECAMAGLALARDKFDLAFANDPDYDRHGIVTPAGLMNPNHYLAVAINYLFQHRPQWGKDVAVGKTLVSSSAMIDRVVNDLGRKLVEVPVGFKWFVDGLFDGSFGFGGGEESAGASFLRFDGTPWSTDKDGIIMCLLAAEITAVTGKNPQEHYNELAKRFGAPSYNRLQAAATSAQKAALSKLSPEMVSASTLAGDPITARLTAAPGNGASIGGLKVMTDNGWFAARPSGTEDAYKIYCESFLGEEHRKQIEKEAVEIVSEVLKNA sequence number 93:E.coli galU MAAINTKVKKAVIPVAGLGTRMLPATKAIPKEMLPLVDKPLIQYVVNECIAAGITEIVLVTHSSKNSIENHFDTSFELEAMLEKRVKRQLLDEVQSICPPHVTIMQVRQGLAKGLGHAVCAHPVGDEPVAVILPDVILDEYESDLSQDNLAEMIRRFDETGHSQIMVEPVADVTAYGVVDCKGVELAPGESVPMVGVVEKPKADVAPSNLAIVGRYVLSADIWPLLAKTPPGAGDEIQLTDAIDMLIEKETVEAYHMKGKSHDCGNKLGYMQAFVEYGIRHNTLGTEFKAWLEEEMGIKK sequence number 94: E.coli ycjU MKLQGVIFDLDGVITDTAHLHFQAWQQIAAEIGISIDAQFNESLKGISRDESLRRILQHGGKEGDFNSQERAQLAYRKNLLYVHSLRELTVNAVLPGIRSLLADLRAQQISVGLASVSLNAPTILAALELREFFTFCADASQLKNSKPPDPEIFLAACAGLVPPQACIGIEDAQAGIDAINASGMRSVGIGAGLTGAQLLLPSTESLTWPRLSAFWQNV SEQ ID NO:95: Bifidobacterium bifidum ugpA MAFAEDLKRTEKMTVDDVFEQSAQKMREQGMSEIAISQFRHAYHVWASEKESAWIREDTVEPLHGVRSFHDVYKTIDHDKAVHAFAKTAFLKLNGGLGTSMGLQCAKSLLPVRRHKARQMRFLDIILGQVLTARTRLNVPLPVTFMNSFRTSDDTMKALRHQRKFKQTDIPLEIIQHQEPKIDAATGAPASWPANPDLEWCPPGHGDLFSTLRESGLLDTLLEHGFEYLFISNDNLGARPSRT LAQYFEDTGAPFMVEVANRTYADRKGGHIVRDTATGRLILREMSQVHPDDKDAAQDIAKHPYFNTNNIWVRIDVLRDMLAEHDGVLPLPVIINNKTVDPIPPQSPAVVQLETAMGAAIGLFEGAICVQVDRMRFLPVKTTNDLFIMRSDRFHLTDSYEMEDGNYIFPNVDLDPRYKNIEDFNERFPYNVPSLAAANSVSIKGDWTFGRDVIMFADARLEDRNEPSYVPNGEYVGPMGIEPGDWV sequence number 96:E.coli adk MRIILLLGAPGAGKGTQAQFIMEKYGIPQISTGDMLRAAAVKSGSELGKQAKDIMDAGKLVTDELVIALVKERIAQEDCRNGFLLDGFPRTIPQADAMKEAGINVDYVLEFDVPDELIVDRIVGRRVHAPSGRVYHVKFNPPKVEGKDDVTGEELTTRKDDQEETVRKRLVEYHQMTAPLIGYYSKEAEAGNTKYAKVDGTKPVAEVRADLEKILG sequence number 97:E.coli ndk MAIERTFSIIKPNAVAKNVIGNIFARFEAAGFKIVGTKMLHLTVEQARGFYAEHDGKPFFDGLVEFMTSGPIVVSVLEGENAVQRHRDLLGATNPANALAGTLRADYADSTLENGTHGSDSVESAAREIAYFFGEGEVCPRTR sequence number 98:E.coli cmk MTAIAPVITIDGPSGAGKGTLCKAMAEALQWHLLDSGAIYRVLALAALHHHVDVASEDALVPLASHLDVRFVSTNGNLEVILEGEDVSGEIRTQEVANAASQVAAFPRVREALLRRQRAFRELPGLIADGRDMGTVVFPDAPVKIFLDASSEERAHRRMLQLQQEKGFSVNFERLLAEIKERDDRNRAVAPLVPAADALVLDSTTLSIEQVIEKALQYARQKLALA

Claims

1. 1. A method for preparing a glycosylated product, comprising: providing a bacterial cell expressing one or more recombinant UDP-dependent glycosyltransferase (UGT) enzymes, said bacterial cell comprising: having one or more genetic modifications that increase the expression of a recombinant sucrose synthase enzyme and the availability of UDP-sugars; The method further comprises culturing the bacterial cells in the presence of a substrate for glycosylation; and recovering said glycosylation product; The method comprising:

2. The method of claim 1 , wherein the bacterial cell is Escherichia coli.

3. 2. The method of claim 1, wherein the bacterial cell expresses a recombinant sucrose synthase enzyme comprising an amino acid sequence having at least about 70% sequence identity to one of SEQ ID NOs: 1-12.

4. The sucrose synthase enzyme is an amino acid sequence having at least about 80% sequence identity with SEQ ID NO:2, optionally having an S11E substitution with respect to SEQ ID NO:2; an amino acid sequence having at least about 80% sequence identity with SEQ ID NO:3, optionally having an L637M and a T640V substitution with respect to SEQ ID NO:3; an amino acid sequence having at least about 80% sequence identity with SEQ ID NO:5; an amino acid sequence having at least about 80% sequence identity with SEQ ID NO:6; an amino acid sequence having at least about 80% sequence identity with SEQ ID NO:7, optionally having an S11E substitution with respect to SEQ ID NO:7; an amino acid sequence having at least about 80% sequence identity with SEQ ID NO:8, optionally having an S11E substitution with respect to SEQ ID NO:8; an amino acid sequence having at least about 80% sequence identity with SEQ ID NO:9; an amino acid sequence having at least about 80% sequence identity with SEQ ID NO:10, optionally having an S11E substitution with respect to SEQ ID NO:10; or An amino acid sequence having at least about 80% sequence identity with SEQ ID NO:11 The method of claim 3 , comprising:

5. The method of claim 1, wherein the bacterial cell comprises the genetic modification, wherein ushA and galETKM or their orthologues are deleted, inactivated, or have reduced expression or activity; pgi or its orthologues are deleted, inactivated, or have reduced expression or activity; E. coli pgm (SEQ ID NO: 92) and / or ycjU (SEQ ID NO: 94) or their orthologues or derivatives are overexpressed or have increased activity; E. coli galU (SEQ ID NO: 93) and / or Bifidobacterium bifidum ugpA (SEQ ID NO: 95) or their orthologues or derivatives are overexpressed or have increased activity.

6. The method according to any one of claims 1 to 5, wherein the substrate for glycosylation is provided as a plant extract or fraction thereof, or is produced synthetically or by a biosynthetic process.

7. The substrate is Stevia leaf extract or a fraction thereof; or Monk fruit extract or fraction thereof, or biosynthetically produced mogrol or mogrol glycoside The method of claim 6, wherein the compound is provided as follows:

8. 8. The method of claim 7, wherein the glycosylation product comprises RebM, RebE, RebD, RebB, RebI, mog.IV, mog.IVA, mog.V, mog VI, isomog V, or siamenoside.

9. The UGT enzyme is Primary glycosylation at the C13 and C19 hydroxyls of the steviol core, and 1-2 and 1-3 branched glycosylation of said C13 and C19 primary glycosyl groups; or Primary glycosylation at the C3 and C24 hydroxyls of the mogrol core, and 1-2 and 1-6 branched glycosylation of the primary glycosyl groups at C3 and / or C24. The method according to claim 8, wherein:

10. The method according to any one of claims 1 to 5, wherein the bacterial cells are cultured in the presence of the substrate for glycosylation by one or more carbon sources.

11. 11. The method of claim 10, wherein harvesting comprises one or more of lowering the pH of the culture to below about pH 5 or raising the pH of the culture to above about pH 9, raising the temperature to at least about 50° C., and adding one or more glycoside solubility enhancers followed by removing enzymes or biomass.

12. A UDP-dependent glycosyltransferase (UGT) enzyme, comprising an amino acid sequence having at least about 70% sequence identity to SEQ ID NO:13; one or more amino acid substitutions selected from V397S, V397C, G5N, S20E, S23D, R45Y, H59P, G94S, K97E, M150L, ​​I185F, A206P, G210E, Q237R, M250K, A251E, C252L, G259E, Q263Y, I287M, C288F, V336I, F338L, D351E, F186I, F186M, F186T, L418F, A451T, A451L, T453K, T453R, V456S, V456W, V456T, V456M; Substitution of residues 270-281 of SEQ ID NO:13 with 5-15 amino acids consisting primarily of glycine and serine amino acids; With respect to SEQ ID NO:13, an insertion of one or two amino acids at position 3 and / or an addition of an amino acid to the C-terminus of SEQ ID NO:13 The UDP-dependent glycosyltransferase enzyme has one or more modifications selected from:

13. A UDP-dependent glycosyltransferase (UGT) enzyme, comprising an amino acid sequence having at least about 70% sequence identity to SEQ ID NO:14; V395A, Q263Y, D269R, K97E, Q262E, H59P, G259E, M150L, ​​Y267H, T3R, V95Q, A238E, S308Q, Q237R, R45Y, E254 D, L203I, S151R, S123D, D351E, T453M, G94T, T186M, V336I, L58S, F338L, F51W, C252L, M250D, A251E, C252V , one or more amino acid substitutions selected from A79P, W401F, S323A, A251E, A130D, S42E, H400Y, S266R, S23D, P56A, A206P, M250K, A143W, V456T, G94S, I427F, T186I, T453F, C252R, V38F, R45F, T37S, Q244K, L11I, I287M, V31P, T43D, and P39T; a deletion of residues 270-281 of SEQ ID NO:2 with a linker of 5-15 amino acids composed primarily of glycine and serine amino acids; With respect to SEQ ID NO:14, an insertion of one or two amino acids at position 3 and / or an addition of an amino acid to the C-terminus of SEQ ID NO:14 The UDP-dependent glycosyltransferase enzyme has one or more modifications selected from:

14. 1. A UDP-dependent glycosyltransferase (UGT) enzyme comprising an amino acid sequence having at least about 70% sequence identity to SEQ ID NO:15, and having one or more amino acid substitutions at positions selected from 125, 152, 153, and 442 relative to SEQ ID NO:

15.

15. 1. A method for glycosylation of a mogrol or mogrol glycoside substrate, the method comprising contacting the substrate with a UDP-dependent glycosyltransferase (UGT) enzyme in the presence of a UDP-sugar, the UGT enzyme comprising an amino acid sequence having at least about 80% sequence identity to an amino acid sequence selected from SEQ ID NO:84, SEQ ID NO:80, SEQ ID NO:46, SEQ ID NO:83, SEQ ID NO:82, SEQ ID NO:73, SEQ ID NO:72, SEQ ID NO:78, SEQ ID NO:54, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:29, and SEQ ID NO:

79.

16. The method of claim 15, wherein the substrate is provided as a plant extract or fraction thereof.

17. The plant extract comprises one or more substrates selected from mogrol, mog. IA, mog. IE, mog. II-A, mog. II-E, mog III, mog IVA, mog. IV, and siamenoside; The glycosylation product comprises mog. IV, mog. IVA, mog. V, mog. VI, or siamenoside; 17. The method of claim 16.

18. 18. The method of any one of claims 15 to 17, wherein the UGT enzyme is capable of primary glycosylation at the C3 and C24 hydroxyls of the mogrol core, and 1-2 and 1-6 branched glycosylation of the C3 and / or C24 primary glycosyl groups.

19. 18. The method of any one of claims 15 to 17, wherein the substrate is cultured with microbial cells expressing the UGT enzyme.

20. 18. The method of any one of claims 15 to 17, wherein the glycosylated product is recovered by one or more of lowering the pH of the reaction or culture to below about pH 5 or raising the pH of the reaction or culture to above about pH 9, increasing the temperature to at least about 50°C, and adding one or more glycoside solubility enhancers, followed by removing enzyme or biomass.

21. 1. A method for producing a glycoside product, comprising: converting a substrate for glycosylation into a target glycoside product by enzymatic transfer of one or more sugar moieties in a cell-free reaction or in a microbial culture; and recovering the glycoside product from the reaction or culture, wherein said recovering comprises one or more of: lowering the pH of the reaction or culture to less than about pH 5 or raising the pH of the reaction or culture to greater than about pH 9, raising the temperature to at least about 50° C., and adding one or more glycoside solubilizing agents followed by removing enzyme or biomass.

22. The substrate for glycosylation, stevia leaf extract or a fraction thereof; and Monk fruit extract or fraction thereof The method of claim 21 , wherein the plant extract is selected from the group consisting of:

23. 23. The method of claim 22, wherein the glycosylation product comprises RebM, RebE, RebD, RebB, RebI, mog.IV, mog.IVA, mog.V, mog VI, isomog V, or siamenoside.

24. 24. The method of any one of claims 21 to 23, wherein the enzymatic transfer occurs in a microbial culture, the microbial culture comprising a microbial strain expressing one or more uridine diphosphate-dependent glycosyltransferase (UGT) enzymes.

25. 25. The method of claim 24, wherein the bacterial strain is E. coli.

26. The method of any one of claims 21 to 23, wherein the process is carried out in a batch, continuous or semi-continuous mode.

27. 27. The method of claim 26, wherein the method is carried out in a fed-batch continuous or semi-continuous process.

28. 27. The method of claim 26, wherein the enzymatic transfer occurs in a bioreactor having a volume of at least 10,000 L, or at least 50,000 L, or at least 100,000 L, or at least 150,000 L, or at least 200,000 L, or at least 500,000 L.

29. The pH is a pH in the range of about 2 to about 4, optionally about 3.5; or Within the range of about 9 to about 12 The method according to any one of claims 21 to 23, wherein the concentration of

30. The method according to any one of claims 21 to 23, wherein the temperature is adjusted to a temperature of about 50°C to about 90°C, optionally to a temperature of about 70°C or about 80°C.

31. 31. The method of claim 30, wherein the reaction or culture medium is transferred from the reaction tank to a harvest tank for pH and / or temperature adjustment, and the reaction tank and harvest tank are optionally in-line.

32. 32. The method of claim 31 , wherein the pH adjustment is by addition of an organic or inorganic acid.

33. 24. The method of any one of claims 21 to 23, comprising adding one or more glycoside solubility enhancers.

34. The method of any one of claims 21 to 23, wherein the biomass and / or enzymes are removed by centrifugation, thereby preparing a clarified broth.

35. 35. The method of claim 34, wherein the process comprises biomass removal using a disc stack separator.

36. 24. The method of any one of claims 21 to 23, wherein the clarified broth is transferred directly or indirectly to one or more crystallization vessels.

37. 37. The method of claim 36, wherein prior to crystallization, the glycoside product is purified from the clarified broth using one or more processes selected from filtration, ion exchange, activated charcoal, bentonite, affinity chromatography, and digestion.

38. 38. The method of claim 37, wherein the affinity chromatography employs one or more of a styrene-divinylbenzene adsorption resin, a strong acid cation exchange resin, a weak acid cation exchange resin, a strong base anion exchange resin, a weak base anion exchange resin, and a hydrophobic interaction resin.

39. 38. The method of claim 37, wherein the process uses simulated moving bed chromatography.

40. 39. The method of claim 38, wherein prior to crystallization, the glycoside product is optionally purified by tangential flow filtration (TFF) with a membrane pore size of about 5 kD.

41. 38. The method of claim 37, wherein no organic solvent is used in the recovery.

42. 38. The method of claim 37, wherein at least two crystallization steps are used.

43. 43. The method of claim 42, wherein a basket centrifuge or a belt filter is used to isolate the crystals, thereby isolating the glycoside wet cake.

44. 24. The method of any one of claims 21 to 23, wherein the recovery process from clarified broth is non-chromatographic and optionally consists essentially of filtration and crystallization.

45. 45. The method of claim 44, wherein the wet cake from recrystallization is optionally dried using a belt dryer, paddle dryer, or spray dryer, and the dry cake is ground and, optionally, packaged.

46. 24. The method of any one of claims 21 to 23, wherein the target glycoside product is at least about 75% by weight of the recovered composition.

47. 24. The method of any one of claims 21 to 23, wherein the production rate of the glycosylation product is at least about 25 g / L, or at least about 50 g / L, or at least about 75 g / L, or at least about 100 g / L, or at least about 125 g / L, or at least about 150 g / L, or at least about 200 g / L of the culture or reaction volume.